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1. INTRODUCTION
Cancer hallmarks
Hanahan and Weinberg were the first to propose the six hallmarks of cancer, which provided 
a useful conceptual structure for understanding the complex biology of cancer (1). These 
hallmarks are proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, activating invasion and metastasis. Genome 
instability underlies these hallmarks, which generates the genetic diversity that accelerates their 
acquisition, and inflammation supporting multiple hallmark function. Theoretical progress in 
the last decade has added additional hallmarks potentially characteristic of all cancers which 
transform cellular metabolism and evade the immune system (Figure 1) (2). 
Figure 1. The hallmarks of cancer.
Tumor microenvironment
Made up of tumor cells and stroma, the tumor microenvironment (TME) is a dynamic milieu, 
which is continuously evolving and includes blood vessels, lymph vessels, extracellular 
matrix (ECM), stromal cells, immune/inflammatory cells, secreted proteins, RNAs and small 
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organelles. Cancer cells manipulate their microenvironment through the secretion of various 
cytokines, chemokines, growth factors and extracellular vesicles (EVs). The development of a 
supporting niche is critical for the continuous and uncontrolled growth of cancer. Meanwhile, 
tumor cells persistently shape their microenvironment, thereby establishing an abnormal 
ambience (3). Stromal cells of the TME can be educated to promote cancer development 
and progression. Whereas normal fibroblasts do not show potent tumorigenesis, tumor-
associated fibroblasts promote tumorigenesis. These properties indicate that the tumorigenesis 
of inflammatory fibroblasts is due to the influence of cancer cells (4,5). Recruitment of 
monocytes is one of the primary events in tumor development, and the functional plasticity of 
macrophages, the phenotype of tumor-associated-macrophage (TAM) is strongly influenced 
by microenvironmental factors present within the developing tumor, which appear to promote 
their pro-tumoral function (6). Tumor–stroma interactions modulate the microenvironment to 
be more permissive towards cancer cells (7). Tumor cell hierarchies, as well as multiple cellular 
elements in the microenvironment, co-evolve during the process of carcinogenesis (8). 
Mesenchymal stem cells in TME
Mesenchymal stem cells (MSCs) are a major component of the TME. The MSCs home to a 
cancer microenvironment in response to various cytokines, chemokines and EVs secreted by 
cancer cells. MSCs are a population of adult multipotent cells capable of self-renewal; they 
differentiate into many different cells of mesodermal origin, such as osteoblasts, chondrocytes 
and adipocytes (9).
Under tumoral influence, MSCs have been shown to differentiate into multiple tumor-associated 
cells types. Additionally, MSCs can maintain their phenotype and alter their cytokine secretion 
profile. Tumor-associated MSCs secrete increased levels of cytokines, chemokines, growth 
factors, and other small molecules, which interact with the tumor cells and the microenvironment. 
Conflicting data and concepts on antitumor and tumor-promoting roles of MSCs have been 
reported. Indeed, cellular fate could depend on the cancer type and also on the status of the 
affected MSCs. Activated MSCs can secrete pro-angiogenic soluble factors and are able to 
differentiate to vessel wall-associated cells (10) or to cancer-associated fibroblasts (11,12). 
Most reports suggest MSCs have tumor-promoting roles (13). MSC can prompt osteosarcoma 
progression through interleukin (IL)-6 secretion induced by tumor exosomes (14). The bone 
marrow-derived cells enhance the metastatic behavior of primary malignant melanoma via 
permanent education by tumor cell-derived exosomes (15). On the other hand, the MSCs similar 
to the pro- and antitumor phenotypes described for macrophages can either stimulate or inhibit 
tumor progression depending on the environmental cue. For instance, it has been shown that 
MSCs can inhibit the malignant phenotypes of human liver cancer cell lines, in a number of 
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ways, including proliferation, colony-forming ability, and oncogene expression both in vitro and 
in vivo (16).
An enhanced understanding of crosstalk between MSCs and tumor cells may reveal better 
targets for new therapies.
Macrophages in tumorigenesis
Macrophages are immune cells derived from the myeloid lineage, and they play an important role 
in tissue development, homeostasis and immune surveillance (17). TAMs are among the most 
abundant immune cells in the TME, and they play a key role in oncogenic processes of tumor 
proliferation, angiogenesis and metastasis. Mirroring the paradigm of Th1/Th2 lymphocytes, 
macrophages can be subdivided into two polarized subsets; classically activated macrophages 
and alternatively activated macrophages, M1 and M2, respectively (18). Macrophages polarize 
along the type 1 pathway in response to Th1-derived cytokines, such as interferon gamma, 
colony stimulating factor 2 (CSF2 or GM-CSF) or toll-like receptor (TLR) agonism (19). 
This induces expression of major histocompatibility complex II (MHC II) and costimulatory 
molecules (CD80 and CD86) leading to efficient T-cell priming. M1 cells produce nitric oxide 
(NO) and reactive oxygen species (ROS) associated with microbicidal and tumoricidal activity. 
Furthermore, M1 polarized macrophages recruit new Th1 cells via chemokines CXCL9 and 
CXCL10 and produce proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) 
and IL-1β, IL-6, IL-12, and IL-23 (20). M1 infiltration in tumors is associated with a good 
prognosis in some cancers (20,22). On the other end of the spectrum are M2 macrophages. This 
immunosuppressive state is initiated by Th2-derived cytokines, such as IL-4, IL-10, IL-13, 
transforming growth factor beta (TGF-β), prostaglandin E2 (PGE2) or colony stimulating 
factor 1 (CSF1 or M-CSF) (23,24). M2 macrophages lose their antigen presenting capabilities 
and are involved in tissue remodeling, debris scavenging and immune modulation (17). They 
support angiogenesis by secretion of adrenomedullin and vascular epithelial growth factors 
(VEGFs), and express immunosuppressive molecules such as IL-10, programmed death ligand 1 
(PD-L1) and TGF-β (25,26). 
This simplified M1/M2 definition provides a useful framework to classify macrophage function in 
macrophage biology. However, this definition overlooks the spectrum of  trophic/developmental 
macrophages involved in tissue repair, angiogenesis or bone remodeling, which is found in 
normal physiology (27,28). During tumor development, at least six distinct TAM populations are 
found, which often share features of both M1 and M2 types (19,29). This spectrum of activation 
states is controlled by the cytokine profile of the TME, where different cytokines can integrate 
and induce a broad and dynamic range of functions (Figure 2).
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 M2 macrophage M1 macrophage
Figure 2. Schematic representation of the functions of M1 and M2 macrophages in tumor development.
Because the tumor mass contains a great number of M2 macrophages, TAMs may be used as a 
target for cancer treatment. Reducing the number of TAMs or polarizing them towards an M1 
phenotype can help destroy cancer cells or impair tumor growth (30,32).
Coley’s toxin
It has been recognized over 100 years ago that cancer patients sometimes recover following 
bacterial infections (33). In a notable experiment, William B. Coley induced erysipelas by local 
injection of streptococcal cultures in a patient bearing a lymphoma. Surprisingly, he observed 
decreased tumor volume and a prompt improvement of the patient’s general condition. Based on 
experiences of the initial study, a large-scale effort to cure cancer patients was initiated using 
inactivated suspensions of Streptococcus pyogenes and Serratia marcescens (34–39). In 2003, 
a large clinical study carried out by the European Organization for Research and Treatment of 
Cancer provided unexpected evidence supporting the positive effect of microbial induction in 
cancer. Krone B. et al. showed that febrile infections or vaccinations with intracellular pathogens 
Bacillus Calmette–Guérin or Vaccinia virus in early childhood significantly decrease incidence 
of melanoma (40). Nevertheless, as these exciting data in most cases were not reproducible, we 
still lack detailed and convincing explanations of this phenomenon.
Although it is generally accepted that anti-tumor immune effector mechanisms overlap with 
antibacterial immune responses (41), the exact anti-tumor mechanism induced by microbes is 
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not yet understood. With respect to the anti-tumor mechanisms, it is also known that alterations 
in the polarization patterns of the overall immune system determine the outcome of malignant 
diseases (42). Key players of the immune responses include macrophages whose M1 type 
polarization mediates the anti-tumor action of the immune system (43,44).
Metastasis
Metastasis is the hallmark of cancer that is responsible for the greatest number of cancer-related 
deaths. In 1889, the English surgeon Stephen Paget proposed the “seed and soil” hypothesis 
(45). This hypothesis suggested that the metastasis is dependent on the interactions between the 
cancer cells (’seed’) and the host microenvironment (’soil’). The question that first captivated 
Paget was why tumor cells emerge only as disseminated tumor cells within specific organs. 
This organ specificity observed in metastasis is known as organotropism and remains one of the 
most intriguing unanswered questions in cancer research.
In recent years, additional fundamental discoveries have brought fresh insight into our 
understanding of cancer metastasis, and several novel concepts have been established. Tumors 
can induce the formation of microenvironments in distant organs that are conducive to the 
survival and outgrowth of tumor cells before their arrival at these sites (46). These predetermined 
microenvironments are termed pre-metastatic niches (PMNs) (47). Since the existence of PMNs 
was first demonstrated, numerous studies have identified various molecules that regulate its 
stepwise evolution, highlighting the complex molecular and cellular changes that occur in the 
PMN to support future metastatic tumor growth (48,49). PMNs are the result of the combined 
systemic effects of tumor-secreted factors and tumor-shed EVs that promote a temporal sequence 
of events shaping the evolution of PMNs. Although congruent with both theories of Paget, the 
concept of the PMN is unique as it proposes that the primary tumor preconditions specific organ 
sites for future metastatic disease (that is, before CTC arrival) via tumor-derived factors (50).
Exosomes
Exosomes are a subset of extracellular vesicles. Most living cells release an array of EVs, 
nanoparticles which are 20–1,000 nm in size. The nomenclature of the different vesicle types 
depends on their cell of origin, as well as their function and size, and has generated confusion 
regarding the definition of exosomes. The EV terms used in this expanding area of research 
encompass exosomes, ectosomes, microvesicles, microparticles, prostasomes, tolerosomes 
(which induce immunological tolerance to dietary antigens), apoptotic bodies (released by 
apoptotic cells), and nanovesicles. Cells deliver microRNA (miRNA), messenger RNA (mRNA), 
proteins, and other biomolecules between intracellular organelles by membrane vesicles, which 
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contain receptors to ensure traffic specificity. These membrane vesicles are actively secreted by 
most cells and exist in most body fluids, including blood, saliva, breast milk and sperm. There 
are three main types of such membrane vesicles: microparticles, microvesicles (100–1,000 nm), 
and exosomes (20–200 nm) (51).
In 2014, the International Society for Extracellular Vesicles (ISEV) proposed Minimal 
Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field and updated 
these guidelines in 2018. MISEV2018 (52) aims to standardize the nomenclature, and includes 
suggestions for the separation/isolation and characterization protocol of EVs. MISEV2018 
suggests the use of the operational term for EV subtypes that refer to physical characteristics, 
such as size or density, biochemical composition, or releasing conditions. In this study, small 
EVs (sEVs) were isolated on the basis of their size (<200 nm), and the isolated vesicles are 
referred to as “exosomes” by their characterization, shape, and markers.
Exosomes are small, multivesicular body (MVB)-derived EVs constitutively secreted by almost 
all cell types. During the endocytosis of exosomes, exosomes membrane often incorporates lipid 
rafts, which contain a variety of tumor-specific receptors and common membrane proteins, such 
as tetraspanins (e.g. CD9, CD63, CD81), MHC I and II, and adhesion molecules (e.g. integrins, 
cadherins), and results in the formation of early endosomes. Exosomes show inward budding 
of the MVB. During this process, numerous proteins (e.g. receptors, ubiquitin-related proteins, 
heat shock proteins), nucleic acids (e.g. miRNAs, RNAs, DNAs, lnRNAs), transcriptional 
factors, and lipids (e.g. cholesterol, ceramide) can be selectively packed into MVB in a cell 
type-dependent manner (Figure 3). After early-to-late endosome conversion, late endosomes 
containing MVB fuse with the plasma membrane to secrete exosomes into the extracellular 
space by exocytosis, which is mainly controlled by endosome-specific Rab GTPases including 
Rab11/35, Rab7, and Rab27. The uptake of exosomes by recipient cells can be mediated by direct 
fusion of exosomes with the cell membrane of the recipients via receptor-ligand interactions or 
by endocytosis (53).
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Figure 3. Biogenesis, secretion, and uptake of exosomes.
These exosomal-molecular patterns, as unique entities of the complex intercellular 
communication, are not independent of the quality or state of the mother cell (54). Indeed, 
exosomes are claimed to be capable of carrying and conveying tumor-related information and 
might have a significant role in formation of the tumor microenvironment.
Exosomes in tumorigenesis
In most cases, primary cancers can be cured by surgical resection and adjuvant treatment. 
However, metastatic cancers are difficult to completely alleviate and are the cause of about 90% 
of cancer-related deaths (55). Stephen Paget’s “seed and soil” hypothesis of metastasis claims 
that the distribution of cancers is not random (45). Before metastasis, the target organs are 
specifically modified to establish a microenvironment suitable for tumor cell growth, known as 
the PMN. In recent years, EVs have been shown to play a critical role in mediating the interaction 
between tumor cells and host cells, which prepares the pre-metastatic niche for the formation 
of secondary sites (56). Notably, cancer cells secrete considerably more EVs than normal cells, 
leading to a substantial increase in detectable EVs circulating in the blood. Exosomes have 
been recognized long ago, but their identification, characterization, and isolation are still under 
intense investigation. Moreover, whereas the definition of exosomes is based on the pathway of 
biogenesis, oncosomes form a functional class of extracellular vesicles (57). Indeed, oncosomes 
are claimed to be capable of carrying and conveying tumor-related information (58) and can 
mediate important cancer-related pathways to enhance tumor invasion and metastasis through 
different manners, including controlling angiogenesis (59), modulating stromal cells (60), 
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remodeling the ECM (61), transferring malignant traits, and establishing the PMN. Exosomes 
containing ncRNAs and proteins play significant roles in these pathways. While the mechanism 
by which exosomes secreted by cancer cells act on the target tissue has been elucidated, it has 
also been shown that exosomes secreted by the primary lesion lead to the formation of the 
metastatic lesion in distant tissues (i.e., PMN formation) before the cancer cells themselves 
migrate to the particular tissue. Baglio et al. showed that extracellular vesicles secreted by 
the tumor promote osteosarcoma progression via TGF-β signaling-induced IL-6 production 
by MSCs (14). Moreover, Peinado et al. demonstrated that exosomes from highly metastatic 
melanomas increase the metastatic behavior of primary tumors by permanently educating bone 
marrow progenitors through the receptor tyrosine kinase MET (15).
However, there are many details that remain unknown, and recent research findings also raise 
new questions. For instance, while the content of exosomes varies among cells and changes 
even for the same cell depending on the environment, the mechanism for this diversity is yet 
to be understood. Elucidating the role of the molecules on the exosomal surface and those 
encapsulated within may help reveal the pathological conditions caused by the exosome and 
develop methods to counter them.
Melanoma
Melanoma is a highly invasive, metastatic cancer with poor prognosis and survival rate. 
According to the World Health Organization, 287,800 new cases of melanoma were diagnosed 
worldwide in 2018, and about 60,715 cancer deaths (0.7% of all cancer deaths) were due to 
cutaneous melanoma in the same year. The incidence and mortality rates of cutaneous melanoma 
differ widely across the globe depending on access to early detection and primary care. In 2018, 
the age standardized (world standard population) incidence was 12.6 per 100,000 person-year 
in the EU (62).
A melanoma develops through malignant transformation of melanocytes. The pathogenic 
features of melanomas are characterized by their growth and – with the amplification of atypical 
melanocytes – self-sufficiency of growth factors, insensitivity to growth inhibitors, evasion 
of cellular apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion, 
and metastasis. These pathogenic events may result from the complex interaction between 
exogenous and endogenous triggers as well as tumor-intrinsic and immune-related factors 
(63). Similarly to other cancers, melanoma development and progression follows a sequential 
genetic model that results in activation of oncogenes or inactivation of tumor-suppressor genes 
(64). At the protein level, some genetic alteration (mutations in BRAF or TERT promoters; 
CDKN2A, PTEN and TP53 genes) leads to a reciprocal overstimulation of the affected cellular 
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pathways, mainly the mitogen-activated 
protein kinase (MAPK) pathway, the 
phosphoinositide 3-kinase (PI3K), protein 
kinase B (AKT), phophatase and tensine 
homologue (PTEN), and mammalian 
target of rapamycin (mTOR) pathway 
(Figure 4) (64–67). 
Melanoma cells are able to escape 
the immune system, and modify the 
immune response in order to survive, 
for example, by reinforcing immune 
checkpoints. The cytotoxic T lymphocyte 
associated  antigen-4 (CTLA-4) on T-cells 
competitively binds to B7 ligands on 
melanoma cells, interfering with CD28 
interactions, thus preventing costimulation 
and the priming phase of T-cell activation. 
Additional immunosuppressive 
mechanisms include the downregulation 
of tumor-associated antigens and MHC I 
(68). The Janus kinase (JAK), and signal 
transducer and activator of transcription 
(STAT) pathway is a major regulator of the 
programmed cell death protein 1 (PD-1) 
immune checkpoint. Upon tumor antigen 
recognition by T-cells, the interferons 
released trigger JAK-STAT-mediated 
Figure 4. Crucial pathways in melanoma 
pathogenesis. 
(a) MAPK, PI3K-AKT signaling, and cell-cycle 
regulation under normal conditions permits bal-
anced control of basic cell functions.
(b) In melanomas, genetic alterations lead to con-
stitutive pathway activation with loss of cellular 
homeostasis. 
(c) The PD-1-PD-L1 immune checkpoint is pri-
marily regulated by interferon-γ signaling. 
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expression of PD-1 ligands (PD-L1 and PD-L2) on the surface of melanoma cells. Interaction 
of PD-1 with its ligands leads to the suppression of T-cell effector activity and inhibits the 
antitumor immune response (69).
Notably, PD-1 expression is not a default property of melanoma cells. Of further importance, 
Kleffel et al. recently demonstrated that PD-1 overexpressing melanoma cell subpopulations are 
especially aggressive, and that melanoma PD-1:PD-L1 interactions modulate mTOR signaling, 
whereby they interfere with programmed cell death (70). This work addressed the consequences 
of PD-1 overexpression and experimental inhibition of PD-1 functions (using Pdcd1 shRNA 
or anti-PD-1 antibodies). However, it failed to define the factors whose activation leads to the 
generation of PD-1 overexpressing subpopulations. This question is especially intriguing, if 
one considers that one of the most effective immunotherapies available today is based on the 
blockade of the PD-1:PD-L1 interaction mentioned above.
In addition to genetic changes in melanocytes, the interaction between the elements of the 
microenvironment is also a key part of melanoma formation. The melanoma microenvironment 
is also markedly heterogenic and involves a wide variety of collocated cells: fibroblasts, 
macrophages, lymphocytes, other immune cells, mesenchymal stem cells, adipocytes and cells 
from the structural elements of cutaneous blood vessels sunk in the extracellular matrix (71).
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2. AIMS
The TME includes nonmalignant cells, immune cells, secreted proteins, extracellular vesicles, 
blood vessels, etc. that surround and support the growth of the tumor. Interactions between the 
various components of the TME are crucially important; tumor cells can change the nature of 
the microenvironment, and conversely, the microenvironment can affect the spread and growth 
of tumors. The structure and composition of the TME varies among different types of cancers.
In this study, we aimed to investigate how TME factors promote the pro-metastatic 
characteristics of melanoma. Pro-metastatic characteristics often depend on the specific tissue 
microenvironment. The TME was investigated from two different points of view – from the 
aspect of tumor, and from the behavior of tumor-infiltrating immune cells. 
We aimed to investigate how tumor progression is influenced on the one hand by the tumor-
derived exosomes, and, on the other hand, by the various types of tumor-infiltrating macrophages 
(M1, M2).
We hypothesized that the tumor-derived exosomes promote tumor progression, whereas the M1 
polarization of tumor-associated macrophages induces tumor regression. 
In this project, we addressed four specific aims:
1. Investigate the cellular and molecular signals of melanoma-derived exosome-induced, 
intercellular communication-mediated malignant transformation of MSC cultures.
2. Inspect the alteration in the expression of PD-1, a melanoma progression marker and 
therapeutic target, upon exposure to melanoma-derived exosomes.
3. Examine the melanoma-derived exosome-induced tumor progression in vivo.
4. Evaluate the impact of macrophage polarization on tumor regression.
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3. MATERIALS AND METHODS
Mice 
C57BL/6N and immunodeficient NOD/Scid IL2rg null (NSG) mice were obtained from 
Charles River Laboratories, Sulzfeld, Germany. Mice were housed in pathogen-free conditions 
and experiments were performed in accordance with national (1998. XXVIII; 40/2013) and 
European (2010/63/EU) animal ethics guidelines. The experimental protocols were approved 
by the Animal Experimentation and Ethics Committee of the BRC-HAS and the Hungarian 
National Animal Experimentation and Ethics Board (clearance numbers: XVI./03521/2011, 
CSI/01/3929-4/2017, XVI./03521/2011, and CSI/01/3929-4/2017).
Cell cultures and cell line
The B16F1 mouse melanoma cell line was obtained from ECACC and cultured in Dulbecco’s 
modified Eagle’s medium (DMEM, Lonza) containing 10% fetal bovine serum (Euroclone), 
0.01% sodium pyruvate, 1% MEM non-essential amino acids, 1% MEM vitamin solution, 
2 mM L-glutamine and 1% Penicillin-Streptomycin-Amphotericin B Mixture (all from Lonza).
Murine MSCs were isolated from C57BL/6N (Charles River Laboratories) 8-week-old male mice 
(72). Abdominal inguinal fat pads were excised, rinsed with RPMI 1640 medium, transferred 
to sterile tissue culture dishes and mechanically dissociated. The dissociated tissue was 
resuspended in RPMI 1640 containing 100 µg/ml collagenase (Sigma-Aldrich) and incubated 
at 37°C for 50 min. Collagenase was neutralized with a growth medium containing 10% fetal 
bovine serum (FBS). After centrifugation at 470 × g for 15 min, cell pellets were resuspended 
and washed in the culture medium. After the centrifugation, cell pellets were resuspended 
in complete MecenCult medium (Stemcell Technologies) and filtered through a 100 µm cell 
strainer (BD Biosciences) to tissue culture dishes and cultured for 48 h at 37°C in 5% CO2 and 
90% humidity. Unattached cells and debris were then removed and fresh medium was added 
to the adherent cells. The cells were cultured to 80% confluence before being released with 
trypsin–EDTA and sub-cultured.
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The purity of MSC cultures were checked by flow cytometry analysis using the Mouse 
Multipotent Mesenchymal Stromal Cell Marker Antibody Panel (R&D Systems) according to 
the manufacturer’s instructions.
Cell cultures for in vitro experiments
Passage 2 MSCs (6 × 104 cell/ml) were plated in cell culture dishes (1.5 × 104/cm2). After 24 h 
incubation, MSC cultures were exposed to B16F1-derived exosomes (40 µg/ml exosomal 
proteins; 1.5 × 1011 exosomes) every 24 hours. Samples were exposed to exosomes for 24 h, 
48 h, 72 h and 96 h and then harvested in method-competent buffer.
Mouse model for exosomal treatment
B16F1 melanoma cells were administered intravenously (1 × 105 cell/100 μl) to 6 to 8-week-old 
female C57BL/6N mice. One week later, tumor bearing mice were randomized and divided into 
3 groups (n = 10/group). Mice were injected intravenously with control buffer (100 μl), exosome-
exposed MSCs (1 × 105 cell/100 μl) or exosomes (40 μg/100 μl) 7, 8, 9, 10, and 11 days after the 
tumor injection (Table S1). One week after the first MSC administration, 3 animals/group were 
euthanized, their lungs were removed, photographed and stored at −80°C for further protein, 
mRNA and histological analysis. The remained mice were observed for 10 more days. At the 
end point, the animals were euthanized, and the tumor metastases were investigated not only in 
their lung, but also in their entire body and removed for histological analysis. Experiments were 
repeated 3 times.
Tumor coverage
The tumor coverage of lungs was determined by the analysis of acquired images using the 
ImageJ software. The area of tumors and the healthy regions was measured, and the mean 
percentage, SD and p values were calculated in Microsoft Excel. 
Quantification of metastases-associated vessel diameter
From native animal lungs, 4 μm cryostat sections were made on silanized slides, then fixed 
and retrieved by Fix&Perm A-B solution (Thermo Fisher Scientific) for 20 minutes. Sections 
were counterstained by conventional hematoxilin for 30 minutes, then washed in tap water and 
coverslipped. Sections were digitalized by automatic slide-scanner (3DHistech, Hu), using the 
software 3DHISTECH Pannoramic Viewer (3DHistech, Hu). Strict tumor border was carefully 
marked, then vessel diameters were measured.
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The mouse model for Chlamydia treatment
B16F1 melanoma cells (DTP, DCTP Tumor Repository) were administered intravenously 
(1 × 105 cell/100 μl) to 6 to 8-week-old female immunocompetent C57BL/6 or immunodeficient 
NOD/Scid IL2rg null (NSG) mice. One week after tumor cell administration, mice were 
treated with Chlamydia pneumoniae (C. pneumoniae) strain CWL-029 propagated in Hep2 
cells (73). C. pneumoniae and the mock control (processed Hep2 cells) were heat-inactivated 
at 90°C for 30 minutes. Mice were mildly sedated with sodium pentobarbital (7.5 mg/ml) and 
treated intranasally with 1 × 106 IFU C. pneumoniae 7, 9, 11, 14, and 16 days after tumor 
implantation. Since the physical condition of NSG mice deteriorated extremely rapidly, animals 
were euthanized at day 14 after the third C. pneumoniae treatment. The special advantages of 
this model are: (i) with intravenous injection of melanoma cells, visible lung tumor metastases 
develop within 7 days after injection without significant spreading into other organs; and (ii) 
C. pneumoniae is a lung-specific intracellular pathogen with a significant invasion rate even 
to the lung metastases. Two hours after the first inhalation (day 7), 4 hours after 2nd, 12 hours 
after 3rd and 24 hours after 5th inhalation, 3 animals/group were anaesthetized and their lungs 
were harvested for protein, mRNA and histological analysis. The remaining mice received the 
4th (day 14) and the 5th (day 16) treatments and were followed for survival. At the endpoint, 
the animals were euthanized, their lungs were removed and 3 independent persons counted the 
number of surface metastases in a blind fashion.
For the survival experiments, groups of mice (n = 15) were treated as described 5 times after 
melanoma implantation. Kaplan-Meier survival curves were analyzed by a log-rank statistical 
test and p ≤ 0.05 was regarded as statistically significant. All animal experiments were authorized 
by the institutional and national animal welfare committees.
Exosome isolation and characterization
Exosomes were isolated by adapting the protocol of Peinado et al. (15) from melanoma cell 
culture supernatant. B16F1 supernatants were harvested, supplemented by complete protease 
inhibitor cocktail (Roche) and centrifuged at 780 × g for 5 min at 4°C to remove intact cells. 
Then, the supernatants were centrifuged at 3,900 × g for 15 min at 4°C and filtered through a 
0.2 µm membrane (Millipore) to remove larger cell fragments and microvesicles. Exosomes 
were pelleted by ultracentrifugation at 150,000 × g (T-1270 rotor at 40,500 rpm) for 1 h at 4°C. 
The pellet was washed twice and resuspended in DPBS and stored at −80°C.
The concentration of exosomal proteins was determined using a Pierce BCA Protein assay kit 
(Thermo Fisher Scientific) and a Benchmark Microplate Reader (Bio-Rad,) according to the 
manufacturer’s instructions.
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Determination of shape and size of the isolated vesicles
Scanning Electron Microscopy (SEM)
Five microliters of isolated exosomes in DPBS were spotted on glass coverslips coated with 0.01% 
Poly-L-Lysine (Sigma-Aldrich) and incubated overnight at 4°C. Using sterile forceps, coverslips 
were transferred into a plastic plate. Exosomes were fixed by gently adding 2% paraformaldehyde 
buffer pH 7.2 diluted in DPBS for 30 min. The coverslips were washed twice with DPBS and 
dehydrated with a graded series of ethanol (40%, 60%, 80%, and 100% ethanol, each for 5 min). 
The samples were dried with a critical point dryer (QUORUM K850) and the coverslips were 
mounted onto a microscope stub one at a time using carbon tape, followed by a 7 nm gold 
coating (QUORUM Q150) and observed under a field-emission scanning electron microscope 
(JEOL JSM-7100F/LV).
Atomic force microscopy (AFM)
Exosomes were allowed to adsorb to the freshly cleaved muscovite mica (SPI-ChemTM Mica 
Sheets, Structure Probe, Inc.) surface directly from buffer solution (DPBS, Lonza). All AFM 
measurements were carried out with an Asylum MFP-3D head and Molecular Force Probe 
Controller (Asylum Research), using the Asylum Research MFP-3D program (version 15.09.112) 
written in Igor Pro software (version 6.37, Wavemetrics). Image processing and data calculation 
were carried out using the same software. Rectangular silicon cantilevers (OMLC-AC240TS, 
Olympus Optical Co., Ltd.) with a typical spring constant of 2 N/m were used in a dry condition 
and silicon nitride rectangular cantilevers with “V” shaped tips (Bio-Lever BL-RC150VB, 
Olympus Optical Co. Ltd.) with a typical spring constant of 0.03 N/m in buffer solution. 
Typically, 512 × 512 points were taken at a scan rate of 1 line/s. The measurements presented 
here are amplitude images and height profiles.
Identification of exosomal proteins by mass spectrometry
Exosomal proteins (24 μg) were separated in 4-12% Bis-Tris Protein Gels and stained with 
Coomassie blue (0.1% Coomassie Brilliant Blue R-250, 50% methanol and 10% acetic acid).
The lanes were each cut into 12 equal bands and subjected to in-gel digestion. The gel bands 
were diced into smaller pieces, and the SDS and CBB dyes were washed out with 3 × 50 µl 
25 mM ammonium-bicarbonate (ABC)/50% Acetonitrile (AcN). After reduction with DTT 
(1,4dithiothreitol, Sigma-Aldrich; 20 µl, 10 mM DTT in 25 mM ABC) at 56°C for 30 min, and 
alkylation with IAM (iodoacetamide, Sigma-Aldrich; 20 µl, 55 mM IAM in 25 mM ABC) at 
RT in the dark for 30 min, the gel samples were dried in a vacuum centrifuge, and after that 
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rehydrated in 20 µl of trypsin (Sequencing Grade Modified Trypsin, Promega; 5 ng/µl in 25 mM 
ABC) and incubated at 37°C. The digestion was stopped after 4 hours by lowering the pH of 
the buffer below 3 and by adding 2 µl of 10% formic acid. Tryptic peptides were extracted from 
the gel with 3 × 50 µl of 2% formic acid in 50% AcN and dried. Prior to mass spectrometric 
analysis, each sample was dissolved in 50 µl of 0.1% formic acid.
Samples were analyzed in an LTQ-Orbitrap Elite (Thermo Fisher Scientific) mass spectrometer 
on-line coupled with a nanoHPLC (nanoAcquity, Waters) system. Five µl of each of the in-
gel digests were loaded (for 3 min at a flow rate of 8 µl/min, using 0.1% Formic acid [FA] 
in 3% Acetonitrile 97% water) onto a reversed phase trap column (Waters, Symmetry C18, 
0.180 × 20 mm) and separated on a C18 reversed phase (Waters, BEH300C18 1.7 µm) nanocolumn 
(0.075 × 200 mm). The flow rate was 330 nl/min and a linear gradient was used from 3% to 40% 
B in 37 min (solvent A was 0.1% FA in water and solvent B was 0.1% FA in Acetonitrile). 
The high voltage (1.2 kV) was applied through liquid junction between the chromatographic 
column and the non-coated silica nanospray emitter (NewObjective, 10 µm tip ID). The mass 
spectrometer operated in data-dependent mode: the survey mass spectra were detected in the 
orbitrap with high resolution (R = 60 k @ m/z: 400, mass range m/z: 380–1,400) and the most 
abundant multiply charged 20 peaks were selected for ion-trap fragmentation (NCE: 35%; 
activation q: 0.25; activation time: 10 ms; minimum signal intensity: 5,000 counts). The MS/ MS 
spectra were detected in the ion trap. Dynamic exclusion was used; the precursors were excluded 
for 15 sec after the first fragmentation event.
Data analysis: searchable peaklists (mgf format) were extracted using ProteomeDiscoverer (ver:1.4 
Thermo Fisher Scientific) and subjected to database search on our in-house ProteinProspector 
(ver: 5.14.1) search engine using the following parameters: parent ion tolerance: 5 ppm; fragment 
ion tolerance: 0.6 Da; Cys carbamidomethylation was set as constant, and Met oxidation, 
cyclisation of peptide N-terminal Glu to pyroglutamic acid, protein N terminal acetylation were 
set as variable modifications. Only fully tryptic peptides were considered with a maximum of 
2 missed cleavage sites. The Mus musculus and Bos taurus protein sequences of the Uniprot 
(UniProtKB.06.11.2014) database completed with human keratins and pig trypsin, altogether 
106,330 protein sequences were searched. For the false discovery rate (FDR) estimation, the 
searches were performed on the database concatenated with the randomized sequences. Protein 
identification was accepted if the ProteinProspector expectation value was less than 0.01, and 
the protein was identified with at least 2 unique peptides (expectation value less than 0.05 and 
score higher than 15). FDR values were less than 1% in all cases. 
For the functional validation, the obtained protein list was analyzed by the “Core Analysis” 
function included in Ingenuity Pathway Analysis (IPA, Qiagen Bioinformatics) software.
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Isolation and detection of exosomal miRNAs
miRNA sequencing was performed using SOLiD Total RNA-Seq lit for Small RNA Libraries 
(Applied Biosystems now part of Thermo Fisher Scientific) according to the manufacturer’s 
instructions. Purification was performed on 10% TBE-Urea gels stained with Sybr Gold nucleic 
acid gels stain (both from Invitrogen now part of Thermo Fisher Scientific). Final purification 
was performed using PureLink PCR Micro Kit (Invitrogen). Final libraries were quality checked 
using High Sense DNA kit on Bioanalyzer (all from Agilent). Concentration of each library was 
determined using the SOLID Library TaqMan Quantitation Kit (Life Technologies now part 
of Thermo Fisher Scientific). Each library was clonally amplified on SOLiD P1 DNA Beads 
by emulsion PCR (ePCR). Emulsions were broken with butanol, and ePCR beads enriched for 
template-positive beads by hybridization with magnetic enrichment beads. Template-enriched 
beads were extended at the 3’ end in the presence of terminal transferase and 3’ bead linker. 
Beads with the clonally amplified DNA were deposited onto a SOLiD sequencing slide and 
sequenced on the SOLiD 5500 Instrument using the 50-base sequencing chemistry.
Bioinformatic Analysis Raw data quality assessment, read trimming, read mapping and miRNA 
expression profiling was carried out in CLC Genomics Workbench tool version 8.0.2 (CLC 
Bio now part of Qiagen) using annotated Mus musculus miRNA sequences according to the 
miRBase release 21 as a mapping reference.
Detection of proteins by Western blotting
Protein samples were resuspended in 4x sample buffer (NuPAGE® LDS Sample Buffer (4X), 
NuPAGE® Sample Reducing Agent (10X), Thermo Fisher Scientific), boiled at 96°C for 10 min, 
and immediately cooled on ice. Electrophoresis of the proteins was performed using 4‒12% Bis-
Tris Protein Gels (NuPAGE™ Novex™, Thermo Fisher Scientific), ProSieve™ Color Protein 
Markers (Lonza), and electrophoresis buffer (NuPAGE™ MOPS SDS Running Buffer, Thermo 
Fisher Scientific) at 200 V and 0.03 A for 40 min.
The proteins of electrophoresed gels were transferred to Immobilon transfer membrane 
(Millipore) using transfer buffer (NuPAGE® Transfer Buffer (20X)) at 30 V and 170-110 mA 
for 60 min. Membranes were blocked in TBST buffer (25 mM Tris-HCl, 150 mM NaCl, 
0.05% Tween-20, pH 7.2) containing 5% non-fat milk for 60 min at room temperature. After 
blocking, membranes were incubated with each primary antibody in TBST buffer containing 
1% non-fat milk overnight at 4°C. Membranes were washed three times for 10 min with TBST 
buffer and incubated for 60 min at room temperature with secondary antibody in TBST buffer 
containing 1% non-fat milk. Membranes were washed three times for 10 min with TBST 
buffer. Bound antibodies were visualized by chemiluminescence using an ECL Plus Western 
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Blotting detection system (Advansta). Immunoreactive signals were detected by using LI-COR 
ODYSSEY® Fc (Dual-mode imaging system) imager followed by analysis with Odyssey v1.2.
Western blot analysis of exosome markers
For exosomal marker identification, Western blot analyses were performed with an anti-CD63 
polyclonal antibody (1:250 dilution; Biorbyt), an anti-CD9 rabbit monoclonal antibody (clone: 
EPR2949, 1:500 dilution, LifeSpan Biosciences), an anti-CD81 hamster monoclonal antibody 
(clone: EAT2, 1:1,000 dilution, LifeSpan Biosciences), an anti-HSP70 monoclonal antibody 
(clone: C92F3A-5, 1:8,000 dilution; Enzo Life Sciences), an anti-rabbit IgG HRP-Conjugated 
antibody (1:1,000 dilution, R&D Systems), and an anti-Hamster IgG HRP-Conjugated antibody 
(1:30,000 dilution, Thermo Fisher Scientific). 
PD-1 detection by Western blotting
The cells were washed three times in PBS, then lysed in TENT Buffer (50 mM Tris-HCl, 2 mM 
EDTA, 150 mM NaCl, 1% TritonX-100, completed with 1x protease inhibitor cocktail (Roche). 
Protein samples were separated and blotted as described above.
For PD-1 protein level detection, an anti-PD-1 mouse monoclonal antibody (clone: RMP1-14, 
1:1,000 dilution, Biolegend) and an anti-rat IgG HRP-conjugated secondary antibody (1:500 
dilution, R&D Systems) was used.
Cytokine and chemokine detection by proteome profiling 
Lung samples were lysed in NP40 cell lysis buffer (Thermo Fisher Scientific), and protein content 
was measured by the Pierce BCA Protein Assay kit (Thermo Fisher Scientific). Expression 
levels of different cytokines in pooled lung specimens were determined using Mouse Cytokine 
Array Panel A (R&D Systems), according to the manufacturer’s instructions. Immunoreactive 
signals were detected by using LI-COR ODYSSEY® Fc (Dual-mode imaging system) imager 
followed by analysis with Image Studio Lite v5.2.
Quantitative reverse transcription PCR (qRT-PCR) 
Mlana and Mitf qRT-PCR
Total RNA of biological samples was purified using the Quick-RNA MiniPrep isolation kit 
of #R1054S (Zymo Research). All the preparation steps were carried out according the 
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manufacturer’s instructions. RNA samples were stored at –80°C in the presence 30 U of Prime 
RNAse inhibitor (Fermentas, part of Thermo Fisher Scientific) for further analysis. The quantity 
of isolated RNA samples was checked by spectrophotometry (NanoDrop 3.1.0).
qRT-PCR was performed on a RotorGene 3000 instrument (Corbett Research) with gene-
specific primers and SybrGreen protocol to monitor gene expression. 1 μg of total RNA 
was reverse transcribed with random primers using the High-Capacity cDNA Archive Kit 
(Applied Biosystems) according to the manufacturer’s instructions in final volume of 30 μl. The 
temperature profile of the reverse transcription was the following: 10 min at room temperature, 
2 hours at 37°C, 5 min on ice and finally 10 min at 75°C for enzyme inactivation. These steps were 
carried out in a Thermal Cycler machine (MJ Research, Marshall Scientific). After dilution with 
30 μl of water, 1 μl of the diluted reaction mix was used as template in the qRT-PCR. Reactions 
were done with FastStart SYBR Green Master mix (Roche) according to the manufacturer’s 
instructions at a final primer concentration of 250 nM under the following conditions: 15 min at 
95°C, 40 cycles of 95°C for 15 sec, 60°C for 25 sec and 72°C for 25 sec. The fluorescence intensity 
of SybrGreen dye was detected after each amplification step. Melting temperature analysis was 
done after each reaction to check the quality of the products. Primers were designed using the 
online Roche Universal Probe Library Assay Design Center. The quality of the primers was 
verified by MS analysis provided by Bioneer (Daejeon, Korea). Relative expression ratios were 
calculated as normalized ratios to MmRpl27 (Mus musculus ribosomal protein L27) gene. Non-
template control sample was used for each PCR run to check the primer-dimer formation. The 
final relative gene expression ratios were calculated as delta-delta Ct values. Information about 
the genes and the primers is collected in Table S2.
TaqMan panel of 40 oncogenes
qRT-PCR was performed on an ABI Prism 7000 sequence detection system (Applied Biosystems) 
using specific pre-designed customized 96-well TaqMan Array oncogene panels (Thermo 
Fisher Scientific) containing 44 primers and probes specifically selected based on extensive 
literature work. RNA was isolated from MSC cells with Qiagen RNeasy mini kit (Qiagen) 
based on the manufacturer’s instructions. RNA concentrations were measured by NanoDrop 
spectrophotometer (NanoDrop). cDNAs were reverse transcribed with TaqMan Reverse 
Transcription Reagents (Thermo Fisher Scientific) following the manufacturer’s instructions. 
For the TaqMan qRT-PCR panel, cDNA mixture of three parallel samples was used for each 
of the following conditions: control, 6 h, 24 h and 72 h exosome treatment applied on MSC 
cells derived from four mice. 80 ng cDNA and TaqMan Gene Expression Master Mix (Thermo 
Fisher Scientific) was used for the qRT-PCR experiment.
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Total RNA was isolated using TRIzol (Thermo Fisher Scientific) from the lung samples, DNase 
treatment was performed according to the manufacturers’ protocol, and then total RNA was 
transcribed into cDNA using the High Capacity cDNA Kit (Thermo Fisher Scientific). PCR 
amplification was performed using TaqMan primers and probes, and thermal cycle conditions 
were set as follows: 2 min at 50°C, 10 min at 95°C, 40 cycles of 15 sec at 95°C and 1 min at 
60°C. As internal control transcripts of ACTB (Assay ID: Mm00607939_s1), GAPDH (Assay 
ID: Mm99999915_g1) and PPIA (Assay ID: Mm02342430_g1) were determined. The amount 
of the transcripts was normalized to those of the housekeeping genes using the ΔCt method. 
Finally, the results were normalized to the expression of the vehicle control (ΔΔCt method).
For relationship discovery, Hierarchical Cluster Analysis was performed by R software. In 
detail, the “bottom up” agglomerative hierarchical clustering strategy was used, and the results 
were presented in a tree-based dendrogram. (R software: R. D. C. Team, R: A Language and 
Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, 
Austria, 2008).
Cytokines and chemokines qRT-PCR
Total RNA of lungs was purified using a NucleoSpin RNA II RNA isolation kit; first-strand 
cDNA was synthesized and qRT-PCR reactions were performed on pooled samples (n=3) on 
a RotorGene 3000 instrument with gene-specific primers (CCL2, CCL3, CD86, IL-12, IL-6, 
IL-10, CXCL16, CCL7, CD80, CXCL11, CXCL9, IL-23, TNF-α), and SYBR Green protocol to 
monitor gene expression. Each individual Ct value was normalized to the average Ct values of 
four internal control genes (ΔCt values). The final relative gene expression ratios (fold change) 
were calculated as comparisons of ΔCt values (ΔΔCt values). Non-template control sample was 
used for each PCR run to check the primer-dimer formation. Primer sequences are available 
upon request.
Histology, immunohistochemistry
Lung specimens were fixed in 4% buffered formaldehyde; then, routine HE histology as well 
as standardized immunohistochemistry tissue microarray were performed using anti-CD11b 
(clone M1/70; R&D Systems) and anti-CD80 (B7-1; R&D Systems) antibodies.
Visualization of labeled exosome internalization in MSCs
To examine the uptake of exosomes by MSCs, cells were plated to black 24-well Visiplates 
(1 × 104 cells/well) and incubated for 24 h. The exosomes were labeled with Dil dye 
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(1,1’dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate, PromoKine) and the MSC 
cultures were labeled with DiO dye (3,3’-dioctadecyloxacarbo-cyanine perchlorate, PromoKine) 
according to the manufacturer’s instructions. Dil-labeled exosomes were washed in PBS by 
ultracentrifugation (at 150,000 × g for 1 h at 4°C). Forty micrograms per milliliter Dil-labeled 
exosomes were added to DiO-labeled MSC cultures, and the exosome uptake was followed for 
24 h in the Celldiscoverer 7 automated live cell imaging system (Zeiss). After 24 h, the cells 
were fixed with 4% paraformaldehyde solution and a nucleus staining was performed using 
DAPI (Life Technologies now part of Thermo Fisher Scientific). Then, 5 image z-stacks were 
acquired for both channels by Operetta High Content Screening System (PerkinElmer). The 
stacks were maximum intensity projected and then analyzed automatically using a customized 
version of CellProfiler (74). Nuclei were detected with Otsu-adaptive threshold combined with 
diameter-based filtering, then cytoplasms were identified with propagation method seeded from 
the nuclei and using the exosome channel. Exosomes were located with a customized version 
of A-trous wavelet transform based spot detection (75). Several wavelet levels were used to 
ensure the detection of exosomes with various sizes and then the overlaps were removed based 
on circularity measures. Finally, the exosome numbers per cell were identified using MATLAB 
programming, the diagrams were created in Microsoft Excel.
Cell proliferation 
After 72 h incubation, exosome-exposed and control MSC cultures were dissociated with trypsin 
from the culture surface. Cells were washed in medium and counted in a Bürker chamber and a 
cell counter (Bio-Rad, TC10 Automated Cell Counter).
Detection of apoptosis 
Exosome-exposed MSCs and control cells were treated with 100 ng/ml mouse TNF-α (R&D 
Systems). After 24 h incubation, cell death was determined by the Annexin V Apoptosis 
Detection Kit with PI (Biolegend) according to the manufacturer’s recommendations. Samples 
were measured by FACS Calibur flow cytometer (BD Biosciences), data were analyzed by 
Flowing Software (Cell Imaging Core, Turku Centre for Biotechnology) where percent of 
positive cells was determined by relative fluorescence intensity, and the results were expressed 
as mean of percentage of positive cells (%) ±SD. Cells that are annexin V/propidium iodide (PI) 
double positive show the sign of late apoptosis, while cells that are annexin V positive and PI 
negative indicate early apoptosis. Annexin V negative and PI positive cells are necrotic; viable 
cells are both annexin V and PI negative. 
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PD-1 and MLANA detection by immunofluorescence microscopy
MSC cultures were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.1% 
Triton X-100, and blocked in PBS buffer containing 5% BSA (Sigma-Aldrich) for 60 min at 
room temperature. After blocking, cells were incubated with primary antibody in PBS buffer 
containing 1.2% BSA overnight at 4°C. As primary antibodies, 1:200 anti-PD-1 (clone: RMO1-
14, Biolegend) or 1:200 anti-MLANA (Byorbit) were used. Then, cells were incubated for 
1 h at room temperature with 1:100 Alexa Fluor 647 conjugated anti-rat antibody (Jackson 
ImmunoResearch Laboratories) or 1:500 Alexa Fluor 555 conjugated anti-rabbit antibody 
(Thermo Fisher Scientific). Tubulin was stained with 1:500 Alexa Fluor 488 conjugated anti-
tubulin-α antibody (clone: 10D8, Biolegend). Nucleus staining was performed using DAPI (Life 
Technologies). Slides were washed three times with DPBS between each step. Images were 
obtained at 60x magnification using an Olympus confocal laser scanning microscope.
PD-1 detection by STORM super-resolution imaging
All dSTORM super-resolution experiments were performed on a custom-made inverted 
microscope based on a Nikon Eclipse Ti-E frame. After conditioning (through spatial filtering 
via fiber coupling and beam expansion), the applied laser beams were focused onto the back 
focal plane of the microscope objective (Nikon CFI Apo 100x, NA = 1.49), which produced a 
collimated beam on the sample. The angle of illumination was set via a tilting mirror mounted into 
a motorized gimbal holder and placed onto the conjugate plane of the sample. All the dSTORM 
images were captured under EPI illumination at an excitation wavelength of 647 nm (Nikon: 
647 nm, 300 mW). The laser power, controlled via an acousto-optic tunable filter (AOTF), was 
set to 4 kW/cm2 on the sample plane. An additional laser (Nichia, 405 nm, 60 mW) was used 
for both reactivation and reference measurements. Images were captured by an Andor iXon3 
897 BV EMCCD digital camera (512 × 512 pixels with a pixel size of 16 μm). The size of the 
illuminated region of the sample was matched to the size of the detector, which determined the 
field of view (FOV = 80 × 80 μm2). Frame stacks for dSTORM super-resolution imaging were 
typically captured at a reduced image size (crop mode), when only the central 128 × 128 pixel 
region was selected. A fluorescence filter set (Semrock, LF405/488/561/635-A-000) was used to 
select and separate the excitation and emission lights in the microscope. Additional emission 
filters (Semrock, BLP01647R-25) were used in the detection path to further clean the fluorescent 
light spectrally for the reduction of spectral crosstalk.
During the measurements, the perfect focus system of the microscope was used to keep the 
sample in focus with a precision of <30 nm. The storage buffer on the sample was replaced with 
a special switching buffer (76). Typically, 10,000 frames were captured with an exposure time 
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of 30 ms. Reference images with full size FOV were captured at low intensity when the majority 
of fluorescent molecules were still active and the overall structure of the labeled sample could 
be visualized.
The captured and stored image stacks were evaluated and analyzed by rainSTORM localization 
software (77). The individual images of single molecules were fitted with a Gaussian point 
spread function and their center positions were associated with the position of the fluorescent 
molecule. Localizations were filtered via their intensity, ellipticity and standard deviation 
values. Localizations with precisions of <45 nm were only used to form the final image. The 
estimated mean precision of the accepted localizations was 19 nm. Mechanical drift introduced 
by either the mechanical movement of the sample or thermal effects was analyzed and reduced 
by means of a blind drift correction algorithm. Spatial coordinates of the localized molecules 
were stored and the final super-resolved image was visualized. The multicolor merged images 
were generated by ImageJ software.
Network representation by Ingenuity Pathway Analysis
According to literature data, we established a protein network from the in vivo overexpressed 
genes in the exosome-related animal groups. A custom graphical representation of this network 
was generated using the Path Explorer tool of the Ingenuity Pathway Analysis (IPA) Path 
Designer. Genes are represented as red nodes, using various shapes that represent the functional 
class of the gene product. In a few cases, proteins are substituted with the complex, which they are 
a part of. To identify potential exosomal factors, which can induce the activation of the network, 
a list was generated from the exosomal proteins detected by LC-MS/MS and the exosomal 
miRNAs identified by SOLiD sequencing. The Grow tool in the IPA Path Designer revealed 
significant interactions between the network and the generated list (the interacting exosomal 
factors are listed in grey boxes and the types of relationships are indicated in parentheses). 
During construction in the IPA, the significance level was set to “experimentally observed” data 
to avoid the representation of predicted, unproven interactions.
Statistical analysis
All of the data are presented as the mean ±SD or SEM and represent a minimum of three 
independent experiments. Statistical parameters including statistical analysis, statistical 
significance, and n values are reported in the Figure legends. For in vivo experiments n = number 
of animals. For statistical comparison, we performed two-tailed Student’s t-test. A value of 
p ≤ 0.05 was considered significant (represented as *p ≤ 0.05, not significant [n.s.]).
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4. RESULTS
Isolated vesicles show exosomal properties
First, we isolated extracellular vesicles from B16F1 mouse melanoma cells. As it was shown 
by SEM and AFM (Figures 5a,b), the isolated fraction indeed contained exosomes, as the 
particles were cap-shaped, and their size was within the 40–120 nm range. Then, the presence 
of molecules (CD9, CD63, CD81 and HSP70) characteristic for exosomes (51,52) was assessed 
by Western blotting (Figure 5c). Overall, the physical properties, the shape and size, and also the 
protein composition of the isolated vesicles meet the MISEV2018 requirements (52).
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Figure 5. Characterization of B16F1 melanoma cell culture-derived exosomes. 
(a) Scanning electron micrograph of exosomes secreted by melanoma cells. (b) Atomic force microscopy images 
of exosomes. The left and middle pictures represent the shape, and surface topography of vesicles; the graph to 
the right represents height profile. (c) Western blot analysis of common exosome markers (CD9, CD63, CD81 and 
HSP70). (d and e) The top 5 molecular and cellular functions identified by IPA of exosomal proteins and miRNAs.
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Exosomes were then subjected to large-scale analysis to determine their protein and miRNA 
profiles. Whole proteome analysis (using LC-MS/MS) and bioinformatics tools (used to identify 
elements of the exosomes’ proteomics spectrum in the UniProt database, and to compare the 
findings with entries of the ExoCarta database) revealed that 95 distinct proteins were identified 
in melanoma exosomes (Table S3). These proteins exhibited an 86.3% overlap with molecules 
listed as characteristic exosome protein markers in ExoCarta. Furthermore, miRNA sequencing 
(using SOLiD 5500xl technology) identified 168 known miRNA elements (Table S4) which, 
similarly to the proteomics data, exhibited a large (93.5%) overlap with molecules listed as 
characteristic exosome miRNA markers in ExoCarta.
To uncover the functional significance of the proteomics and miRNA sequencing data, IPA 
was employed. This analysis has shown that the identified proteins most probably participate in 
cellular and molecular processes such as “Cell Death and Survival”, “Cellular Movement”, “Cell-
to-Cell Signaling and Interaction”, “Cellular Growth and Proliferation” and “Cell Morphology” 
(prange = 7.53 × 10
-15 – 9.32 × 10-4) (Figure 5d). Very similarly to these data, functions of the 
identified miRNAs were suggested to be linked to mechanisms of “Cellular Development”, 
“Cellular Growth and Proliferation”, “Cellular Movement”, “Cell Cycle” and “Cell Death and 
Proliferation” (prange = 1.25 × 10
-12 – 4.88 × 10-2) (Figure 5e).
Tumor exosome exposure resulted in oncogenic reprogramming of MSCs  
in vitro
Then, we investigated the impact of exosomes on the biological processes (e.g. proliferation, 
survival, malignant transformation, etc.) of MSCs, which are generally considered as adequate 
in vitro models of tumor stroma (14). For these experiments, MSC cultures were initiated from 
mouse abdominal adipose tissue (72) and were subjected to melanoma exosome treatment.
First, we assessed whether exosomes were internalized by MSCs. High-throughput microscopy 
showed that MSCs (labeled green by the DiOC18 (3) lipid dye) indeed took up exosomes (labeled 
red by the DilC18 (3) lipid dye) as early as 1-2 h after application (Figure S1). Importantly, after 
24 h, the majority of MSCs were populated by exosomes (Figure 6a,b). Indeed, image analysis 
and statistical evaluation revealed a 91% internalization efficacy. This suggests that functional 
alterations demonstrated by this study were due to exosome-induced cell-population, and not 
individual cell level effects.
Then, we determined whether the internalized exosomes could induce a melanoma-like malignant 
transformation of the MSCs. By employing two complementary cell-counting methods, we 
found that proliferation rate of the MSCs significantly accelerated 72 h after exosome exposure 
(Figure 6c). Flow cytometry also showed that the exosome-treated MSCs exhibited a partial 
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resistance to the cell death-inducing effects of 100 ng/ml TNF-α, as the fraction of the dead cells 
was significantly decreased in these cultures (Figure 6d).
Since the exosomes were isolated from melanoma cells, we were then intrigued to see whether 
the above alterations (which all argue for the malignant transformation of the susceptible cells) 
also resulted in de novo appearance of melanoma-specific features in the transformed MSCs. 
To answer this question, we assessed the expression of the melanoma-specific markers MLANA 
and MITF. By qRT-PCR, we found that mRNA transcript levels of both markers elevated 
markedly in MSCs upon exosome treatment (Figure 6e and Figure S2), albeit the kinetics of 
elevation of the two molecules were slightly different. Moreover, in good accordance with the 
mRNA data, immunofluorescence labeling showed that exosome exposure markedly increased 
the expression of MLANA at the protein level as well (Figure 6f).
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Figure 6. Internalized melanoma exosomes induce malignant transformation of the recipient MSCs.
(a) Fluorescent images of exosome uptake by MSCs. DiO (green lipid dye)-labeled cells were exposed to Dil (red 
lipid dye)-labeled exosomes for 24 h and fixed in 4% PFA. Control cells were treated in the same manner without 
exosomes. Pictures were acquired by an Operetta high content screening system (Perkin Elmer). The lower two 
images represent an experiment where nuclei were counterstained with DAPI. Exosomes were detected with a 
customized version of A-torus wavelet transform and were highlighted with yellow. (b) Quantitative analysis 
of exosome uptake. The graph shows the number of detected exosomes (Y axis) in each cell (X axis) in three 
exosome-exposed (24 h) and three control cell cultures (ctrl). (c) Cell proliferation assay of exosome-exposed 
MSCs. Cells were plated at a density of 1 × 104 cell/cm2 density in control and exosome-exposed cultures, and 
72 h after the exosome treatment, the cell number was determined by manual counting and by an automated cell 
counter. Both methods showed significantly increased cell proliferation of exosome-treated cells. Results are 
presented as mean ±SD (n = 3). (d) Apoptosis analysis of exosome-exposed MSCs by flow cytometry. Exosome-
pre-exposed cells were treated by 100 ng/ml TNF-α for 24 h, stained with Annexin V-FITC and propidium 
iodide. TNF-α-treated and the untreated control cell cultures were both analyzed by flow cytometry. The graph 
represents the percentage of early apoptotic, late apoptotic, and necrotic cells. Both TNF-α-induced total cell 
death (Σ) and necrosis were significantly lower (Σp = 0.03 and p = 0.02, respectively) in exosome-pretreated cell 
cultures compared to the corresponding control cells. Results are presented as mean +SD (n = 3). (e) qRT-PCR 
analysis of Mlana and Mitf in MSC cultures treated by exosomes every 24 h as indicated by arrows in the 
graph. The expression of both mRNAs increased after exosome exposure, but they showed different kinetics. 
(f) Fluorescent immunocytochemistry of MLANA in exosome-exposed MSC cultures using a primary rabbit 
antibody to MLANA and a secondary AlexaFluor555-conjugated antibody to rabbit IgG (red). α-tubulin network 
of cells was directly labeled by an AlexaFluor488-conjugated antibody (green) and the nuclei were stained with 
DAPI (blue).
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Next, we assessed whether the above effects of exosomes – whereby they induce a malignant-
like transformation of the MSCs – was accompanied by a cellular-molecular oncogenic 
reprogramming of the target cells. Naïve MSCs were exposed to a standardized volume of 
exosomes for various time intervals (to avoid the experimental fluctuations, we collected pooled 
samples from multiple independent in vitro experiments). Then, samples were subjected to qRT-
PCR analysis using a self-designed panel of 40 oncogenes and tumor suppressor genes that were 
previously suggested to play a role in melanoma progression (Table 1).
Table 1. List of genes investigated by a self-designed oncopanel 
Gene Protein Function References
Alcam ALCAM  (CD166)
Activated leukocyte cell adhesion molecule
plays an important role in human malignant melanoma progression 
and formation of locoregional and distant metastases
78
Bmi1 BMI1
B cell-specific Moloney murine leukemia virus 
integration site 1
induces an invasive signature in melanoma that promotes metasta-
sis and chemoresistance 
79
Cd44 CD44 is a CD44s interaction with HA plays a crucial role in cell inva-
siveness 
80
Eng ENG 
Endoglin (CD105)
has a crucial role in angiogenesis, important protein for tumor 
growth, survival and metastasis of cancer cells to other locations 
in the body
81
Flot2 FLOT1
Flotillin-2
is associated with melanoma progression 82
Itga2 ITGA2
Integrin alpha2
is associated with increased risk of melanoma 83
Itga4 ITGA4
Integrin alpha 4
α4β1 integrin plays an important role in metastasis of malignant 
melanoma 
83
Itga6 ITGA6
Integrin alpha 6  
α6β1 integrin as a  laminin receptor expression is associated with 
invasive potential in a highly metastatic melanoma cell line 
83
Itgb1 ITGB1
Integrin beta-1 (CD29)
α4β1 integrin plays an important role in metastasis of malignant 
melanoma 
83
Kit KIT (CD117) 
Mast/stem cell growth factor receptor (SCFR) 
c-Kit signaling activates the MAPK and PI3K signaling cascades 84
Muc1 MUC1 
Mucin1 cell surface associated 
promotes melanoma migration through the Akt signaling pathway 84
Pecam1 PECAM1 
Platelet endothelial cell adhesion mole-
cule (CD31)
can play multiple roles in diverse processes related to melanoma 
development, dormancy, migration/invasion and angiogenesis 
85
Prom1 Prominin-1 (CD133) is a melanoma stem cell marker 86
Thy CD90 is a cell adhesion molecule. Melanoma cells use Thy-1 on endo-
thelial cells for metastasis formation 
87
Cdc42 CDC42
Cell division control protein 42 homolog
is vital for the transforming Ras signal emanating from endomem-
branes
88
Tiam1 TIAM1
T-cell lymphoma invasion and metastasis 1
has crucial roles in regulation of the actin cytoskeleton, cell migra-
tion, cell cycle progression, gene transcription and cell adhesion 
89
Continued
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Table 1. Continued
Gene Protein Function References
Bcl2 BCL-2
B-cell lymphoma 2
plays a pivotal role in the regulation of molecules associated with 
the migratory and invasive phenotype, contributing, in cooperation 
to hypoxia, to tumor progression 
84
Bax BAX
Bcl-2-associated X protein
plays a crucial role in apoptotic cell death induced, the Bax/Bcl-2 
ratio determines the susceptibility of melanoma cells 
90
Casp9 CASP9
Caspase-9
is linked to the mitochondrial death pathway 90
Casp8 CASP8
Caspase-8
plays a central role in the execution-phase of cell apoptosis 91
Cdk4 CDK4
Cyclin-dependent kinase 4
promotes cell-cycle progression and inhibit both cell senescence 
and apoptosis 
84
Elk1 ELK1 
ETS domain-containing protein Elk-1
is a member of ETS oncogene family, transcription activator 92
Ets1 ETS1
E26 transcription factor
is required for migration in cell lines with an active RAS/ERK 
signaling pathway 
84
Hgf HGF
Hepatocyte growth factor
can activate the MAP-kinase pathway, which is upregulated in the 
majority of melanoma, through the proto-oncogene c-MET 
93
Jak2 JAK2 
Janus kinase 2
is an activator of transcription (STAT) pathway is thought to play a 
central role in melanoma cell biology 
94
Met MET
Hepatocyte growth factor receptor
induces several biological responses that collectively give rise to a 
program known as invasive growth
95
Myb MYB 
transcriptional activator Myb
is a transcription factor; among other genes, MYB regulates the 
transcription of the Kit, Bcl2, Ets-2 and N-Ras
96
Nras NRAS 
Neuroblastoma RAS viral oncogene homolog
recruits and stimulates a number of intracellular signaling path-
ways including the Raf/MEK/ERK mitogen activated protein 
kinase (MAPK) pathway, the PI3K/AKT pathway
84
Stat3 STAT3
Signal transducer and activator of transcription 3
promotes transcription of many genes that involve in melanoma 
metastasis
97
Kitl KIT-ligand
Stem cell factor (CD117)
is a cytokine that binds to the c-KIT receptor. This cytokine plays 
an important role in melanogenesis
84
Rb1 RB1
Retinoblastoma 1 protein
is a tumor suppressor protein that is dysfunctional in several ma-
jor cancers
98
Pik3ca PI3K 
Phosphatidylinositide 3-kinases
is a PI3K/AKT pathway play a pivotal role in tumor development, 
growth and metastasis of melanoma
84
Raf1 RAF1 
Proto-oncogene serine/threonine-protein kinase
is a crucial regulators of the ERK MAP kinase signaling cascade 99
Mtor mTOR
Serine/threonine-protein kinase
mechanistic target of rapamycin, is a serine/threonine protein 
kinase that regulates cell growth, cell proliferation, cell motility, 
cell survival
83
Akt1 AKT
Protein kinase B
plays a key role in multiple cellular processes such as glucose 
metabolism, apoptosis, cell proliferation, transcription and cell 
migration
84
Map2k1 MEK1
Dual specificity mitogen-activated protein 
kinase kinase 1
is an essential component of the MAP kinase signal transduction 
pathway, this kinase is involved in many cellular processes such 
as proliferation, differentiation, transcription regulation and devel-
opment
84
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Table 1. Continued
Gene Protein Function References
Map2k2 MEK2
Dual specificity mitogen-activated protein 
kinase kinase 2 
plays a critical role in mitogen growth factor signal transduction. 
It phosphorylates and thus activatesMAPK1/ERK2 and MAPK2/
ERK3
84
Mapk3 ERK1
Extracellular-signal-regulated kinases
Ras-Erk1/2 is a key regulator pathway in melanoma cell prolifer-
ation.
84
Mapk1 ERK2 
Mitogen-activated protein kinase 1
Ras-Erk1/2 is a key regulator pathway in melanoma cell prolifer-
ation
84
Rac1 RAC1 
Ras-related C3 botulinum toxin substrate 1
functions in multiple signaling pathways are leading to cell adhe-
sion, migration, proliferation and transformation
100
As shown in Figure 7a, the gene expression pattern of MSCs exposed to melanoma exosomes 
exhibited a clear oncogenic dominance (compared to the non-exposed cells). This was verified 
by statistical analysis of the mean relative gene expression levels of all molecules investigated. 
Statistically higher values were obtained in the case of exosome-treated cells (p = 1.9 × 10-5, 
p = 0.031 and p = 2.3 × 10-8 for the 6 h, 24 h and 72 h time points, respectively).
As mentioned above, Kleffel et al. has recently shown that melanoma cell subpopulations which 
overexpress PD-1, quite intriguingly exhibit remarkably increased invasiveness and aggressive 
growth properties (70). However, the authors did not define the factor(s) which induced the 
above PD-1 overexpression. Since the above finding strongly suggested an “MSC re-education” 
capacity of melanoma exosomes to induce malignant-like behavior, we next assessed the 
expression of PD-1 in MSC cultures.
As expected, only insignificant PD-1 expression (both at the mRNA and protein levels) could be 
identified in control, non-treated MSCs. In contrast, a marked, significant, and time-dependent 
elevation of PD-1 expression was detected upon exosome treatment by qRT-PCR (Figure 7b), 
Western blot and an immunocytochemical analysis (Figure 7c,d). Furthermore, by employing 
super-resolution microscopy, we were able to identify a dramatic upregulation of PD-1 at the 
single molecular level in exosome-treated MSCs (Figure 7e).
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Figure 7. Exosome re-educated MSCs show oncogene dominance and PD-1 expression. 
(a) qRT-PCR analysis of 40 tumor-related genes in exosome-exposed MSCs using a self-designed panel. The 
graph shows the relative expression values for each gene after 6 h, 24 h and 72 h of exosome exposure. The 
trend line of the altered gene expression pattern (indicated by thick black line) shows an increasing tendency 
over time (mean ± SD). (b) qRT-PCR analysis of PD-1 in MSCs after 2 h and 24 h of exosome exposure. The 
graph represents mean +SEM (n = 3). (c) Representative immunoblot of PD-1 protein expression in control and 
exosome-exposed MSCs after 24 h of exosome treatment. (d,e) Fluorescent immunocytochemistry of PD-1 in 
24 h exosome-exposed MSC cultures, using a primary rat antibody to PD-1 and a secondary AlexaFluor647-
conjugated antibody to rat IgG (red). Nuclei were stained with DAPI. (d) α-tubulin network of cells was directly 
labeled by an AlexaFluor488-conjugated antibody (green). Images were acquired by confocal microscopy. (e) 
Images were taken by STORM super-resolution microscopy. STORM super-resolution imaging of PD-1 revealed 
that PD-1 was localized mostly around the nucleus, which were blurred and were not resolvable using diffraction-
limited confocal microscopy (d) of the same region.
Importantly, since proteomics analysis did not identify the presence of PD-1 in exosomes, 
these data suggest that the high PD-1 protein content in exosome-exposed MSCs was a result 
of de novo induction and not of exosome-mediated molecular transfer. Our findings therefore 
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suggest that melanoma exosome-mediated “re-education” of the cells resulted in a novel MSC 
population which could be identified as MSCPD-1+.
B16F1 exosomes augment in vivo tumorigenesis and tumor progression 
After presenting evidence for the in vitro tumorigenic induction potential of exosomes on 
cultured MSCs, we hypothesized that this phenomenon could be identified in vivo as well. 
To probe this assumption, we employed the well-known animal model, routinely used in our 
laboratories, in which tumors, developed mostly in the lungs, are induced in mice by intravenous 
administration of mouse B16F1 melanoma cells (to the tail vein). These tumor-bearing mice 
were then administered by buffer, or exosomes isolated from the same B16F1 melanoma cells, 
or exosome-induced MSCPD-1+ cells.
Notably, the exosome-related groups (i.e. groups treated with exosomes or MSCPD-1+) were 
characterized by a markedly increased size of tumor-covered lung tissues (the increase proved 
to be significant in the MSCPD-1+ group) (Figure 8a). Of further importance, we also found that 
in both exosome-related groups, the number of distant metastases were significantly elevated 
when compared to the control (Figure 8b), and the diameter of blood vessels associated with 
metastases significantly increased in exosome and MSCPD-1+ injected groups of tumor bearing 
mice (Figure S3). Levels of tumor supportive cytokines and chemokines (C5/C5a, TIMP-1, 
IL-16, IL-1F3, SDF1, CCL5) were elevated in the exosome-related groups (Figure S4). In this 
animal-model, we have previously observed that these metastases were mostly localized to the 
ovaries and kidneys (and very rarely to the lymph nodes) of control tumor-bearing animals. 
However, besides these sites, the presence of exosomes resulted in frequent metastases in the 
lymph nodes and, as a new location, in the liver. Interestingly, in MSCPD-1+ treated mice, exosome-
transformed MSCs could be identified in the paraaortic lymph nodes by FISH (fluorescence in 
situ hybridization) (Figure 8c) verifying the successful in vivo adherence of MSCPD-1+ cells.
Lung tissues of the different groups were then subjected to in-depth expressional profiling 14 days 
after injection of exosomes or MSCPD-1+ cells. Namely, qRT-PCR analysis was performed using 
a self-designed panel of 40 genes; besides housekeeping genes, we assessed the expression of (i) 
proto-oncogenes; (ii) genes reportedly involved in malignant transformation; and/or (iii) genes 
found to be involved in melanoma development and progression.
Hierarchical cluster analysis (HCA) of the gene expression patterns clearly showed a robust 
proto-oncogenic dominance in lung samples from the exosome-related groups when compared 
to the control tissues (Figure 8d). Indeed, we identified significant de novo induction of the 
following genes: Alcam1, Eng, Flot2, Itga4, Itga6, Kit, Pecam1, Prom1, Thy, Cdc42, Tiam1, 
Bcl2, Bax, Casp9, Casp8, Ets1, Hgf, Jak2, Met, Myb, Map2k1, Map2k2, Mapk1 in both groups 
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(23 genes in total) and Elk1, Rb1, Itga2 in the exosome group (26 genes in total). Six additional 
genes (Cd44, Itgb1, Muc1, Pik3ca, Akt1, and Rac1) in the exosome group and an three additional 
genes (Cd44, Itgb1, Rac1) in the MSCPD-1 + group were identified with at least 10-fold increases.
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Figure 8. Melanoma exosomes promote tumor progression and metastasis formation in vivo. 
(a) Tumor coverage of lungs on day 15 in the three different animal groups. The graph represents mean +SD 
(n = 3). (b) The number of distant metastases on day 25. One dot represents one animal in each group, red lines 
show the average number of metastases per animal. (c) FISH analysis of a paraaortic lymph node metastases, 
which showed the presence of exosome-exposed MSCs. Y chromosome (red dot) of the male mouse-derived 
MSC was detected in the metastases of a female mouse. (d) Heatmap and cluster analysis of the gene expression 
pattern, which show protooncogenic dominance in exosome or MSCPD-1+ groups. Robust hierarchical clustering 
based on fold changes in the gene expression data between the selected groups divide the treated groups into 
several upper classes. Groups treated by exosomes or MSCPD-1+ were compared to untreated controls. Exosomes 
and MSCPD-1+ treatments were closely related. (e) qRT-PCR analysis of PD-1 in the lung samples using TaqMan 
probes (n = 3). (f) The Venn diagram shows possible relations between a finite collection of different sets of genes 
measured during gene expression profiling (see Figure 8d).
41
Furthermore, six genes (Bmi1, Cdk4, Stat3, Kitl, Raf1, Mtor) for the MSCPD-1+ group and eight 
genes (Bmi1, Muc1, Cdk4, Stat3, Kitl, Pik3ca, Mtor, Akt1) for the exosome group showed at 
least two-fold mRNA level elevations. Figure 8d presents a heatmap of overexpressed genes 
induced by exosome exposure.
Moreover, we showed that, besides the above genes, expression of PD-1 was also significantly 
increased in both exosome-related groups (Figure 8e). Notably, although mRNA transcript level 
of PD-1 was close to two-fold in MSCPD-1+ lung tissues in comparison to samples in the exosome 
group, the difference was not significant (most probably due to the large inter-animal variability 
and standard error).
We constructed a Venn-diagram (Figure 8f) to show all possible logical connections between 
the various gene expressions patterns presented in Figure 8d. Importantly, according to cluster 
analysis, we could not identify a single gene which was missing from the exosome-related 
groups in comparison to the control tumor-bearing mice. In other words, whereas the exosome-
related mice exhibited gene expression profiles specific to the group, such individual profiles 
could not be detected in the control group.
Specifically, the following gene expression patterns were defined:
• three genes (Elk1, Rb1, Igta2) were exclusively induced only in the exosome-treated group;
• twenty-three genes (Prom1, Tiam1, Bcl2, Bax, Casp9, Hgf, Jak2, Met, Mapk2k2, Alcam1, 
Eng, Flot2, Itga4, Itga6, Kit, Pecam1, Thy, Cdc42, Casp8, Ets1, Myb, Map2k1, Mapk1) were 
found to be upregulated both in the exosome group and the MSCPD-1+ cell treated group;
• fourteen genes (Bmi1, Cd44, Itgb1, Muc1, Cdk4, Nras, Sat3, Kitl, Raf1, Mtor, Akt1, Mapk3, 
Pik3ca, Rac1) were found to be upregulated in all three groups.
Finally, it should be noted that the dramatic gene expression alterations seen in the exosome-
related groups were exclusively due to the presence of the exosomes as the “MSCPD-1+ only” 
cluster contained no genes (Figure 8f).
Melanoma-derived exosomes promote tumorigenic and cell survival 
signaling pathway(s)
Figure 9 shows the map of interaction pathways based on the overexpressed molecules (red 
symbols) from the in vivo experiments. We detected overexpressed elements from three main 
pathways which participate in tumor progression and metastasis formation (101). 
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Figure 9. An integrated associative network of the in vivo overexpressed genes supplemented with the 
interacting exosomal factors. We created this network of overexpressed genes (red symbols) based on literature 
data. The relationships between molecules were also supported by the IPA knowledge base. Network visualization 
was performed using the Path Explorer tool of the IPA Path Designer. The exosomal proteins and miRNAs 
(grey boxes) were connected to elements of the network by the Grow tool of the IPA Path Designer based on 
experimental data from the IPA knowledge base. Activation of the established network by exosomal components 
may support the survival, migration, growth and metastasis of tumor cells.
Using the IPA Path Designer Grow tool, we generated an interaction map which contains 
proteins (or their established complexes) encoded by the overexpressed genes, and exosomal 
miRNAs and proteins (grey boxes) which were previously shown to control or affect the marked 
signaling molecules.
To demonstrate these results and to identify potential causative exosomal factors, we performed 
an IPA again. The analysis allowed further refinement of the underlying molecular processes 
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and pathways involved in the summarized effect of this gene expression profile. The previously 
described 40-gene qRT-PCR panel is abundant in genes related to cellular movement and 
migration, cell survival and connective tissue development and function, involving tumor 
cells. Additional processes included growth and proliferation of tumor cells as well as the 
PD-1:PD-1L interaction (and its consequences). Focusing on the PD-1 and mTOR pathways, 
a network was built from the overexpressed genes and their complexes known to be related to 
tumor progression using the Path Explorer tool in the IPA Path Designer. After that, a list was 
generated that contained the exosomal proteins detected by MS, and the exosomal miRNAs 
identified by SOLiD sequencing. The Grow tool in the IPA Path Designer revealed significant 
interactions between the exosome-induced expression network and the molecular content of 
these vesicles. The resulting interaction network shows both direct and indirect interactions, 
but it contains only experimentally observed relationships based on the Ingenuity Knowledge 
Base. This network demonstrates that 61 exosomal molecules (Table S5,S6) may affect tumor 
progression through pathways controlled by key components including MET, RAS, RAF1, 
MEK, ERK1/2, MITF, BCL2, PI3K, AKT, mTOR, PD-1, KIT, JAK STAT3 or ETS1.
Taken together, these findings demonstrate that the interaction between exosomes and MSCs 
induces a tumor-like phenotype with PD-1 overexpression of naïve MSCs in vitro and a fast 
tumor progression in vivo.
On the other hand, we investigated the melanoma TME on the attitude of tumor-infiltrating 
immune cells and we demonstrate that bacterial infection may induce a complex anti-tumor 
immune response.
Treatment of immunocompetent mice with C. pneumoniae reduces the 
number of lung metastases and increases survival
To clarify the role of the tumor associated macrophages in the anti-tumor immune mechanisms 
induced by C. pneumoniae, metastatic melanomas were generated in immunocompetent C57BL/6 
mice or immunodeficient NSG mice. B16F1 melanoma cells were administered intravenously to 
6 to 8-week old female immunocompetent C57BL/6 or immunodeficient NSG mice. One week 
after tumor cell administration, the mice were treated with heat-inactivated C. pneumoniae or 
the mock as a negative control. In immunocompetent animals, the number of lung metastases 
significantly decreased (p = 0.003; 3 independent experiments) in the inactivated C. pneumoniae-
treated group vs. mock (Figure 10a). Moreover, the survival of the inactivated C. pneumoniae-
treated mice (Figure 10b) was significantly increased (p = 0.04; 3 independent experiments). 
Importantly, such phenomena were not observed in immunodeficient mice suggesting the anti-
tumor role of the immune response. It is also notable that the treated animals (in either strain) 
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did not have fever (33.2ºC ±1.0 control vs. 34.8ºC ±0.5 treated) which is against the “fever 
hypothesis” (33) according to which the fever induction may be considered as part of a Coley’s 
immunological therapy regimen for cancers.
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Figure 10. C. pneumoniae treatment results in melanoma metastasis regression and increases survival 
of animals. (a) The number of lung metastases and (b) survival rate of mock or C. pneumoniae (C. pn.) treated 
immunocompetent C57BL/6 mice.
C. pneumoniae treatment induces tumor regression and immune cell 
infiltration 
Histological sections of lungs from mock-treated melanoma-bearing immunocompetent 
C57BL/6 mice showed high number of metastases, with frequent intra-tumor necrosis indicating 
high tumor burden and tumor mass replacing the normal lung tissue (Figure 11a). In contrast, 
fewer and smaller foci of regressive metastases (with residual pneumonitis) were observed in 
the C. pneumoniae-treated immunocompetent animals (Figure 11b). Moreover, in this group, a 
high number of tumor infiltrating mononuclear histiocytes and lymphoid cells were identified 
in the regressive metastases compared to mock-treated samples. Notably, in both mock and 
C. pneumoniae-treated immunodeficient NSG mice, the abundant metastases showed mostly 
subpleural and intraparenchymal localization and no significant intratumor immune reactions 
(Figure 11c,d).
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Figure 11. C. pneumoniae treatment induces tumor regression and immune cell infiltration
Representative photos and HE-stained histological sections of dissected lungs of mock (a) and C. pneumoniae 
(b) treated immunocompetent mice as well as of mock (c) and C. pneumoniae (d) treated immunodeficient (NSG) 
animals. Scale bars, 100 µm. (a) Trophical necroses indicating high tumor burden. Insert: atypical tumor cells 
and regions of necrosis. (b) Circles and right insert, foci of regressive metastases, left insert: areas of residual 
pneumonitis after C. pneumoniae treatment. (c, d) In both mock and C. pneumoniae treated NSG mice, military 
metastases were developed subpleurally (arrowheads) and intraparenchymally (circles) without significant 
inflammatory reactions (inserts: higher magnification of intraparenchymal metastases).
The markedly increased immune reaction in the lungs of the C. pneumoniae-treated melanoma-
bearing C57BL/6 mice was also verified by immunolabeling of cell surface activation markers 
CD11b and CD80 (Figure 12). Invasion of immune cells was not detected in the control group where 
the immune cells were chiefly concentrated in the marginal zones of the tumors (Figure 12a,c). 
However, dramatically increased numbers of tumor-infiltrating, activated (i.e. CD11b and CD80 
positive) lymphocytes were detected within the internal tumor stroma of the C. pneumoniae-
treated animals (Figure 12b,d); the differences show high levels of significance in both cases 
(Figure 12e,f). C. pneumoniae treatment induces M1 type macrophage polarization.
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high tumor burden and tumor mass replacing the normal lung tissue (Figure 11a). In contrast, 
fewer and smaller foci of regressive metastases (with residual pneumonitis) were observed in 
the C. pneumoniae-treated immunocompetent animals (Figure 11b). Moreover, in this group, a 
high number of tumor infiltrating mononuclear histiocytes and lymphoid cells were identified 
in the regressive metastases compared to mock-treated samples. Notably, in both mock and 
C. pneumoniae-treated immunodeficient NSG mice, the abundant metastases showed mostly 
subpleural and intraparenchymal localization and no significant intratumor immune reactions 
(Figure 11c,d).
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Figure 12. C. pneumoniae treatment results CD11b+ and CD80+ immune cell infiltration of tumor tissues 
Immunohistochemistry of CD11b (a, b, DAB, brown) and CD80 (c,d, Fast red) on lungs of mock (a, c) or 
C. pneumoniae (b, d) treated C57BL/6 mice. Dashed lines indicate tumor border. (a-d). Intratumoral number of 
CD11b+ (e) and CD80+ (f) cells determined as a ratio of 100 tumor cells. (e, f) Data are expressed as mean + SD.
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The C. pneumoniae treatment induces the macrophage differentiation shift 
toward an M1 phenotype
As a next step, we assessed whether C. pneumoniae treatment induced macrophage polarization. 
To this end, we mapped the cytokine and chemokine transcriptome profiles, characteristics for M1 
(anti-tumor) or M2 (protumor) type macrophages (102,103) of tumor bearing immunocompetent 
mice. M1 and M2 type macrophage markers were detected with qRT-PCR from pooled lung 
samples (3 animals/pool) 2, 4 and 12 hours after mock or C. pneumoniae treatment. qRT-PCR 
was performed using M1 (CCL2, CCL3, CD86, IL-12, IL-6, IL-10, CXCL16, CCL7, CD80, 
CXCL11, CXCL9, IL-23, TNF-α) and M2 type (CD163, CXCL13, TGF-β, IL-1Ra, CD23, 
CCL1, CCL22, IL-4, CCL17, CCL24, CD150, IL-10, CXCL1) markers. Four hours after the 
treatment with C. pneumoniae, markedly increased levels of specific mRNA transcripts for 
CCL2, CCL3, IL-6, CXCL10, CCL7, CD80, CXCL11, CXCL9, IL-23, and TNF-α – markers 
of M1 type macrophage polarization – were detected (Figure 13a). In line with these data, 
mRNA expression of CD163, CCL1, TGF-β, and IL-10 (known M2 type macrophage markers) 
was decreased by the treatment; yet, levels of other important M2 markers (CXCL13, IL-1Ra) 
were increased (Figure 13b). Significantly, statistical analysis revealed that upon C. pneumoniae 
administration, the amount of M1 type cytokine and chemokine-specific mRNA transcripts 
significantly increased (p = 0.014) (Figure 13a) after 4 hours in comparison to M2 type 
macrophage markers (Figure 13b).
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Figure 13. C. pneumoniae treatment induces M1 type macrophage polarization 
(a) Relative alterations in the levels of individual M1 type cytokine/chemokine specific mRNA transcripts in lung 
samples of C. pneumoniae (C. pn.) vs. mock-treated tumor-bearing C57BL/6 mice, as determined by real-time 
PCR. (b) Mean values of relative M2 type cytokine mRNA expressions; at 4 hours after treatment, M1 and M2 
levels are significantly different (two-tailed t-test).
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5. DISCUSSION
It is obvious now that the biology of cancer can no longer be understood simply by specifying the 
traits of the cancer cells. The contribution of the “tumor microenvironment” to tumorigenesis 
must also be incorporated into this understanding. Exosomes produced by tumor cells in the 
TME emerge as a new means of communication operating between cells engaged in supporting 
tumor progression. 
In this study, we aimed to investigate how TME factors influence the pro-metastatic characteristics 
of melanoma. The TME was investigated from two different points of view; first, the aspect 
of tumor, and second, the attitude of tumor infiltrating immune cells. We hypothesized that 
tumor-derived exosomes promote the tumor progression, while the M1 polarization of tumor-
associated macrophages induces tumor regression.
As a first step, we intended to precisely define the EV population which we later used in in 
vitro and in vivo experimental approaches. Besides applying the experimental requirements 
of the International Society for Extracellular Vesicles (ISEV) (i.e. determination of shape, size 
distribution and protein markers) (52), we thoroughly defined the miRNA and protein content 
of melanoma exosomes. Findings of these systematic assays showed us that the isolated vesicles 
contain factors that may regulate signaling pathways related to cell death and survival, cellular 
movement, development and cell proliferation. Given the appropriate uptake of these vesicles 
by the targeted, multipotent recipient cells, it is highly probable that most of these signaling 
pathways are significantly affected. In accordance with previous results in the literature, we 
showed successful internalization of exosomes by recipient MSCs. As expected, following 72 h 
of exposure, MSCs displayed accelerated proliferation presumably initiated by the transforming 
exosome cargo. Moreover, melanoma exosomes were able to hinder the induction of the cell 
death response commonly triggered by TNF-α. TNF-α is a soluble tumor-suppressing factor 
frequently identified in cancerous microenvironments (104). This inhibition strongly suggested 
that exosomes initialize and sustain the malignant transformation of MSCs.
Furthermore, we described numerous, exosome-induced phenotypic manifestations of the 
malignant re-education process in the recipient cells addressed above. Apart from the tumor 
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markers that were identified, the transformation of exposed cells is also characterized by 
considerably modified gene expression patterns. As discussed previously, specific gene expression 
alterations are often associated with specific steps of the cancerous transformation. Altered gene 
expression in malignant cell lines is responsible for apoptotic regulation (BAX, BCL2, caspases), 
regulating metastasis (integrins, ITGA2-6, ITGB1, KIT) or various growth factors (ETS1, HGF, 
MET, etc.). Importantly, we successfully identified two melanoma-specific markers, MITF 
(Microphthalmia-associated transcription factor) and MLANA (Melanoma antigen recognized 
by T-cells), in the exosome-exposed MSCs. MLANA and its regulator MITF play a fundamental 
role in melanocyte development, tumor progression and they were overexpressed in melanoma 
cells (105). The presence of these markers in exosome-exposed MSCs shows effective transfer 
of the encoded tumorigenic information, and this information may have a pivotal role in disease 
progression. In addition, we also identified a characteristic set of genes, which belong mostly to 
proto-oncogenes, whose expression was significantly elevated upon exosome treatment. Among 
these molecules, we highlight the increased expression of CD44, which was previously assigned 
as cancer stem cell marker, and mTOR, a characteristic indicator of the engagement of the 
PD-1:PD-1L pathway (70). Indeed, the activation of mTOR signaling is particularly important. 
As it was previously demonstrated by Kleffel et al., overexpression of PD-1 in exceptionally 
aggressive melanoma subpopulations facilitated tumor progression by activating the mTOR 
signaling pathway (actually, this response was highly unexpected compared to that of the classic 
PD-1:PD-L1 dependent T-cell anergy, a crucial aspect of immunotherapy in the clinics) (70). 
Quite strikingly, in exosome treated MSCs, we detected a significant induction of PD-1 and 
mTOR. These novel data strongly support that these vesicles might trigger the formation of an 
aggressive, melanoma-like subpopulation of re-educated recipient MSCs.
Therefore, our findings indicate that the re-educated melanoma-like MSCPD-1+ subpopulation, 
originating from multipotent tissue-derived MSCs, is an autonomous entity. It is characterized 
by typical properties of cancerous transformation, such as hyperproliferation, resistance to 
apoptosis, expression of melanoma markers, proto-oncogenic gene expression patterns, and 
PD-1 overexpression. Indeed, the melanoma exosomes that induced in vitro generation of the 
melanoma-like MSCPD-1+ cells, also facilitated in vivo metastasis formation in the lungs or other 
distant organs of treated animals. Actually, our finding, which shows that melanoma exosomes 
or exosome-re-educated MSCPD-1+ promote tumor progression, is in good accordance with the 
previous finding of Kleffel et al., which demonstrates that shRNA or antibody mediated inhibition 
of PD-1 signaling inhibits metastasis formation and tumor progression in experimental animals 
(70). Assessment of the expression patterns of genes related to tumor progression in the exposed 
animal tissues revealed numerous cases of exosome-induced overexpression; this supports our 
hypothesis that melanoma exosomes should be considered as oncosomes (57).
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Our results also demonstrate that melanoma exosomes also generated a characteristic signaling 
pattern in the MSCPD-1+ recipient population. As it was shown in numerous studies, PI3K/
AKT, RAS/MAPK, and STAT3 pathways are commonly activated in tumor cells (101,106). 
In this study, based on our in vitro and in vivo results and literature data, we introduced a 
novel, comprehensive network of common tumor-related proteins, such as PD-1, MET, RAF1, 
STAT3, BCL2 or mTOR. The network highlights the relationship of these elements, and also 
contains upstream exosomal regulating factors which may contribute to the activation of 
tumorigenic signaling; thus, fast tumor progression. According to our best knowledge, this 
associative network between overexpressed genes and the potential exosomal inducers, is the 
first tumor progression signaling pattern connecting experimental response patterns with 
experimentally detected exosomal-molecular-patterns. Moreover, our data also indicate that 
the above complexity of exosomal communication requires system-level approaches.
It is important to note that our conclusions are not based on in silico predictions exclusively, 
but rather on carefully designed and systematically executed in vitro and in vivo experiments, 
which all suggest that the specific, robust molecular content of the isolated exosomes can indeed 
generate a unique intercellular niche responsible for the re-education of neighboring cells via 
oncogenic transformation. These re-educated melanoma-like MSCPD-1+ cells, in turn, facilitate 
metastatic disease progression by initiating a complex series of subsequent events both locally 
and systematically. Thus, based on our results and recently published, additional evidences 
about exosomes, there is an urgent demand to supplement and extend the outdated “seed and 
soil” hypothesis regarding the oncosome-driven re-education process.
On the other hand, it is generally accepted that anti-tumor immune effector mechanisms overlap 
with antibacterial immune responses (107). Coley’s hypothesis claims that fever induced by 
infectious agents causes tumor regression, but the exact anti-tumor mechanism induced by 
microbes is not yet understood (108). With respect to anti-tumor mechanisms, it is also known 
that alterations in the polarization patterns of the overall immune system determine the outcome 
of malignant diseases (102). Macrophages are key players of the immune responses whose M1 
type polarization mediates the anti-tumor action of the immune system (102,103).
In this study, we demonstrated that the heat-inactivated bacterial treatment may induce a complex 
anti-tumor immune response. The C. pneumoniae treatment suppressed metastasis formation 
(and hence prolonged survival) in immunocompetent, but not in immunodeficient mice. As 
shown by the cytokine/chemokine profiles, the C. pneumoniae treatment induced M1 type 
macrophage polarization, which, as reported in numerous publications, may exert anti-tumor 
effects (it must be added that the whole spectrum of M1 polarization was not observed) (102). 
The anti-tumor immune polarization/activation was further verified by detecting the profound 
51
enrichment of CD80 and CD11b expressing immune cells in the lungs of C. pneumoniae-treated 
animals. Indeed, it was previously shown that C. pneumoniae, recognized by TLR2 and TLR4, 
upregulates the expression of the immune activation marker CD11b and the costimulatory 
molecules CD40, CD80 and CD86 on macrophages (109).
These data prompted us to hypothesize that the concomitant anti-microbial immune response 
may contribute to the anti-tumor effect.
6. NEW FINDINGS
1. Internalized melanoma-derived exosomes conveying oncogenic molecular reprogramming 
induce the malignant transformation of the recipient MSCs.
2. The melanoma-derived exosomes generate the formation of a melanoma-like, PD-1 
overexpressing cell population (mMSCPD-1+) from naïve mesenchymal stem cells (MSCs).
4. Melanoma-derived exosomes and the re-educated melanoma-like MSCPD-1+ cell population 
induce tumor progression and facilitate metastatic disease via overexpression of oncogenic 
factors in vivo.
5. Bacterial antigen pattern-induced macrophage polarization and complex anti-tumor immune 
response indeed leads to the regression of melanoma metastasis.
7. CONCLUSIONS
We aimed to understand how the tumor microenvironment impacts tumor progression and 
metastatic behavior. Most of the efforts in the past focused on defining intrinsic and extrinsic 
factors involved in tumor progression and metastasis. However, the interpretation of tumor 
evolution and metastasis has shifted and currently, it is widely accepted that extrinsic factors 
are actively involved in cancer progression and regression. To answer this question, we used 
melanoma models to investigate the role of secreted exosomes in tumor microenvironment 
education and pre-metastatic niche formation. In addition, we explored the influence of bacterial 
antigens on macrophage polarization in anti-tumor immune effector mechanisms.
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In this study, we demonstrated that MSCs, widely abundant in solid tumors as well as in 
healthy tissues, undergo a marked re-education process upon communication with metastatic 
cancer cells via exosome-mediated information transfer. This transformation process results in 
characteristic response patterns corresponding to a given cancerous cell line. We (i)  determined 
the cellular and molecular signals involved in the melanoma-derived exosome-induced, malignant 
transformation of MSC culture; (ii) described the melanoma-derived exosome-induced tumor 
progression; (iii) demonstrated the alteration in the expression of PD-1, a melanoma progression 
marker, and therapeutic target, upon exposure to melanoma-derived exosomes. 
Metastasis, a critical phase of melanoma progression, remains a major cause of melanoma 
mortality and primary challenge in therapy. In this study, we highlighted the emerging roles of 
melanoma exosomes as coordinators of PMN formation.
Our experimental data provide compelling evidence for the significant tumor regression 
following the treatment of melanoma lung metastases with the inactivated intracellular pathogen 
C. pneumoniae, and suggest that this microbe may be responsible for tumor regression via the 
induction of anti-tumoral macrophage polarization.
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SUPPLEMENTARY MATERIAL
Figure S1. Kinetics of exosome uptake by MSCs.
(a) Fluorescent images of exosome uptake by MSCs in early timepoints. DiO (green fluorescent lipid dye) and 
Hoechst 33342 (nucleic acid stain)-labeled cells were exposed to Dil (red fluorescent lipid dye)-labeled exosomes 
and were investigated by a Celldiscoverer 7 automated live cell imaging system (Zeiss). Internalization of 
exosomes was visible as early as 40 min after exosome exposure. (b) Fluorescent images of exosome uptake 
by MSCs 24 h after exosome exposure. Images were taken by an Operetta high content screening system. The 
amount of internalized exosomes showed cell to cell variation.
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Figure S2. QRT-PCR analysis of Mlana and Mitf in exosome-exposed MSCs. 
The Mlana and Mitf mRNA levels were determinated by QRT-PCR using a SyberGreen protocol after 24 h and 
72 h of exosome exposure. Results are presented as mean ± SD (n=3).
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Figure S3. Quantification of vessel diameter of tumor-associated blood vessels in melanoma metastases. 
Diameter of vessels significantly increased in the metastases of exosome and MSCPD1+ injected groups of tumor-
bearing mice inside the lung metastases.
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Figure S4. Exosomes and MSCPD-1+ administration-induced cytokine profiles in the lung tissues of tumor-
bearing mice. (a) cytokine array panels of the lung tissue lysates, cytokines with elevated levels are marked. 
(b) bar graph shows the fold increase values of cytokines for both groups compared to the ctrl one. Data were 
obtained by densitometry.
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Table S1. Treatment schedule of animals
Group B16F1 Control buffer MSCPD-1+ i.v. B16F1 exosome i.v.
ctrl + + - -
MSCPD-1+ + - + -
exosome + - - +
Table S2. Mlana and Mitf primers used in QRT-PCR 
Gene name Symbol Ref. seq. ID Forward primer  sequence
Reverse primer  
sequence
melan-A Mlana NM_029993.1 ggtcctggggattgctct caatatgacgccttttgtcca
microphthalmia-associated 
transcription factor Mitf NM_008601.3 ctaagtggtctgcggtgtctc ggttttccaggtgggtctg
Primers were designed using the online Roche Universal Probe Library Assay Design Center. The quality of the primers was verified by 
MS analysis provided by Bioneer (Daejeon, Korea).
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Table S3. List of exosomal proteins identified by LC-MSMS
ID Symbol Entrez Gene Name
P97857 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif 1
Q3TNX8 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1 motif 4
Q640N1 AEBP1 AE binding protein 1
P05064 ALDOA aldolase, fructose-bisphosphate A
P97429 ANXA4 annexin A4
P48036 ANXA5 annexin A5
P08226 APOE apolipoprotein E
Q3TWT5 ASAH1 N-acylsphingosine amidohydrolase 1
Q3TXF9 ATP1A1 ATPase Na+/K+ transporting subunit alpha 1
P97370 ATP1B3 ATPase Na+/K+ transporting subunit beta 3
Q1XID4 ATP6AP2 ATPase H+ transporting accessory protein 2
Q9JL18 BACE2 beta-site APP-cleaving enzyme 2
O55107 BSG basigin (Ok blood group)
Q8R2Q8 Bst2 bone marrow stromal cell antigen 2
Q9WVT6 CA14 carbonic anhydrase 14
P41731 CD63 CD63 molecule
P35762 CD81 CD81 molecule
P10605 CTSB cathepsin B
P18242 CTSD cathepsin D
P29812 DCT dopachrome tautomerase
P57776 EEF1D eukaryotic translation elongation factor 1 delta
Q3UAM9 ENG endoglin
P17182 ENO1 enolase 1
P19096 FASN fatty acid synthase
P30416 FKBP4 FK506 binding protein 4
P11276 FN1 fibronectin 1
P09528 FTH1 ferritin heavy chain 1
P16858 GAPDH glyceraldehyde-3-phosphate dehydrogenase
P08752 GNAI2 G protein subunit alpha i2
Q3TAV1 GPNMB glycoprotein nmb
P19157 GSTP1 glutathione S-transferase pi 1
P11499 HSP90AB1 heat shock protein 90 alpha family class B member 1
B1B0C7 HSPG2 heparan sulfate proteoglycan 2
Q9CQW9 IFITM3 interferon induced transmembrane protein 3
G3UYZ1 IGSF8 immunoglobulin superfamily member 8
Q91VK4 ITM2C integral membrane protein 2C
P02468 LAMC1 laminin subunit gamma 1
Q60961 LAPTM4A lysosomal protein transmembrane 4 alpha
P35951 LDLR low density lipoprotein receptor
Q07797 LGALS3BP galectin 3 binding protein
Q3U2W5 LGALS8 galectin 8
P16056 MET MET proto-oncogene, receptor tyrosine kinase
P21956 MFGE8 milk fat globule-EGF factor 8 protein
Q2TA50 MLANA melan-A
Q6NVG5 MREG melanoregulin
Q9EPX2 PAPLN papilin, proteoglycan like sulfated glycoprotein
Q3UIP2 PCOLCE procollagen C-endopeptidase enhancer
Q811J2 LOC72520 LOC72520 protein
Continued
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Table S3. Continued
ID Symbol Entrez Gene Name
Q80Y09 PDCD6IP programmed cell death 6 interacting protein
P62962 PFN1 profilin 1
P09411 PGK1 phosphoglycerate kinase 1
P52480 PKM pyruvate kinase, muscle
Q9CZB2 PMEL premelanosome protein
P17742 PPIA peptidylprolyl isomerase A
P35700 PRDX1 peroxiredoxin 1
Q61171 PRDX2 peroxiredoxin 2
Q543S0 PRELP proline and arginine rich end leucine rich repeat protein
P53994 RAB2A RAB2A, member RAS oncogene family
Q8CCG5 RALB RAS like proto-oncogene B
O89086 RBM3 RNA binding motif (RNP1, RRM) protein 3
P35980 RPL18 ribosomal protein L18
Q3U5P4 SCPEP1 serine carboxypeptidase 1
O08992 SDCBP syndecan binding protein
Q0VGP2 SEMA3B semaphorin 3B
P32261 SERPINC1 serpin family C member 1
P10852 SLC3A2 solute carrier family 3 member 2
Q3UQM7 SLC7A5 solute carrier family 7 member 5
O09044 SNAP23 synaptosome associated protein 23
Q64337 SQSTM1 sequestosome 1
Q8CI59 STEAP3 STEAP3 metalloreductase
Q3TDG9 STX12 syntaxin 12
O70439 STX7 syntaxin 7
P40749 SYT4 synaptotagmin 4
O88968 TCN2 transcobalamin 2
Q542D9 TFRC transferrin receptor
P39876 TIMP3 TIMP metallopeptidase inhibitor 3
Q4FJX7 TINAGL1 tubulointerstitial nephritis antigen like 1
Q9DCS1 TMEM176A transmembrane protein 176A
Q9R1Q6 TMEM176B transmembrane protein 176B
Q9CZX7 TMEM55A transmembrane protein 55A
Q9QY73 TMEM59 transmembrane protein 59
O88746 TOM1 target of myb1 membrane trafficking protein
O89023 TPP1 tripeptidyl peptidase 1
Q3UCW0 TSG101 tumor susceptibility 101
Q4FJW7 TSPAN4 tetraspanin 4
Q8BJU2 TSPAN9 tetraspanin 9
P11344 TYR tyrosinase
P07147 TYRP1 tyrosinase related protein 1
O70404 VAMP8 vesicle associated membrane protein 8
Q8R0J7 VPS37B VPS37B, ESCRT-I subunit
Q8R105 VPS37C VPS37C, ESCRT-I subunit
O88384 VTI1B vesicle transport through interaction with t-SNAREs 1B
A8DUQ1 HBBT1 beta-globin
P70356 MELA Gag-pol poliprotein
P70355 MELA envelope protein
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Table S4. List of exosomal miRNAs identified by SOLiD 5500xl technology
Symbol Seed regio ID Symbol Seed regio ID
let-7a-3p UAUACAA mmu-let-7a-1-3p miR-146a-5p GAGAACU mmu-mir-146a-5p
mmu-let-7b-3p miR-148a-3p CAGUGCA mmu-mir-148b-3p
mmu-let-7c-2-3p miR-151-3p UAGACUG mmu-mir-151-3p
mmu-let-7f-1-3p miR-15a-3p AGGCCAU mmu-mir-15a-3p
let-7a-5p GAGGUAG mmu-let-7a-5p mmu-mir-15b-5p
mmu-let-7b-5p mmu-mir-16-5p
mmu-let-7c-5p mmu-mir-195a-5p
mmu-let-7d-5p mmu-mir-322-5p
mmu-let-7e-5p mmu-mir-497a-5p
mmu-let-7f-5p miR-17-3p CUGCAGU mmu-mir-17-3p
mmu-let-7g-5p miR-17-5p AAAGUGC mmu-mir-106b-5p
mmu-mir-98-5p mmu-mir-17-5p
let-7d-3p UAUACGA mmu-let-7d-3p mmu-mir-20a-5p
let-7i-3p UGCGCAA mmu-let-7i-3p mmu-mir-93-5p
miR-100-5p ACCCGUA mmu-mir-99a-5p miR-181a-1-3p CCAUCGA mmu-mir-181a-1-3p
mmu-mir-99b-5p miR-181a-5p ACAUUCA mmu-mir-181a-5p
miR-101-3p ACAGUAC mmu-mir-101a-3p mmu-mir-181b-5p
miR-103-1-5p GCUUCUU mmu-mir-107-5p mmu-mir-181c-5p
miR-103-3p GCAGCAU mmu-mir-103-3p mmu-mir-181d-5p
mmu-mir-107-3p miR-1827 GAGGCAG mmu-mir-709
miR-10a-5p ACCCUGU mmu-mir-10a-5p miR-1839-3p GACCUAC mmu-mir-1839-3p
mmu-mir-10b-5p miR-185-5p GGAGAGA mmu-mir-185-5p
miR-1191a AGUCUUA mmu-mir-1191a miR-186-5p AAAGAAU mmu-mir-186-5p
miR-1249-3p CGCCCUU mmu-mir-1249-3p miR-187-3p CGUGUCU mmu-mir-187-3p
miR-125b-5p CCCUGAG mmu-mir-125a-5p miR-188-3p UCCCACA mmu-mir-188-3p
mmu-mir-125b-5p miR-188-5p AUCCCUU mmu-mir-188-5p
mmu-mir-351-5p miR-18a-5p AAGGUGC mmu-mir-18a-5p
miR-126a-5p AUUAUUA mmu-mir-126a-5p miR-191-5p AACGGAA mmu-mir-191-5p
miR-128-3p CACAGUG mmu-mir-128-3p miR-193a-3p ACUGGCC mmu-mir-193a-3p
miR-129-1-3p AGCCCUU mmu-mir-129-1-3p miR-1981-3p AUCUAAC mmu-mir-1981-3p
mmu-mir-129-2-3p miR-199a-3p CAGUAGU mmu-mir-199a-3p
miR-129b-5p CUUUUUG mmu-mir-129b-5p mmu-mir-199b-3p
miR-130a-3p AGUGCAA mmu-mir-130a-3p miR-199a-5p CCAGUGU mmu-mir-199a-5p
mmu-mir-130b-3p mmu-mir-199b-5p
mmu-mir-301a-3p miR-19b-3p GUGCAAA mmu-mir-19a-3p
mmu-mir-301b-3p mmu-mir-19b-3p
miR-130a-5p CUCUUUU mmu-mir-130a-5p miR-204-5p UCCCUUU mmu-mir-211-5p
miR-130b-5p CUCUUUC mmu-mir-130b-5p miR-21-5p AGCUUAU mmu-mir-21a-5p
miR-132-3p AACAGUC mmu-mir-132-3p miR-210-3p UGUGCGU mmu-mir-210-3p
miR-132-5p ACCGUGG mmu-mir-132-5p miR-210-5p GCCACUG mmu-mir-210-5p
miR-135a-5p AUGGCUU mmu-mir-135a-5p miR-219a-5p GAUUGUC mmu-mir-219a-5p
miR-138-5p GCUGGUG mmu-mir-138-5p miR-22-3p AGCUGCC mmu-mir-22-3p
miR-139-5p CUACAGU mmu-mir-139-5p miR-22-5p GUUCUUC mmu-mir-22-5p
miR-140-3p ACCACAG mmu-mir-140-3p miR-221-3p GCUACAU mmu-mir-222-3p
miR-140-5p AGUGGUU mmu-mir-140-5p miR-223-3p GUCAGUU mmu-mir-223-3p
miR-142-3p GUAGUGU mmu-mir-142a-3p miR-224-5p AAGUCAC mmu-mir-224-5p
miR-143-5p mmu-mir-143-5p miR-23a-3p UCACAUU mmu-mir-23a-3p
miR-144-3p ACAGUAU mmu-mir-144-3p mmu-mir-23b-3p
miR-144-5p GAUAUC mmu-mir-144-5p miR-24-1-5p UGCCUAC mmu-mir-24-2-5p
miR-24-3p GGCUCAG mmu-mir-24-3p
miR-145-5p UCCAGUU mmu-mir-145a-5p miR-24-1-5p UGCCUAC mmu-mir-24-2-5p
Continued
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Table S4. Continued
Symbol Seed regio ID Symbol Seed regio ID
miR-24-3p GGCUCAG mmu-mir-24-3p miR-34a-5p GGCAGUG mmu-mir-34a-5p
miR-26a-5p UCAAGUA mmu-mir-26a-5p mmu-mir-34b-5p
miR-26a-5p UCAAGUA mmu-mir-26a-5p mmu-mir-34c-5p
mmu-mir-26b-5p miR-350 UCACAAA mmu-mir-350-3p
miR-27a-3p UCACAGU mmu-mir-27a-3p miR-361-5p UAUCAGA mmu-mir-361-5p
mmu-mir-27b-3p miR-362-5p AUCCUUG mmu-mir-362-5p
miR-29a-5p CUGAUUU mmu-mir-29a-5p miR-374b-5p UAUAAUA mmu-mir-374b-5p
miR-29b-1-5p CUGGUUU mmu-mir-29b-1-5p miR-378a-3p CUGGACU mmu-mir-378a-3p
miR-29b-3p AGCACCA mmu-mir-29a-3p mmu-mir-378c
mmu-mir-29b-3p miR-378a-5p UCCUGAC mmu-mir-378a-5p
mmu-mir-29c-3p miR-3909 GUCCUCU mmu-mir-877-3p
miR-3065-5p CAACAAA mmu-mir-3065-5p miR-423-3p GCUCGGU mmu-mir-423-3p
miR-30c-5p GUAAACA mmu-mir-30a-5p miR-423-5p GAGGGGC mmu-mir-423-5p
mmu-mir-30b-5p miR-425-5p AUGACAC mmu-mir-425-5p
mmu-mir-30c-5p miR-451a AACCGUU mmu-mir-451a
mmu-mir-30d-5p miR-501-5p AUCCUUU mmu-mir-501-5p
mmu-mir-30e-5p miR-503-5p AGCAGCG mmu-mir-503-5p
miR-31-3p GCUAUGC mmu-mir-31-3p miR-532-5p AUGCCUU mmu-mir-532-5p
miR-31-5p GGCAAGA mmu-mir-31-5p miR-542-3p GUGACAG mmu-mir-542-3p
miR-3176 CUGGCCU mmu-mir-378d miR-574-5p GAGUGUG mmu-mir-574-5p
miR-324-5p GCAUCCC mmu-mir-324-5p miR-582-5p UACAGUU mmu-mir-582-5p
miR-328-3p UGGCCCU mmu-mir-328-3p miR-652-3p AUGGCGC mmu-mir-652-3p
miR-329-3p ACACACC mmu-mir-362-3p miR-670-5p UCCCUGA mmu-mir-670-5p
miR-33-5p UGCAUUG mmu-mir-33-5p miR-700-5p AAGGCUC mmu-mir-700-5p
miR-330-5p CUCUGGG mmu-mir-326-3p miR-744-3p UGUUGCC mmu-mir-744-3p
miR-331-3p CCCCUGG mmu-mir-331-3p miR-744-5p mmu-mir-744-5p
miR-339-5p CCCUGUC mmu-mir-339-5p miR-7a-5p GGAAGAC mmu-mir-7a-5p
miR-340-3p CCGUCUC mmu-mir-340-3p miR-872-3p GAACUAU mmu-mir-872-3p
miR-344a-5p CAGGCUC mmu-mir-484 miR-872-5p AGGUUAC mmu-mir-872-5p
miR-345-5p CUGACCC mmu-mir-345-5p miR-9-5p CUUUGGU mmu-mir-9-5p
miR-3473b GGCUGGA mmu-mir-3473b miR-92a-3p AUUGCAC mmu-mir-25-3p
mmu-mir-3473e mmu-mir-32-5p
miR-34c-3p AUCACUA mmu-mir-34b-3p mmu-mir-92a-3p
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Table S5. List of exosomal proteins connected to the integrated associative network by IPA Path Designer 
ID Symbol Entrez Gene Name
Q640N1 AEBP1 AE binding protein 1
P48036 ANXA5 annexin A5
P08226 APOE apolipoprotein E
Q3TWT5 ASAH1 N-acylsphingosine amidohydrolase 1
Q3TXF9 ATP1A1 ATPase Na+/K+ transporting subunit alpha 1
O55107 BSG basigin (Ok blood group)
Q9WVT6 CA14 carbonic anhydrase 14
P41731 CD63 CD63 molecule
P35762 CD81 CD81 molecule
P29812 DCT dopachrome tautomerase
Q3UAM9 ENG endoglin
P17182 ENO1 enolase 1
P19096 FASN fatty acid synthase
P11276 FN1 fibronectin 1
P09528 FTH1 ferritin heavy chain 1
P16858 GAPDH glyceraldehyde-3-phosphate dehydrogenase
P08752 GNAI2 G protein subunit alpha i2
Q3TAV1 GPNMB glycoprotein nmb
P19157 GSTP1 glutathione S-transferase pi 1
P11499 HSP90AB1 heat shock protein 90 alpha family class B member 1
B1B0C7 HSPG2 heparan sulfate proteoglycan 2
P02468 LAMC1 laminin subunit gamma 1
Q3U2W5 LGALS8 galectin 8
P21956 MFGE8 milk fat globule-EGF factor 8 protein
P62962 PFN1 profilin 1
P52480 PKM pyruvate kinase, muscle
P17742 PPIA peptidylprolyl isomerase A
Q61171 PRDX2 peroxiredoxin 2
Q8CCG5 RALB RAS like proto-oncogene B
O08992 SDCBP syndecan binding protein
Q0VGP2 SEMA3B semaphorin 3B
P10852 SLC3A2 solute carrier family 3 member 2
Q3UQM7 SLC7A5 solute carrier family 7 member 5
O09044 SNAP23 synaptosome associated protein 23
Q64337 SQSTM1 sequestosome 1
Q542D9 TFRC transferrin receptor
P39876 TIMP3 TIMP metallopeptidase inhibitor 3
Q9R1Q6 TMEM176B transmembrane protein 176B
Q3UCW0 TSG101 tumor susceptibility 101
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Table S6. List of exosomal miRNAs connected to the integrated associative network by IPA Path Designer 
Symbol Seed regio ID
let-7a-3p UAUACAA mmu-let-7a-1-3p, mmu-let-7b-3p
mmu-let-7c-2-3p, mmu-let-7f-1-3p
let-7a-5p GAGGUAG mmu-let-7a-5p, mmu-let-7b-5p
mmu-let-7c-5p, mmu-let-7d-5p
mmu-let-7e-5p, mmu-let-7f-5p
mmu-let-7g-5p, mmu-mir-98-5p
miR-100-5p ACCCGUA mmu-mir-99a-5p, mmu-mir-99b-5p
miR-125b-5p CCCUGAG mmu-mir-125a-5p, mmu-mir-125b-5p
mmu-mir-351-5p
miR-126a-5p AUUAUUA mmu-mir-126a-5p
miR-139-5p CUACAGU mmu-mir-139-5p
miR-16-5p AGCAGCA mmu-mir-15a-5p, mmu-mir-15b-5p
mmu-mir-16-5p, mmu-mir-195a-5p
mmu-mir-322-5p, mmu-mir-497a-5p
miR-17-5p AAAGUGC mmu-mir-106b-5p, mmu-mir-17-5p
mmu-mir-20a-5p, mmu-mir-93-5p
miR-181a-5p ACAUUCA mmu-mir-181a-5p, mmu-mir-181b-5p
mmu-mir-181c-5p, mmu-mir-181d-5p
miR-18a-5p AAGGUGC mmu-mir-18a-5p
miR-193a-3p ACUGGCC mmu-mir-193a-3p
miR-199a-3p CAGUAGU mmu-mir-199a-3p, mmu-mir-199b-3p
miR-199a-5p CCAGUGU mmu-mir-199a-5p, mmu-mir-199b-5p
miR-19b-3p GUGCAAA mmu-mir-19a-3p, 
mmu-mir-19b-3p
miR-21-5p AGCUUAU mmu-mir-21a-5p
miR-221-3p GCUACAU mmu-mir-222-3p
miR-223-3p GUCAGUU mmu-mir-223-3p
miR-23a-3p UCACAUU mmu-mir-23a-3p
mmu-mir-23b-3p
miR-30c-5p GUAAACA mmu-mir-30a-5p
mmu-mir-30b-5p
mmu-mir-30c-5p
mmu-mir-30d-5p
mmu-mir-30e-5p
miR-330-5p CUCUGGG mmu-mir-326-3p
miR-34a-5p GGCAGUG mmu-mir-34a-5p
mmu-mir-34b-5p
mmu-mir-34c-5p
miR-7a-5p GGAAGAC mmu-mir-7a-5p
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Recently, it has been described that programmed cell death protein 1 (PD-1)
overexpressing melanoma cells are highly aggressive. However, until now it has not been
defined which factors lead to the generation of PD-1 overexpressing subpopulations.
Here, we present that melanoma-derived exosomes, conveying oncogenic molecular
reprogramming, induce the formation of a melanoma-like, PD-1 overexpressing cell
population (mMSCPD-1+) from naïve mesenchymal stem cells (MSCs). Exosomes and
mMSCPD-1+ cells induce tumor progression and expression of oncogenic factors
in vivo. Finally, we revealed a characteristic, tumorigenic signaling network combining
the upregulated molecules (e.g., PD-1, MET, RAF1, BCL2, MTOR) and their upstream
exosomal regulating proteins and miRNAs. Our study highlights the complexity of
exosomal communication during tumor progression and contributes to the detailed
understanding of metastatic processes.
Keywords: PD-1, exosome, melanoma/tumor progression, stem cell, reprogramming, signalization pattern,
metastasis
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INTRODUCTION
Heterogeneous tumor tissue is comprised of a wide variety
of collocated cells. Their spatiotemporal co-existence facilitates
direct communication between them. Cancer cells contribute to
tumor niche formation not only by soluble factor production
and receptor-ligand interactions (1), but also by releasing vesicles
whose molecular contents add up to a complex information
package. Previous studies demonstrated that cultured human
tumor cells release extracellular vesicles such as exosomes of 20–
120 nm diameters (2). Among others, exosomes carry structural
and signaling proteins, MHC molecules, cell surface molecules
typically associated with apoptosis, and mRNAs/miRNAs with
multiple functions (3). Therefore, these exosomal-molecular-
patterns, as unique entities of the complex intercellular
communication, are not independent of the quality or state of
the mother cell (4, 5). Exosomes have been recognized long ago,
but their identification, characterization, and isolation are still
under intense investigation. Further, whereas the definition of
exosomes is based on the pathway of biogenesis, oncosomes form
a functional class of extracellular vesicles. Indeed, oncosomes are
suggested being capable of carrying and conveying tumor-related
information (6) and might have a significant role in formation of
tumor microenvironment (7).
Mesenchymal stem cells (MSCs) were first described as
stromal cells of the bonemarrow withmultipotent differentiation
potential and characteristic immunomodulatory effects (8). In
relation to their immunological and differentiation properties,
there is a debate about the role of MSCs in tumor progression (9).
Indeed, the cellular fate could depend on the cancer type and also
on the status of the affected MSCs. Activated MSCs can secrete
pro-angiogenic soluble factors and are able to differentiate to
vessel wall associated cells (10) or to cancer associated fibroblasts
(CAFs) (11). Furthermore, Baglio et al. showed that tumor
secreted extracellular vesicles promote osteosarcoma progression
via TGFβ signaling induced IL-6 production by MSCs (12).
Moreover, Peinado et al. demonstrated that exosomes from
highly metastatic melanomas increase the metastatic behavior
of primary tumors by permanently educating bone marrow
progenitors through the receptor tyrosine kinase MET (13).
Malignant melanoma is a highly invasive, metastatic cancer
with poor prognosis and survival rate. Since melanoma has been
long recognized as a highly immunogenic tumor, therapeutic
approaches target different immunological mechanisms to treat
patients with this aggressive skin cancer. In the past decade,
besides IL-2 and CTLA-4 therapies, the PD-1:PD-L1 blockade
proved to be an effective treatment in metastatic melanoma
(14). Programmed cell death protein 1 (PD-1), mainly expressed
by immune cells such as activated T cells, dendritic cells and
macrophages is a cell surface receptor with a central role in
modulation of T cell responses. PD-1 binding to its ligand,
PD-L1, can result in apoptosis and anergy of immune cells.
Notably, PD-1 expression is not a default property of
melanoma cells. Of further importance, recently Kleffel
et al. demonstrated that PD-1 overexpressing melanoma cell
subpopulations are especially aggressive, and that melanoma
PD-1:PD-L1 interactions modulate mTOR signaling, whereby
they interfere with programmed cell death (15). This work
is remarkably instrumental with respect to the consequences
of PD-1 overexpression and experimental inhibition of PD-1
functions (Pdcd1-shRNA or anti-PD-1 antibody). However,
it does not define the factors the activation of which lead to
the generation of PD-1 overexpressing subpopulations. This
question, though, is an especially intriguing one, if one considers
that one of the most effective immunotherapies available today
is based on the blockade of the aforementioned PD-1:PD-L1
interaction (16).
Based on the above, in the current study, we
aimed at specifically and systematically addressing the
following questions:
1. Can we unambiguously define the cellular and molecular
signs of melanoma-derived exosome-induced, intercellular
communication-mediated malignant transformation of
MSC cultures?
2. Can we detect the melanoma-derived exosome-induced
tumor progression in vivo?
3. What alteration can be detected in the expression of PD-1, a
melanoma progression marker and therapeutic target, upon
exposure to melanoma-derived exosomes?
Here, we present the first piece of evidence that melanoma
exosomes, by conveying a complex oncogenic molecular
reprogramming, induce the formation of a PD-1 overexpressing
cell population (melanoma-like MSCPD-1+; mMSCPD-1+)
from naïve MSCs. These mMSCPD-1+ cells represent a
new entity with melanoma-like gene expression profile and
phenotypic properties. Further, exosomes and exosome-
activated mMSCPD-1+ cells induce rapid tumor progression in
vivo, due to their strong expression of oncogenic dominance
factors and decreased susceptibility to programmed cell death.
MATERIALS AND METHODS
Cell Culture and Cell Line
B16F1 mouse melanoma cell line was obtained from ECACC
and cultured in Dulbecco’s modified Eagle’s medium (DMEM,
Lonza, Basel, Switzerland) containing 10% fetal bovine serum
(FBS) (Euroclone, Milano, Italy), 1% sodium pyruvate, 1% MEM
non-essential amino acids, 1% MEM vitamin solution, 2mM
L-glutamine, and 1% Penicillin-Streptomycin-Amphotericin B
Mixture (all from Lonza).
Murine MSCs were isolated from C57BL/6N (Charles River
Laboratories, Sulzfeld) 8 week-old male mice (17). Abdominal
inguinal fat pads were excised, rinsed with RPMI 1640 medium,
transferred to sterile tissue culture dishes and mechanically
dissociated. The dissociated tissue was resuspended in RPMI
1640 containing 100µg/ml collagenase (Sigma-Aldrich, St. Louis,
MO) and incubated at 37◦C for 50min. Collagenase was
neutralized with a growth medium containing 10% FBS. After
centrifugation at 470 g for 15min, cell pellets were resuspended
and washed in the culture medium. After the centrifugation,
cell pellets were resuspended in complete MesenCult medium
(Stemcell Technologies, Vancouver, British Columbia, Canada)
and filtered through a 100µm cell strainer (BD Biosciences,
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Franklin Lakes, NJ) to tissue culture dishes, and cultured for 48 h
at 37◦C in 5% CO2 and 90% humidity. Unattached cells and
debris were then removed and fresh medium was added to the
adherent cells. The cells were cultured to 80% confluence before
being released with trypsin–EDTA and sub-cultured.
Purity of MSC cultures were checked by flow cytometry
analysis using the Mouse Multipotent Mesenchymal Stromal
Cell Marker Antibody Panel (R&D Systems, Minneapolis, MN)
according to the manufacturer’s instructions.
Isolation and Characterization of the
Melanoma-Derived Exosomes
Exosome Isolation by Filtration and Differential
Centrifugation
Exosomes were isolated by adapting the protocol of Peinado
et al. (13) from melanoma cell culture supernatant. B16F1
supernatants were harvested, supplemented by complete protease
inhibitor cocktail (Roche, Mannheim, Germany) and centrifuged
at 780 g for 5min at 4◦C to remove intact cells. Then, the
supernatants were centrifuged at 3,900 g for 15min at 4◦C and
filtered through a 0.2µm membrane (Millipore, Billerica, MA)
to remove larger cell fragments and microvesicles. Exosomes
were pelleted by ultracentrifugation at 150,000 g (T-1270 rotor
at 40,500 rpm) for 1 h at 4◦C. The pellet was washed twice and
resuspended in DPBS and stored at−80◦C.
The concentration of exosomal proteins was determined
using a Pierce BCA Protein assay kit (Thermo Fisher Scientific,
Waltham, MA) and a Benchmark Microplate Reader (Bio-Rad,
Hercules, CA) according to the manufacturer’s instructions.
Determination of Shape and Size of the Isolated
Vesicles
Scanning electron microscopy (SEM)
Five microliters of isolated exosomes in DPBS were spotted
on glass coverslips coated with 0.01% Poly-L-Lysine (Sigma-
Aldrich) and incubated overnight at 4◦C. Using sterile forceps,
coverslips were transferred into a plastic plate. Exosomes were
fixed by gently adding 2% paraformaldehyde buffer pH 7.2
diluted in DPBS for 30min. The coverslips were washed twice
with DPBS and dehydrated with a graded ethanol series (40,
60, 80, and 100% ethanol, each for 5min). The samples were
dried with a critical point dryer (QUORUM K850, Quorum
Technologies Ltd, Laughton, UK) and the coverslips were
mounted onto a microscope stub at a time using carbon tape,
followed by 7 nm gold coating (QUORUM Q150, Quorum
Technologies Ltd) and observed under a field-emission scanning
electron microscope (JEOL JSM-7100F/LV).
Atomic force microscopy (AFM)
Exosomes were let to adsorb to the freshly cleaved muscovite
mica (SPI-ChemTM Mica Sheets, Structure Probe, Inc., West
Chester, PA) surface directly fromDPBS. All AFMmeasurements
were carried out with an Asylum MFP-3D head and Molecular
Force Probe Controller (Asylum Research, Santa Barbara, CA),
using Asylum Research MFP-3D program (version 15.09.112)
written in Igor Pro software (version 6.37, Wavemetrics, Lake
Oswego, OR). Image procession and data calculation were made
using the same software. Silicon rectangular cantilevers (OMLC-
AC240TS, Olympus Optical Co., Ltd., Tokyo, Japan) with the
typical spring constant of 2 N/m were used in dry condition and
silicon nitride rectangular cantilevers with “V” shaped tips (Bio-
Lever BL-RC150VB, Olympus Optical Co. Ltd.) with the typical
spring constant of 0.03 N/m in buffer solution. Typically, 512
× 512 points was taken at 1 line/s scan rate. The measurements
presented here are amplitude images and height profile.
Detection of Exosomal Markers by Western Blotting
Protein samples were resuspended in 4x sample buffer (NuPAGE
LDS Sample Buffer (4X), NuPAGE Sample Reducing Agent
(10X), Thermo Fisher Scientific), boiled at 96◦C for 10min,
and immediately cooled on ice. Electrophoresis of the proteins
was performed using 4–12% Bis-Tris Protein Gels (NuPAGE
Novex, Thermo Fisher Scientific), ProSieve Color Protein
Markers (Lonza), and electrophoresis buffer (NuPAGE MOPS
SDS Running Buffer, Thermo Fisher Scientific) at 200V and
0.03A for 40 min.
The proteins of electrophoresed gels were transferred to
Immobilon transfermembrane (Millipore, Darmstadt, Germany)
using transfer buffer [NuPAGE Transfer Buffer (20X)] at 30V
and 170–110mA for 60min. Membranes were blocked in TBST
buffer (25mM Tris-HCl, 150mM NaCl, 0.05% Tween-20, pH
7.2) containing 5% non-fat milk for 60min at room temperature
(RT). After blocking, membranes were incubated with each
primary antibody in TBST buffer containing 1% non-fat milk
overnight at 4◦C.Membranes were washed three times for 10min
with TBST buffer and incubated for 60min at room temperature
with secondary antibody in TBST buffer containing 1% non-
fat milk. Membranes were washed three times for 10min with
TBST buffer.
For exosomal marker identification western blot analyses
were performed with an anti-CD63 polyclonal antibody (1:250
dilution; Biorbyt, Cambridge, UK) anti-CD9 monoclonal
antibody (clone EPR2949, 1:500 dilution, LifeSpan Biosciences,
Seattle, WA), anti-CD81 monoclonal antibody (clone: EAT2,
1:1,000 dilution, LifeSpan Biosciences, Seattle, WA), and
anti-HSP70 monoclonal antibody (clone: C92F3A-5, 1:8,000
dilution; Enzo Life Sciences, Farmingdale, NY), anti-rabbit IgG
HRP-Conjugated antibody (1:1,000 dilution, R&D Systems),
anti-Hamster IgG HRP-Conjugated antibody (1:30,000 dilution,
Thermo Fisher Scientific). Bound antibodies were visualized
by chemiluminescence using an ECL Plus Western Blotting
detection system (Advansta, Menlo Park, CA). Immunoreactive
signals were detected by using LI-CORODYSSEY Fc (Dual-mode
imaging system) imager followed by analysis with Odyssey v1.2,
Image Studio Lite v5.2.
Identification of Exosomal Proteins by Mass
Spectrometry
Exosomal proteins (24 µg) were separated in 4–12% Bis-Tris
Protein Gels and stained with Coomassie blue (0.1% Coomassie
Brilliant Blue R-250, 50% methanol and 10% acetic acid).
Each lane was cut to 12–12 equal bands and subjected to in-
gel digestion. Gel bands were diced to smaller pieces, and the
SDS and CBB dyes were washed out with 3 × 50 µl 25mM
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ammonium-bicarbonate (ABC)/50% Acetonitrile (AcN). After
reduction with DTT (1,4-dithiothreitol, Sigma-Aldrich; 20 µl,
10mM DTT in 25mM ABC) at 56◦C for 30min, and alkylation
with IAM (iodoacetamide, Sigma- Aldrich; 20 µl, 55mM IAM
in 25mM ABC) at RT in the dark for 30min, the gel samples
were dried in a vacuum centrifuge and after that rehydrated in
20 µl of trypsin (Sequencing Grade Modified Trypsin, Promega,
Fitchburg, WI; 5 ng/µl in 25mM ABC) and incubated at 37◦C.
The digestion was stopped after 4 h by lowering the pH of the
buffer below 3, by adding 2 µl of 10% formic acid. Tryptic
peptides were extracted from the gel with 3 × 50 µl of 2%
formic acid in 50% AcN and dried. Prior mass spectrometric
analysis, all samples were redissolved in 50–50 µl of 0.1%
formic acid (FA).
Samples were analyzed on an LTQ-Orbitrap Elite (Thermo
Fisher Scientific) mass spectrometer on-line coupled with a
nanoHPLC (nanoAcquity, Waters, Milford, MA) system. 5–5 µl
of the in-gel digests were loaded (for 3min at 8 µl/min flow,
using 0.1% FA in 3% Acetonitrile−97% water) onto a reversed
phase trap column (Waters, Symmetry C18, 0.180 × 20mm)
and separated on a C18 reversed phase (Waters, Milford, MA,
BEH300C18 1.7µm) nanocolumn (0.075 × 200mm). The flow
rate was 330 nl/min and a linear gradient was used from 3 to 40%
B in 37min (solvent A was 0.1% FA in water and solvent B was
0.1% FA in Acetonitrile).
The high voltage (1.2 kV) was applied through liquid junction
between the chromatographic column and the non-coated silica
nanospray emitter (NewObjective, Woburn, MA, 10µm tip
ID). The mass spectrometer operated in data-dependent mode:
the survey mass spectra were detected in the orbitrap with
high resolution (R = 60 k @ m/z: 400, mass range m/z: 380–
1,400) and the most abundant multiply charged 20 peaks were
selected for ion-trap fragmentation (NCE: 35%; activation q: 0.25;
activation time: 10ms; minimum signal intensity: 5,000 counts).
The MSMS spectra were detected in the ion trap. Dynamic
exclusion was used, the precursors were excluded for 15 s after
the first fragmentation event.
Data analysis: searchable peaklists (mgf format) were
extracted using ProteomeDiscoverer (ver:1.4 Thermo Fisher
Scientific) and subjected to database search on our in-house
ProteinProspector (ver: 5.14.1) search engine using the following
parameters: parent ion tolerant: 5 ppm; fragment ion tolerant:
0.6 Da; Cys carbamidomethylation was set as constant and Met
oxidation, cyclisation of peptide N-terminal Glu to pyroglutamic
acid, protein N terminal acetylation were set as variable
modifications. Only fully tryptic peptides were considered with
maximum of 2 missed cleavage sites. The Mus musculus and Bos
taurus protein sequences of the Uniprot (UniProtKB.06.11.2014)
database completed with human keratins and pig trypsin,
altogether 106,330 protein sequences were searched. For the false
discovery rate (FDR) estimation, the searches were performed
on the database concatenated with the randomized sequences.
Protein identification was accepted if the ProteinProspector
expectation value was <0.01 and the protein was identified
with at least 2 unique peptides (expectation value <0.05
and score higher than 15). FDR values were <1% in
all cases.
For functional validation, the resulted protein list was
analyzed by the “Core Analysis” function included in Ingenuity
Pathway Analysis (IPA, Quiagen Bioinformatics) software.
Isolation and Detection of Exosomal miRNAs
miRNA sequencing was performed using SOLiD Total RNA-
Seq lit for Small RNA Libraries (Applied Biosystems now part
of Thermo Fisher Scientific) according to the manufacturer’s
instructions. Purification was performed on 10% TBE-Urea
gels stained with Sybr Gold nucleic acid gel stain (both
from Invitrogen now part of Thermo Fisher Scientific). Final
purification was performed using PureLink PCR Micro Kit
(Invitrogen). Final libraries were quality checked using High
Sense DNA kit on Bioanalyzer (all from Agilent, Santa Clara,
CA). Concentration of each library was determined using the
SOLID Library TaqMan Quantitation Kit (Life Technologies
now part of Thermo Fisher Scientific). Each library was clonally
amplified on SOLiD P1 DNA Beads by emulsion PCR (ePCR).
Emulsions were broken with butanol, and ePCR beads enriched
for template-positive beads by hybridization with magnetic
enrichment beads. Template-enriched beads were extended at
the 3′ end in the presence of terminal transferase and 3′ bead
linker. Beads with the clonally amplified DNA were deposited
onto SOLiD sequencing slide and sequenced on SOLiD 5500
Instrument using the 50-base sequencing chemistry.
Bioinformatic Analysis Raw data quality assessment, read
trimming read mapping and miRNA expression profiling were
carried out in CLCGenomicsWorkbench tool version 8.0.2 (CLC
Bio now part of Qiagen, Venlo, Netherlands) using annotated
Mus musculus miRNA sequences according to the miRBase
release 21 as a mapping reference.
In vitro Experiments
Cell Cultures
6 × 104 cell/ml passage 2 MSCs were plated in cell culture
dishes (1.5 × 104/cm2). After 24 h incubation, MSC cultures
were exposed to B16F1-derived exosomes (40µg/ml exosomal
proteins; 1.5 × 1011 exosomes) at every 24 h. Samples were
exposed to exosomes for 24, 48, 72, and 96 h and then harvested
in method-competent buffers.
Visualization of Labeled Exosome Internalization in
MSCs
To examine the uptake of exosomes by MSCs, cells were plated
to black 24-well Visiplates (1 × 104 cells/well) and incubated for
24 h. The exosomes were labeled with Dil dye (1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine perchlorate, PromoKine,
Heidelberg, Germany) and the MSC cultures were labeled
with DiO dye (3,3′-dioctadecyloxacarbo-cyanine perchlorate,
PromoKine) according to the manufacturer’s instructions. Dil-
labeled exosomes were washed in DPBS by ultracentrifugation
(at 150,000 g for 1 h at 4◦C). Forty micrograms per milliliter
DiL-labeled exosomes were added to DiO-labeled MSC cultures
and the exosome uptake was followed for 24 h in the
Celldiscoverer 7 automated live cell imaging system (Zeiss,
Oberkochen, Germany). After 24 h, the cells were fixed with 4%
paraformaldehyde solution and a nucleus staining was performed
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using DAPI (Life Technologies now part of Thermo Fisher
Scientific). Then, 5 image z-stacks were acquired for both
channels by Operetta High Content Screening System (Perkin
Elmer, Waltham, MA). The stacks were maximum intensity
projected and then analyzed automatically using a customized
version of CellProfiler (18). Nuclei were detected with Otsu-
adaptive threshold combined with diameter based filtering, then
cytoplasms were identified with propagation method seeded
from the nuclei and using the exosome channel. Exosomes were
located with a customized version of A-trous wavelet transform
based spot detection (19). Several wavelet levels were used to
ensure the detection of exosomes with various size and then the
overlaps were removed based on circularity measures. Finally,
the exosome numbers per cell were identified using MATLAB
programming, the diagrams were created in Microsoft Excel.
Cell Proliferation
After 72 h incubation, exosome-exposed and control MSC
cultures were dissociated with trypsin from the culture surface.
Cells were washed in medium and counted in a Bürker chamber
and a cell counter (Bio-Rad, TC10 Automated Cell Counter).
Detection of Apoptosis
Exosome-exposed MSCs and control cells were treated with
100 ng/ml mouse TNFα (R&D Systems). After 24 h incubation,
cell death was determined by the Annexin V Apoptosis Detection
Kit with PI (Biolegend, San Diego, CA) according to the
manufacturer’s recommendations. Samples were measured by
FACS Calibur flow cytometer (BD Biosciences), data were
analyzed by Flowing Software (Cell Imaging Core, Turku Center
for Biotechnology, Finland) where percent of positive cells was
determined by relative fluorescence intensity and the results were
expressed as mean of percentage of positive cells (%) ±SD. Cells
that are annexin-V/PI double positive show the sign of late
apoptosis, while cells that are annexin-V positive and PI negative
indicate early apoptosis. Annexin-V negative and PI positive
cells are necrotic, viable cells are both annexin-V, and propidium
iodide (PI) negative.
RNA Preparation, Melan-A, and Mitf Quantitative
Real-Time PCR (QRT-PCR)
Total RNA of biological samples was purified using the Quick-
RNA MiniPrep isolation kit of #R1054S (Zymo Research Irvine,
CA). All the preparation steps were carried out according the
manufacturer’s instructions. RNA samples were stored at −80◦C
in the presence 30U of Prime RNAse inhibitor (Fermentas, part
of Thermo Fisher Scientific) for further analysis. The quantity
of isolated RNA samples was checked by spectrophotometry
(NanoDrop 3.1.0, Rockland, DE).
QRT-PCR was performed on a RotorGene 3000 instrument
(Corbett Research, Sydney, Australia) with gene-specific primers
and SybrGreen protocol to monitor gene expression. One
microgram of total RNA was reverse transcribed with random
primers using the High-Capacity cDNA Archive Kit (Applied
Biosystems) according to the manufacturer’s instructions in
final volume of 30 µl. The temperature profile of the reverse
transcription was the following: 10min at room temperature, 2 h
at 37◦C, 5min on ice, and finally 10min at 75◦C for enzyme
inactivation. These steps were carried out in a Thermal Cycler
machine (MJ Research, Marshall Scientific, Hampton, NH). After
dilution with 30 µl of water, 1 µl of the diluted reaction mix
was used as template in the QRT-PCR. Reactions were done
with FastStart SYBR Green Master mix (Roche) according to
the manufacturer’s instructions at a final primer concentration
of 250 nM under the following conditions: 15min at 95◦C, 40
cycles of 95◦C for 15 s, 60◦C for 25 s, and 72◦C for 25 s. The
fluorescence intensity of SybrGreen dye was detected after each
amplification step. Melting temperature analysis was done after
each reaction to check the quality of the products. Primers
were designed using the online Roche Universal Probe Library
Assay Design Center. The quality of the primers was verified by
MS analysis provided by Bioneer (Daejeon, Republic of Korea).
Relative expression ratios were calculated as normalized ratios
to MmRpl27 (Mus musculus ribosomal protein L27) gene. Non-
template control sample was used for each PCR run to check the
primer-dimer formation. The final relative gene expression ratios
were calculated as delta-delta Ct values. Information about the
genes and the primers is collected in Table S1.
RNA Isolation, Reverse Transcription, and TaqMan
Panel
RNAs were isolated from MSC cells with Qiagen RNeasy mini
kit (Qiagen) based on the manufacturer’s instruction. RNA
concentrations were measured by NanoDrop spectrophotometer
(NanoDrop). cDNAs were reverse transcribed with TaqMan
Reverse Transcription Reagents (Thermo Fisher Scientific)
following the manufacturer’s instruction. For the TaqMan QRT-
PCR panel, cDNA mixture of three parallel samples was
used in case of each condition: control, 6, 24, and 72 h
exosome treatment applied on MSC cells derived from four
mice. Eighty nanogram cDNA and TaqMan Gene Expression
Master Mix (Thermo Fisher Scientific) were used for the
qPCR experiment. Expression of the examined 44 genes was
calculated by 11Ct method and normalized to the average
Ct values of 4 internal controls (PPIA, 18S RNA, ACTB,
and GAPDH).
PD-1 Detection
PD-1 detection by Western blotting
The cells were washed three times in PBS, then were lysed
in TENT Buffer (50mM Tris-HCl, 2mM EDTA, 150mM
NaCl, 1% TritonX-100, completed with 1x protease inhibitor
cocktail (Roche). Protein samples were separated and blotted as
described above.
For PD-1 protein level detection, anti-PD-1 (clone: RMO1-
14, Biolegend) antibody was used in 1:1,000 dilution. Anti-rat
horseradish peroxidase (HRP)-conjugated secondary antibody
(R&D Systems) was used in 1:500 dilution.
PD-1 detection by Immunofluorescence microscopy
MSC cultures were fixed with 4% paraformaldehyde for 10min,
and blocked in PBS buffer containing 5% BSA (Sigma-Aldrich)
for 60min at room temperature. After blocking, cells were
incubated with primary antibody in DPBS buffer containing
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1.2% BSA overnight at 4◦C. As primary antibodies, 1:200 anti-
PD-1 (clone: RMO1-14, Biolegend,) and 1:200 anti-MLANA
(Byorbit) were used. After incubation, cells were washed three
times in PBS, and incubated for 1 h at room temperature with
1:100 Alexa Fluor 647-conjugated anti-rat antibody (Jackson
ImmunoResearch Laboratories, Baltimore, PA) or 1:500 Alexa
Fluor 555-conjugated anti-rabbit antibody (Thermo Fisher
Scientific). Tubulin was stained with 1:500 Alexa Fluor 488-
conjugated anti-tubulin-α antibody (clone: 10D8, Biolegend).
Nucleus staining was performed using DAPI (Life Technologies).
Slides were washed three times with DPBS between each step.
Images were obtained at 60x magnification using an Olympus
confocal laser scanning microscope.
PD-1 detection by STORM super-resolution imaging
All dSTORM super-resolution experiments were performed on
a custom-made inverted microscope based on a Nikon Eclipse
Ti-E frame. After being conditioned (through spatial filtering via
fiber coupling and beam expansion) the applied laser beams were
focused into the back focal plane of the microscope objective
(Nikon CFI Apo 100x, NA= 1.49), which produced a collimated
beam on the sample. The angle of illumination was set via a
tilting mirror mounted into a motorized gimbal holder and
placed into the conjugate plane of the sample. All the dSTORM
images were captured under EPI illumination at an excitation
wavelength of 647 nm (Nikon: 647 nm, 300 mW). The laser
power, controlled via an acousto-optic tunable filter (AOTF), was
set to 4 kW/cm2 on the sample plane. An additional laser (Nichia,
Anan, Tokushima, Japan, 405 nm, 60 mW) was used for both
reactivation and reference measurements. Images were captured
by an Andor iXon3 897 BV EMCCD digital camera (512 × 512
pixels with pixel size of 16µm). The size of the illuminated region
of the sample was matched to the size of the detector, which
determined the field of view (FOV= 80× 80µm2). Frame stacks
for dSTORM super-resolution imaging were typically captured
at a reduced image size (crop mode), when only the central
128 × 128 pixel region was selected. A fluorescence filter set
(Semrock, Rochester, NY, LF405/488/561/635-A-000) was used
to select and separate the excitation and emission lights in
the microscope. Additional emission filters (Semrock, BLP01-
647R-25) were used in the detection path to further clean the
fluorescent light spectrally for the reduction of spectral crosstalk.
During the measurements, the perfect focus system of the
microscope was used to keep the sample in focus with a precision
of <30 nm. The storage buffer on the sample was replaced with
a special switching buffer (20). Typically, 10,000 frames were
captured with an exposure time of 30ms. Reference images with
full size FOV were captured at low intensity when the majority of
fluorescent molecules were still active and the overall structure of
the labeled sample could be visualized.
The captured and stored image stacks were evaluated
and analyzed by rainSTORM localization software (21). The
individual images of single molecules were fitted with a Gaussian
point spread function and their center positions were associated
with the position of the fluorescent molecule. Localizations were
filtered via their intensity, ellipticity and standard deviation
values. Localizations with precisions of <45 nm were only used
to form the final image. The estimated mean precision of the
accepted localizations was 19 nm. Mechanical drift introduced by
either the mechanical movement of the sample or thermal effects
was analyzed and reduced by means of a blind drift correction
algorithm. Spatial coordinates of the localized molecules were
stored and the final super-resolved image was visualized. The
multicolor merged images were generated by ImageJ software.
In vivo Experiments
Mouse Model
B16F1melanoma cells were administrated intravenously (1× 105
cell/100 µl) to 6–8 week old female C57BL/6N mice (Charles
River Laboratories). One week later, tumor bearing mice were
randomized and divided into 3 groups (n = 10/group). Mice
were injected intravenously with control buffer (100µl), exosome
exposed MSCs (1 × 105 cell/100 µl) or exosomes (40 µg/100
µl) 7, 8, 9, 10, 11 days after the tumor injection (Table S2).
One week after the first MSC administration, 3 animals/group
were euthanized, their lungs were removed, photographed and
stored at −80◦C for further protein, mRNA and histological
analyses. The remained mice were observed for 10 more days.
At the end point, the animals were euthanized, and the tumor
metastases were investigated not only in their lung, but also
in their entire body and removed for histological analysis.
Experiments were repeated 3 times. All animal experiments
were performed in accordance with national (1998. XXVIII;
40/2013) and European (2010/63/EU) animal ethics guidelines.
The experimental protocols were approved by the Animal
Experimentation and Ethics Committee of the Biological
Research Centre of the Hungarian Academy of Sciences and the
Hungarian National Animal Experimentation and Ethics Board
(clearance number: XVI./03521/2011 and XV./78/2018).
Tumor Coverage
Tumor coverage of lungs was determined by the analysis of
acquired images using the ImageJ software. The area of tumors
and the healthy regions was measured and the mean percentage,
SD, and p values were calculated in Microsoft Excel.
Quantification of Metastases Associated Vessel
Diameters
From native animal lungs 4µm criostat sections were made on
silanized slides, than fixed and retrieved by Fix and Perm A-B
solution (Thermo Fisher Scientific, USA) for 20min. Sections
were counterstained by conventional hematoxilin for 30min
than washed in tap water and coverslipped. Sections were
digitalized by automatic slide-scanner (3DHistech, Hungary),
using the software 3DHISTECHPannoramic Viewer (3DHistech,
Hungary). Strict tumor border was carefully marked then vessel
diameters were measured.
Cytokine and Chemokine Array
Lung samples were lysed in NP40 cell lysis buffer (Thermo
Fisher Scientific, USA) and protein content was measured by the
Pierce BCA Protein Assay kit (Thermo Fisher Scientific, USA).
Expression levels of different cytokines in pooled lung specimens
were determined using Mouse Cytokine Array Panel A (R&D
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Systems, Cat. no. ARY006), according to the manufacturer’s
instructions. Immunoreactive signals were detected by using LI-
CORODYSSEY Fc (Dual-mode imaging system) imager followed
by analysis with Image Studio Lite v5.2.
Custom TaqMan Array Panels
QRT-PCR was performed on an ABI Prism 7000 sequence
detection system (Applied Biosystems) using specific pre-
designed customized 96-well TaqMan Array oncogene panels
(Thermo Fisher Scientific) containing 44 specifically selected
primers and probes according to extensive literature work.
Total RNA was isolated using TRIzol (Thermo Fisher
Scientific), DNase treatment was performed according
to the manufacturer’s protocol, and then total RNA was
transcribed into cDNA using High Capacity cDNA Kit
(Thermo Fisher Scientific). PCR amplification was performed
using TaqMan primers and probes and thermal cycle
conditions were set as follows: 2min at 50◦C, 10min
at 95◦C, and 40 cycles of 15 s at 95◦C and 1min at
60◦C. As internal control transcripts of ACTB (Assay ID:
Mm00607939_s1), GAPDH (Assay ID: Mm99999915_g1),
and PPIA (Assay ID: Mm02342430_g1) were determined.
The amount of the transcripts was normalized to those of
the housekeeping genes using the 1Ct method. Finally the
results were normalized to the expression of the vehicle
control (11Ct method).
For relationship discovery Hierarchical Cluster Analysis
was performed by R software. In detail, the “bottom up”
agglomerative hierarchical clustering strategy was used and
results represented in a tree-based dendrogram [For refer the R
software: (22)].
Network Representation by Ingenuity Pathway
Analysis
According to literature data, we established a protein network
from the in vivo overexpressed genes. A custom graphical
representation of this network was generated using the Path
Explorer tool of the IPA Path Designer. Genes are represented
as red nodes, using various shapes that represent the functional
class of the gene product. In a few cases proteins are
substituted with the complex, which they are involved in.
To identify the potential exosomal factors, which can induce
the activation of the network, a list was generated from the
exosomal proteins detected by LC-MS/MS and the exosomal
miRNAs identified by SOLiD sequencing. The Grow tool
in the IPA Path Designer revealed significant interactions
between the network and the generated list (the interacting
exosomal factors are listed in gray boxes and the types of
relationships are indicated in parentheses). During construction
in the IPA, the significance level was set to “experimentally
observed” data to avoid the representation of predicted,
unproven interactions.
FIGURE 1 | Characterization of B16F1 melanoma cell culture-derived exosomes. (A) Scanning electron micrograph of melanoma exosomes. (B) Atomic force
microscopy images of exosomes. Left and middle pictures represent the shape and surface topography of vesicles, right graph represents height profile. (C) Western
blot analysis of common exosome markers (CD9, CD63, CD81, and HSP70). (D,E) Top 5 molecular and cellular functions identified by Ingenuity Pathway Analysis of
exosomal proteins and miRNAs.
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TABLE 1 | List of exosomal proteins identified by LC-MS/MS.
ID Symbol Entrez gene name
P97857 ADAMTS1 ADAM metallopeptidase with
thrombospondin type 1 motif 1
Q3TNX8 ADAMTS4 ADAM metallopeptidase with
thrombospondin type 1 motif 4
Q640N1 AEBP1 AE binding protein 1
P05064 ALDOA Aldolase, fructose-bisphosphate A
P97429 ANXA4 Annexin A4
P48036 ANXA5 Annexin A5
P08226 APOE Apolipoprotein E
Q3TWT5 ASAH1 N-acylsphingosine amidohydrolase 1
Q3TXF9 ATP1A1 ATPase Na+/K+ transporting subunit alpha 1
P97370 ATP1B3 ATPase Na+/K+ transporting subunit beta 3
Q1XID4 ATP6AP2 ATPase H+ transporting accessory protein 2
Q9JL18 BACE2 Beta-site APP-cleaving enzyme 2
O55107 BSG Basigin (Ok blood group)
Q8R2Q8 Bst2 Bone marrow stromal cell antigen 2
Q9WVT6 CA14 Carbonic anhydrase 14
P41731 CD63 CD63 molecule
P35762 CD81 CD81 molecule
P10605 CTSB Cathepsin B
P18242 CTSD Cathepsin D
P29812 DCT Dopachrome tautomerase
P57776 EEF1D Eukaryotic translation elongation factor 1
delta
Q3UAM9 ENG Endoglin
P17182 ENO1 Enolase 1
P19096 FASN Fatty acid synthase
P30416 FKBP4 FK506 binding protein 4
P11276 FN1 Fibronectin 1
P09528 FTH1 Ferritin heavy chain 1
P16858 GAPDH Glyceraldehyde-3-phosphate dehydrogenase
P08752 GNAI2 G protein subunit alpha i2
Q3TAV1 GPNMB Glycoprotein nmb
P19157 GSTP1 Glutathione S-transferase pi 1
P11499 HSP90AB1 Heat shock protein 90 alpha family class B
member 1
B1B0C7 HSPG2 Heparan sulfate proteoglycan 2
Q9CQW9 IFITM3 Interferon induced transmembrane protein 3
G3UYZ1 IGSF8 Immunoglobulin superfamily member 8
Q91VK4 ITM2C Integral membrane protein 2C
P02468 LAMC1 Laminin subunit gamma 1
Q60961 LAPTM4A Lysosomal protein transmembrane 4 alpha
P35951 LDLR Low density lipoprotein receptor
Q07797 LGALS3BP Galectin 3 binding protein
Q3U2W5 LGALS8 Galectin 8
P16056 MET MET proto-oncogene, receptor tyrosine
kinase
P21956 MFGE8 Milk fat globule-EGF factor 8 protein
Q2TA50 MLANA Melan-A
Q6NVG5 MREG Melanoregulin
Q9EPX2 PAPLN Papilin, proteoglycan like sulfated
glycoprotein
(Continued)
TABLE 1 | Continued
ID Symbol Entrez gene name
Q3UIP2 PCOLCE Procollagen C-endopeptidase enhancer
Q811J2 LOC72520 LOC72520 protein
Q80Y09 PDCD6IP Programmed cell death 6 interacting protein
P62962 PFN1 Profilin 1
P09411 PGK1 Phosphoglycerate kinase 1
P52480 PKM Pyruvate kinase, muscle
Q9CZB2 PMEL Premelanosome protein
P17742 PPIA Peptidylprolyl isomerase A
P35700 PRDX1 Peroxiredoxin 1
Q61171 PRDX2 Peroxiredoxin 2
Q543S0 PRELP Proline and arginine rich end leucine rich
repeat protein
P53994 RAB2A RAB2A, member RAS oncogene family
Q8CCG5 RALB RAS like proto-oncogene B
O89086 RBM3 RNA binding motif (RNP1, RRM) protein 3
P35980 RPL18 Ribosomal protein L18
Q3U5P4 SCPEP1 Serine carboxypeptidase 1
O08992 SDCBP Syndecan binding protein
Q0VGP2 SEMA3B Semaphorin 3B
P32261 SERPINC1 Serpin family C member 1
P10852 SLC3A2 Solute carrier family 3 member 2
Q3UQM7 SLC7A5 Solute carrier family 7 member 5
O09044 SNAP23 Synaptosome associated protein 23
Q64337 SQSTM1 Sequestosome 1
Q8CI59 STEAP3 STEAP3 metalloreductase
Q3TDG9 STX12 Syntaxin 12
O70439 STX7 Syntaxin 7
P40749 SYT4 Synaptotagmin 4
O88968 TCN2 Transcobalamin 2
Q542D9 TFRC Transferrin receptor
P39876 TIMP3 TIMP metallopeptidase inhibitor 3
Q4FJX7 TINAGL1 Tubulointerstitial nephritis antigen like 1
Q9DCS1 TMEM176A Transmembrane protein 176A
Q9R1Q6 TMEM176B Transmembrane protein 176B
Q9CZX7 TMEM55A Transmembrane protein 55A
Q9QY73 TMEM59 Transmembrane protein 59
O88746 TOM1 Target of myb1 membrane trafficking protein
O89023 TPP1 tripeptidyl peptidase 1
Q3UCW0 TSG101 Tumor susceptibility 101
Q4FJW7 TSPAN4 Tetraspanin 4
Q8BJU2 TSPAN9 Tetraspanin 9
P11344 TYR Tyrosinase
P07147 TYRP1 Tyrosinase related protein 1
O70404 VAMP8 Vesicle associated membrane protein 8
Q8R0J7 VPS37B VPS37B, ESCRT-I subunit
Q8R105 VPS37C VPS37C, ESCRT-I subunit
O88384 VTI1B Vesicle transport through interaction with
t-SNAREs 1B
A8DUQ1 HBBT1 Beta-globin
P70356 MELA Gag-pol poliprotein
P70355 MELA Envelope protein
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Statistical Analysis
All of the data are presented as the mean ± SD or SEM and
represent minimum of three independent experiments. Statistical
parameters including statistical analysis, statistical significance,
and n value are reported in the figure legends. For in vivo
experiments n = number of animals. For statistical comparison,
we performed two-tailed Student’s t-test. A value of p < 0.05
was considered significant [represented as ∗p < 0.05, not
significant (n.s.)].
RESULTS
Isolated Vesicles Show Exosomal
Properties
First, we isolated extracellular vesicles from B16F1 mouse
melanoma cells. As it was shown by SEM and AFM
(Figures 1A,B), the isolated fraction indeed contained exosomes
as the particles were cap-shaped, and their size was within the
40–120 nm range. Then, presence of molecules (CD9, CD63,
CD81, and HSP70), characteristic for exosomes (4, 17) was
assessed by Western blotting (Figure 1C).
Exosomes were then subjected to large-scale analysis to
determine their protein and miRNA profiles. Whole proteome
analysis (using LC-MS/MS) and bioinformatics tools (used
to identify elements of the exosome’s proteomics spectrum
in the UniProt database, and to compare the findings with
entries of the ExoCarta database) revealed that 95 distinct
proteins were identified in melanoma exosomes (Table 1).
These proteins exhibited 86.3% overlap with molecules listed
as characteristic exosome protein markers in ExoCarta. Further,
miRNA sequencing (using SOLiD 5500xl technology) identified
168 known miRNA elements (Table 2) which, similarly to the
proteomics data, exhibited a large (93.5%) overlap withmolecules
listed as characteristic exosome miRNA markers in ExoCarta.
To uncover the functional significance of the proteomics and
miRNA sequencing data, IPA was employed. This analysis has
shown that the identified proteins most probably participated
in cellular and molecular processes such as “Cell Death and
Survival,” “Cellular Movement,” “Cell-to-Cell Signaling and
Interaction,” “Cellular Growth and Proliferation,” and “Cell
Morphology” (Prange = 7.53 × 10−15-9.32 × 10−4 significance
range) (Figure 1D). Very similarly to these data, functions
of the identified miRNAs were suggested to be linked to
mechanisms of “Cellular Development,” “Cellular Growth and
Proliferation,” “Cellular Movement,” “Cell Cycle,” and “Cell
Death and Proliferation” (Prange = 1.25 × 10−12-4.88 × 10−2
significance range) (Figure 1E).
Tumor Exosome Exposure Resulted in
Oncogenic Reprogramming of MSCs
in vitro
Then, we investigated the effect of exosomes on biological
processes (e.g., proliferation, survival, malignant transformation,
etc.) of MSCs, which are generally considered as proper in vitro
models of tumor stroma (12). For these experiments, MSC
TABLE 2 | List of exosomal miRNAs identified by SOLiD 5500xl technology.
Symbol Seed regio ID
let-7a-3p UAUACAA mmu-let-7a-1-3p
mmu-let-7b-3p
mmu-let-7c-2-3p
mmu-let-7f-1-3p
let-7a-5p GAGGUAG mmu-let-7a-5p
mmu-let-7b-5p
mmu-let-7c-5p
mmu-let-7d-5p
mmu-let-7e-5p
mmu-let-7f-5p
mmu-let-7g-5p
mmu-mir-98-5p
let-7d-3p UAUACGA mmu-let-7d-3p
let-7i-3p UGCGCAA mmu-let-7i-3p
miR-100-5p ACCCGUA mmu-mir-99a-5p
mmu-mir-99b-5p
miR-101-3p ACAGUAC mmu-mir-101a-3p
miR-103-1-5p GCUUCUU mmu-mir-107-5p
miR-103-3p GCAGCAU mmu-mir-103-3p
mmu-mir-107-3p
miR-10a-5p ACCCUGU mmu-mir-10a-5p
mmu-mir-10b-5p
miR-1191a AGUCUUA mmu-mir-1191a
miR-1249-3p CGCCCUU mmu-mir-1249-3p
miR-125b-5p CCCUGAG mmu-mir-125a-5p
mmu-mir-125b-5p
mmu-mir-351-5p
miR-126a-5p AUUAUUA mmu-mir-126a-5p
miR-128-3p CACAGUG mmu-mir-128-3p
miR-129-1-3p AGCCCUU mmu-mir-129-1-3p
mmu-mir-129-2-3p
miR-129b-5p CUUUUUG mmu-mir-129b-5p
miR-130a-3p AGUGCAA mmu-mir-130a-3p
mmu-mir-130b-3p
mmu-mir-301a-3p
mmu-mir-301b-3p
miR-130a-5p CUCUUUU mmu-mir-130a-5p
miR-130b-5p CUCUUUC mmu-mir-130b-5p
miR-132-3p AACAGUC mmu-mir-132-3p
miR-132-5p ACCGUGG mmu-mir-132-5p
miR-135a-5p AUGGCUU mmu-mir-135a-5p
miR-138-5p GCUGGUG mmu-mir-138-5p
miR-139-5p CUACAGU mmu-mir-139-5p
miR-140-3p ACCACAG mmu-mir-140-3p
miR-140-5p AGUGGUU mmu-mir-140-5p
miR-142-3p GUAGUGU mmu-mir-142a-3p
miR-143-5p mmu-mir-143-5p
miR-144-3p ACAGUAU mmu-mir-144-3p
miR-144-5p GAUAUCA mmu-mir-144-5p
miR-145-5p UCCAGUU mmu-mir-145a-5p
(Continued)
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TABLE 2 | Continued
Symbol Seed regio ID
miR-146a-5p GAGAACU mmu-mir-146a-5p
miR-148a-3p CAGUGCA mmu-mir-148b-3p
miR-151-3p UAGACUG mmu-mir-151-3p
miR-15a-3p AGGCCAU mmu-mir-15a-3p
miR-15b-3p GAAUCAU mmu-mir-15b-3p
miR-16-2-3p CCAAUAU mmu-mir-16-2-3p
miR-16-5p AGCAGCA mmu-mir-15a-5p
mmu-mir-15b-5p
mmu-mir-16-5p
mmu-mir-195a-5p
mmu-mir-322-5p
mmu-mir-497a-5p
miR-17-3p CUGCAGU mmu-mir-17-3p
miR-17-5p AAAGUGC mmu-mir-106b-5p
mmu-mir-17-5p
mmu-mir-20a-5p
mmu-mir-93-5p
miR-181a-1-3p CCAUCGA mmu-mir-181a-1-3p
miR-181a-5p ACAUUCA mmu-mir-181a-5p
mmu-mir-181b-5p
mmu-mir-181c-5p
mmu-mir-181d-5p
miR-1827 GAGGCAG mmu-mir-709
miR-1839-3p GACCUAC mmu-mir-1839-3p
miR-185-5p GGAGAGA mmu-mir-185-5p
miR-186-5p AAAGAAU mmu-mir-186-5p
miR-187-3p CGUGUCU mmu-mir-187-3p
miR-188-3p UCCCACA mmu-mir-188-3p
miR-188-5p AUCCCUU mmu-mir-188-5p
miR-18a-5p AAGGUGC mmu-mir-18a-5p
miR-191-5p AACGGAA mmu-mir-191-5p
miR-193a-3p ACUGGCC mmu-mir-193a-3p
miR-1981-3p AUCUAAC mmu-mir-1981-3p
miR-199a-3p CAGUAGU mmu-mir-199a-3p
mmu-mir-199b-3p
miR-199a-5p CCAGUGU mmu-mir-199a-5p
mmu-mir-199b-5p
miR-19b-3p GUGCAAA mmu-mir-19a-3p
mmu-mir-19b-3p
miR-204-5p UCCCUUU mmu-mir-211-5p
miR-21-5p AGCUUAU mmu-mir-21a-5p
miR-210-3p UGUGCGU mmu-mir-210-3p
miR-210-5p GCCACUG mmu-mir-210-5p
miR-219a-5p GAUUGUC mmu-mir-219a-5p
miR-22-3p AGCUGCC mmu-mir-22-3p
miR-22-5p GUUCUUC mmu-mir-22-5p
miR-221-3p GCUACAU mmu-mir-222-3p
miR-223-3p GUCAGUU mmu-mir-223-3p
miR-224-5p AAGUCAC mmu-mir-224-5p
miR-23a-3p UCACAUU mmu-mir-23a-3p
mmu-mir-23b-3p
(Continued)
TABLE 2 | Continued
Symbol Seed regio ID
miR-24-1-5p UGCCUAC mmu-mir-24-2-5p
miR-24-3p GGCUCAG mmu-mir-24-3p
miR-26a-5p UCAAGUA mmu-mir-26a-5p
miR-26a-5p UCAAGUA mmu-mir-26a-5p
mmu-mir-26b-5p
miR-27a-3p UCACAGU mmu-mir-27a-3p
mmu-mir-27b-3p
miR-29a-5p CUGAUUU mmu-mir-29a-5p
miR-29b-1-5p CUGGUUU mmu-mir-29b-1-5p
miR-29b-3p AGCACCA mmu-mir-29a-3p
mmu-mir-29b-3p
mmu-mir-29c-3p
miR-3065-5p CAACAAA mmu-mir-3065-5p
miR-30c-5p GUAAACA mmu-mir-30a-5p
mmu-mir-30b-5p
mmu-mir-30c-5p
mmu-mir-30d-5p
mmu-mir-30e-5p
miR-31-3p GCUAUGC mmu-mir-31-3p
miR-31-5p GGCAAGA mmu-mir-31-5p
miR-3176 CUGGCCU mmu-mir-378d
miR-324-5p GCAUCCC mmu-mir-324-5p
miR-328-3p UGGCCCU mmu-mir-328-3p
miR-329-3p ACACACC mmu-mir-362-3p
miR-33-5p UGCAUUG mmu-mir-33-5p
miR-330-5p CUCUGGG mmu-mir-326-3p
miR-331-3p CCCCUGG mmu-mir-331-3p
miR-339-5p CCCUGUC mmu-mir-339-5p
miR-340-3p CCGUCUC mmu-mir-340-3p
miR-344a-5p CAGGCUC mmu-mir-484
miR-345-5p CUGACCC mmu-mir-345-5p
miR-3473b GGCUGGA mmu-mir-3473b
mmu-mir-3473e
miR-34a-5p GGCAGUG mmu-mir-34a-5p
mmu-mir-34b-5p
mmu-mir-34c-5p
miR-34c-3p AUCACUA mmu-mir-34b-3p
miR-350 UCACAAA mmu-mir-350-3p
miR-361-5p UAUCAGA mmu-mir-361-5p
miR-362-5p AUCCUUG mmu-mir-362-5p
miR-374b-5p UAUAAUA mmu-mir-374b-5p
miR-378a-3p CUGGACU mmu-mir-378a-3p
mmu-mir-378c
miR-378a-5p UCCUGAC mmu-mir-378a-5p
miR-3909 GUCCUCU mmu-mir-877-3p
miR-423-3p GCUCGGU mmu-mir-423-3p
miR-423-5p GAGGGGC mmu-mir-423-5p
miR-425-5p AUGACAC mmu-mir-425-5p
miR-451a AACCGUU mmu-mir-451a
miR-501-5p AUCCUUU mmu-mir-501-5p
miR-503-5p AGCAGCG mmu-mir-503-5p
(Continued)
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Symbol Seed regio ID
miR-532-5p AUGCCUU mmu-mir-532-5p
miR-542-3p GUGACAG mmu-mir-542-3p
miR-574-5p GAGUGUG mmu-mir-574-5p
miR-582-5p UACAGUU mmu-mir-582-5p
miR-652-3p AUGGCGC mmu-mir-652-3p
miR-670-5p UCCCUGA mmu-mir-670-5p
miR-700-5p AAGGCUC mmu-mir-700-5p
miR-744-3p UGUUGCC mmu-mir-744-3p
miR-744-5p mmu-mir-744-5p
miR-7a-5p GGAAGAC mmu-mir-7a-5p
miR-872-3p GAACUAU mmu-mir-872-3p
miR-872-5p AGGUUAC mmu-mir-872-5p
miR-9-5p CUUUGGU mmu-mir-9-5p
miR-92a-3p AUUGCAC mmu-mir-25-3p
mmu-mir-32-5p
mmu-mir-92a-3p
cultures were initiated frommouse abdominal adipose tissue (17)
and were subjected to melanoma exosome treatment.
First, we assessed whether exosomes were internalized by
MSCs. High-throughput microscopy showed that MSCs [labeled
green by the DiOC18(3) lipid dye] indeed took up exosomes
[labeled red by the DilC18(3) lipid dye] as early as 1–2 h after
application (Figure S1). Importantly, after 24 h, the majority of
MSCs were loaded by exosomes (Figures 2A,B). Indeed, image
analysis and statistical evaluation revealed a 91% internalization
efficacy. This suggests that functional alterations demonstrated
by this study were due to exosome-induced cell-population, and
not individual cell level effects.
Then, we determined whether the internalized exosomes
could induce a melanoma-like malignant transformation of the
MSCs. By employing two complementary cell-countingmethods,
we found that proliferation rate of the MSCs significantly
accelerated 72 h after exosome exposure (Figure 2C). By flow
cytometry, we also showed that the exosome-treated MSCs
exhibited a partial resistance to the cell death-inducing
effects of 100 ng/ml tumor necrosis factor-α (TNFα) as the
fraction of the dead cells was significantly decreased in these
cultures (Figure 2D).
Since the exosomes were isolated from melanoma cells, we
were then intrigued to uncover whether the above alterations
(which all argue for the malignant transformation of the
susceptible cells) also resulted in de novo appearance of
melanoma-specific features in the transformed MSCs. To answer
this question, expression of the melanoma-specific markers
MLANA and MITF were investigated. By QRT-PCR, we found
that mRNA transcript levels of both markers elevated markedly
in MSCs upon exosome treatment (Figure 2E and Figure S2),
albeit the kinetics of elevation of the two molecules were slightly
different. Moreover, in good accordance with the mRNA data,
immunofluorescence labeling showed that exosome exposure
markedly increased the expression ofMLANA at the protein level
as well (Figure 2F).
Next, we assessed whether the above effects of exosomes
inducing a malignant-like transformation of the MSCs was
accompanied by a cellular-molecular oncogenic reprogramming
of the target cells. Naïve MSCs were exposed to a standardized
volume of exosomes for various time intervals (to avoid the
experimental fluctuations, we collected pooled samples from
multiple independent in vitro experiments). Then, samples were
subjected to QRT-PCR analysis using a self-designed panel of 40
oncogenes and tumor suppressor genes which were previously
suggested to play a role in melanoma progression (Table 3).
As shown in Figure 3A, gene expression pattern of MSCs
exposed to melanoma exosomes, exhibited a clear oncogenic
dominance (compared to the non-exposed cells). This was
verified by statistical analysis of themean relative gene expression
levels of all molecules investigated. Statistically higher values
were obtained in the case of exosome-treated cells (p = 1.9 ×
10−5, p = 0.031 and p = 2.3 × 10−8 for the 6, 24, and 72 h time
points, respectively).
As mentioned above, Kleffel et al. has recently shown
that melanoma cell subpopulations which overexpress PD-1,
quite intriguingly exhibit remarkably increased invasiveness
and aggressive growth properties (15). However, the authors
did not define the factor(s) which induced the above PD-1
overexpression. Since the above finding strongly suggested an
“MSC re-education” capacity of melanoma exosomes to induce
malignant-like behavior, we next assessed the expression of PD-1
in MSC cultures.
As expected, only insignificant PD-1 expression (both at the
mRNA and protein levels) could be identified in control, non-
treated MSCs. In contrast, a marked, significant, and time-
dependent elevation of PD-1 expression was detected upon
exosome treatment by QRT-PCR (Figure 3B), Western blot and
an immunocytochemical analysis (Figures 3C,D). Further, by
employing super-resolution microscopy, we were able to identify
a dramatic upregulation of PD-1 at the single molecular level in
exosome-treated MSCs (Figure 3E).
Importantly, since proteomics analysis did not identify the
presence of PD-1 in exosomes, these data suggest that the high
PD-1 protein content in exosome-exposed MSCs was a result
of de novo induction and not of exosome-mediated molecular
transfer. Our findings therefore suggest that melanoma exosome-
mediated “re-education” of the cells resulted in a novel MSC
population which could be identified as MSCPD-1+.
B16F1 Exosomes Augment in vivo
Tumorigenesis and Tumor Progression
After presenting evidence for the in vitro tumorigenic induction
potential of exosomes on cultured MSCs, we hypothesized
that this phenomenon could be identified in vivo as well. To
probe this assumption, we employed the well-known animal
model, routinely used in our laboratories (46), in which
tumors, developed mostly in the lungs, are induced in mice
by intravenous administration of mouse B16F1 melanoma cells
(to the tail vein). Then, tumor-bearing mice received buffer,
or exosomes isolated from the same B16F1 melanoma cells, or
exosome-induced MSCPD-1+ cells.
Notably, the exosome-related groups (i.e., exosome,
MSCPD-1+) were characterized by a markedly increased
size of tumor-covered lung tissues (the increase proved to be
significant in the MSCPD-1+ group) (Figure 4A). Of further
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FIGURE 2 | Internalized melanoma exosomes induce malignant transformation of the recipient MSCs. (A) Fluorescent images of exosome uptake by MSCs. DiO
(green lipid dye)-labeled cells were exposed to Dil (red lipid dye)-labeled exosomes for 24 h and fixed in 4% PFA. Control cells were treated in the same manner without
exosomes. Pictures were acquired by an Operetta high content screening system (Perkin Elmer). Lower two images represent an experiment, where nuclei were
counterstained with DAPI. Exosomes were detected with a customized version of A-trous wavelet transform, and were highlighted with yellow. (B) Quantitative analysis
of exosome uptake. The graph shows the number of detected exosomes (Y axis) in each cell (X axis) in three exosome-exposed (24 h) and three control cell cultures
(ctrl). (C) Cell proliferation assay of exosome-exposed MSCs. Cells were plated at 1 × 104 cell/cm2 density in control and exosome-exposed cultures, and 72 h after
the exosome treatment, the cell number was determined by manual counting and by an automated cell counter. Both methods showed a significantly increased cell
proliferation of exosome-treated cells. Results are presented as mean ± SD (n = 3). (D) Apoptosis analysis of exosome-exposed MSCs by flow cytometry.
Exosome-pre-exposed cells were treated by 100 ng/ml TNFα for 24 h, stained with Annexin V-FITC and propidium iodide. They were analyzed by flow cytometry both
in the case of the TNFα-treated and the untreated control cell cultures. The graph represents the percentage of early apoptotic, late apoptotic and necrotic cells. Both
TNFα-induced total cell death (Σ ) and necrosis were significantly lower (Σp = 0.03 and p = 0.02, respectively) in exosome-pretreated cell cultures compared to the
corresponding control cells. Results are presented as mean + SD (n = 3). (E) QRT-PCR analysis of Mlana and Mitf in MSC cultures treated by exosomes in every 24 h
indicated by arrows in the graph. The expression of both mRNAs increased after exosome exposure, but they showed different kinetics. (F) Fluorescent
immunocytochemistry of MLANA in exosome-exposed MSC cultures using a primary rabbit antibody to MLANA and a secondary AlexaFluor555-conjugated antibody
to rabbit IgG (red). α-tubulin network of cells was directly labeled by an AlexaFluor488-conjugated antibody (green) and the nuclei were stained with DAPI (blue).
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TABLE 3 | List of genes investigated by a self-designed oncopanel.
Gene Protein Function References
Alcam ALCAM (CD166) Activated leukocyte cell
adhesion molecule
Plays an important role in human malignant melanoma progression and
formation of locoregional and distant metastases
(23)
Bmi1 BMI1 B cell-specific Moloney murine leukemia virus
integration site 1
Induces an invasive signature in melanoma that promotes metastasis and
chemoresistance
(24)
Cd44 CD44 Is a CD44s interaction with HA plays a crucial role in cell invasiveness (25)
Eng ENG Endoglin (CD105) Has a crucial role in angiogenesis, important protein for tumor growth, survival,
and metastasis of cancer cells to other locations in the body
(26)
Flot2 FLOT1 Flotillin-2 Is associated with melanoma progression (27)
Itga2 ITGA2 Integrin alpha2 Is associated with increased risk of melanoma (28)
Itga4 ITGA4 Integrin alpha 4 α4β1 integrin plays an important role in metastasis of malignant melanoma (28)
Itga6 ITGA6 Integrin alpha 6 α6β1 integrin as a laminin receptor expression is associated with invasive
potential in a highly metastatic melanoma cell line
(28)
Itgb1 ITGB1 Integrin beta-1 (CD29) α4β1 integrin plays an important role in metastasis of malignant melanoma (28)
Kit KIT (CD117) Mast/stem cell growth factor receptor
(SCFR)
c-Kit signaling activates the MAPK and PI3K signaling cascades (29)
Muc1 MUC1 Mucin1 cell surface associated Promotes melanoma migration through the Akt signaling pathway (29)
Pecam1 PECAM1 Platelet endothelial cell adhesion
molecule (CD31)
Can play multiple roles in diverse processes related to melanoma development,
dormancy, migration/invasion, and angiogenesis
(30)
Prom1 Prominin-1 (CD133) Is a melanoma stem cell marker (31)
Thy CD90 Is a cell adhesion molecule. Melanoma cells use Thy-1 on endothelial cells for
metastasis formation
(32)
Cdc42 CDC42 Cell division control protein 42 homolog Is vital for the transforming Ras signal emanating from endomembranes (33)
Tiam1 TIAM1 T-cell lymphoma invasion and metastasis 1 Has crucial roles in regulation of the actin cytoskeleton, cell migration, cell cycle
progression, gene transcription, and cell adhesion
(34)
Bcl2 BCL-2 B-cell lymphoma 2 Plays a pivotal role in the regulation of molecules associated with the migratory
and invasive phenotype, contributing, in cooperation to hypoxia, to tumor
progression
(29)
Bax BAX Bcl-2-associated X protein Plays a crucial role in apoptotic cell death induced, the Bax/Bcl-2 ratio
determines the susceptibility of melanoma cells
(35)
Casp9 CASP9 Caspase-9 Is linked to the mitochondrial death pathway (35)
Casp8 CASP8 Caspase-8 Plays a central role in the execution-phase of cell apoptosis (36)
Cdk4 CDK4 Cyclin-dependent kinase 4 Promotes cell-cycle progression and inhibit both cell senescence and apoptosis (29)
Elk1 ELK1 ETS domain-containing protein Elk-1 Is a member of ETS oncogene family, transcription activator (37)
Ets1 ETS1 E26 transformation-specific Is required for migration in cell lines with an active RAS/ERK signaling pathway (29)
Hgf HGF Hepatocyte growth factor Can activate the MAP-kinase pathway, which is upregulated in the majority of
melanoma, through the proto-oncogene c-MET
(38)
Jak2 JAK2 Janus kinase 2 Is an activator of transcription (STAT) pathway is thought to play a central role in
melanoma cell biology
(39)
Met MET Hepatocyte growth factor receptor Induces several biological responses that collectively give rise to a program
known as invasive growth
(40)
Myb MYB transcriptional activator Myb Is a transcription factor. Among other genes, MYB regulates the transcription of
the Kit, Bcl2, Ets-2, and N-Ras
(41)
Nras NRAS Neuroblastoma RAS viral oncogene homolog Recruits and stimulates a number of intracellular signaling pathways including
the Raf/MEK/ERK mitogen activated protein kinase (MAPK) pathway, the
PI3K/AKT pathway
(29)
Stat3 STAT3 Signal transducer and activator of transcription 3 Promotes transcription of many genes that involve in melanoma metastasis (42)
Kitl KIT-ligand Stem cell factor (CD117) Is a cytokine that binds to the c-KIT receptor. This cytokine plays an important
role in melanogenesis
(29)
Rb1 RB1 Retinoblastoma 1 protein Is a tumor suppressor protein that is dysfunctional in several major cancers (43)
Pik3ca PI3K Phosphatidylinositide 3-kinases Is a PI3K/AKT pathway play a pivotal role in tumor development, growth, and
metastasis of melanoma
(29)
Raf1 RAF1 Proto-oncogene serine/threonine-protein kinase Is a crucial regulators of the ERK MAP kinase signaling cascade (44)
(Continued)
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TABLE 3 | Continued
Gene Protein Function References
Mtor mTOR Serine/threonine-protein kinase Mechanistic target of rapamycin, is a serine/threonine protein kinase that
regulates cell growth, cell proliferation, cell motility, cell survival
(29)
Akt1 AKT Protein kinase B Plays a key role in multiple cellular processes such as glucose metabolism,
apoptosis, cell proliferation, transcription, and cell migration
(29)
Map2k1 MEK1 Dual specificity mitogen-activated protein kinase
kinase 1
Is an essential component of the MAP kinase signal transduction pathway, this
kinase is involved in many cellular processes such as proliferation, differentiation,
transcription regulation, and development
(29)
Map2k2 MEK2 Dual specificity mitogen-activated protein kinase
kinase 2
Plays a critical role in mitogen growth factor signal transduction. It
phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3
(29)
Mapk3 ERK1 Extracellular-signal-regulated kinases Ras-Erk1/2 is a key regulator pathway in melanoma cell proliferation (29)
Mapk1 ERK2 Mitogen-activated protein kinase 1 Ras-Erk1/2 is a key regulator pathway in melanoma cell proliferation (29)
Rac1 RAC1 Ras-related C3 botulinum toxin substrate 1 Functions in multiple signaling pathways are leading to cell adhesion, migration,
proliferation, and transformation
(45)
importance, we also found that in both exosome-related groups,
the numbers of distant metastases were significantly elevated
when compared to the control (Figure 4B), and diameter of
metastases associated blood vessels significantly increased in
exosome and MSCPD-1+ injected groups of tumor bearing mice
(Figure S3). Using of cytokine and chemokine arrays, tumor
supportive cytokine and chemokine levels were elevated in
exosome related groups (Figure S4). As we have seen during our
previous studies (46), these metastases were mostly localized to
the ovaries and kidneys (and very rarely to the lymph nodes)
of control tumor-bearing animals. However, besides these sites,
the presence of exosomes resulted in frequent metastases in the
lymph nodes and, as a new location, in the liver. Interestingly, in
MSCPD-1+ treated mice, exosome-transformed MSCs could be
identified in the para-aortic lymph nodes by FISH (Figure 4C)
verifying the successful in vivo adherence of MSCPD-1+ cells.
Lung tissues of the different groups were then subjected to in-
depth expressional profiling 14 days after injection of exosomes
or MSCPD-1+ cells. Namely, QRT-PCR analysis was performed
using a self-designed panel of 40 genes; besides housekeeping
genes, we assessed expression of (i) proto-oncogenes; (ii)
genes reportedly involved in malignant transformation; and/or
(iii) genes found to be involved in melanoma development
and progression.
Hierarchical cluster analysis (HCA) of the gene expression
patterns clearly showed a robust proto-oncogenic dominance
in lung samples of the exosome-related groups when compared
to the control tissues. Indeed, we identified significant de novo
induction of 26 and 23 genes: Alcam1, Eng, Flot2, Itga4,
Itga6, Kit, Pecam1, Prom1, Thy, Cdc42, Tiam1, Bcl2, Bax,
Casp9, Casp8, Ets1, Hgf, Jak2, Met, Myb, Map2k1, Map2k2,
Mapk1 in both group and Elk1, Rb1, Itga2 in the exosome
group. An additional six and three genes were identified
with at least 10-fold increase (Cd44, Itgb1, Muc1, Pik3ca,
Akt1, Rac1 in the exosome group and Cd44, Itgb1, Rac1
in the MSCPD-1+ group). Furthermore, six and eight genes
showed at least two-fold mRNA level elevations (Bmi1,
Cdk4, Stat3, Kitl, Raf1, Mtor and Bmi1, Muc1, Cdk4, Stat3,
Kitl, Pik3ca, Mtor, Akt1, respectively). Figure 4D presents a
heatmap of indicative data of overexpressed genes induced by
exosome exposure.
Furthermore, we showed that, besides the above genes,
expression of PD-1 was also significantly increased in both
exosome-related groups (Figure 4E). Notably, although mRNA
transcript level of PD-1 was close to two-fold in MSCPD-1+ lung
tissues in comparison to samples in the exosome group, the
difference was not significant (most probably due to the large
inter-animal variability and standard error).
We constructed a Venn-diagram (Figure 4F) to show all
possible logical connections between the various gene expression
patterns presented in Figure 4D. Importantly, according to
cluster analysis, we could not identify a single gene which
was missing from the exosome-related groups in comparison
to the control tumor-bearing mice. In other words, whereas
these exosome-related groups did exhibit gene expression profiles
which were characteristic only for them, such individual profiles
could not be detected in the control group.
Specifically, the following gene expression patterns
were defined:
• three genes (Elk1, Rb1, Igta2) were exclusively induced only in
the exosome-treated group;
• twenty-three genes (Prom1, Tiam1, Bcl2, Bax, Casp9, Hgf,
Jak2, Met, Mapk2k2, Alcam1, Eng, Flot2, Itga4, Itga6, Kit,
Pecam1, Thy, Cdc42, Casp8, Ets1, Myb,Map2k1, Mapk1) were
found to be upregulated both in the exosome and MSCPD-1+
cell treated groups;
• fourteen genes (Bmi1, Cd44, Itgb1, Muc1, Cdk4, Nras, Sat3,
Kitl, Raf1, Mtor, Akt1, Mapk3, Pik3ca, Rac1) were found to be
upregulated in all three groups.
Finally, it should be noted that the dramatic gene expression
alterations seen in the exosome-related groups were exclusively
due to the presence of the exosomes as the “MSCPD-1+ only”
cluster contained no genes (Figure 4F).
Melanoma-Derived Exosomes Promote
Tumorigenic and Cell Survival Signaling
Pathway(s)
Figure 5 shows the map of interaction pathways based on
overexpressed molecules (red symbols) in in vivo experiments.
We detected overexpressed elements of three main pathways
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FIGURE 3 | Exosome re-educated MSCs show oncogene dominance and PD-1 expression. (A) QRT-PCR analysis of 40 tumor-related genes in exosome-exposed
MSCs using a self-designed panel. The graph shows the relative expression values for each gene after 6, 24, and 72 h of exosome exposure. The trend line of altered
gene expression pattern (indicated by thick black line) shows an increasing tendency over time (mean ± SD). (B) QRT-PCR analysis of PD-1 in MSCs after 2 and 24 h
of exosome exposure. The graph represents mean + SEM (n = 3). (C) Representative immunoblot of PD-1 protein expression in control and exosome-exposed
MSCs after 24 h of exosome treatment. (D,E) Fluorescent immunocytochemistry of PD-1 in 24 h exosome-exposed MSC cultures, using a primary rat antibody to
PD-1 and a secondary AlexaFluor647-conjugated antibody to rat IgG (red). Nuclei were stained with DAPI. (D) α-tubulin network of cells was directly labeled by an
AlexaFluor488-conjugated antibody (green). Images were acquired by confocal microscopy. (E) Images were taken by STORM super-resolution microscopy. STORM
super-resolution imaging of PD-1 revealed that PD-1 was localized mostly around the nucleus, which were blurred and were not resolvable using diffraction-limited
confocal microscopy (D) of the same region.
which do participate in tumor progression and metastasis
formation (47). Using the IPA Path Designer Grow tool, we
generated an interaction map which contains proteins (or
their established complexes) encoded by the overexpressed
genes, and exosomal miRNAs and proteins (gray boxes)
which were previously shown to control or affect the marked
signaling molecules.
To demonstrate these results and to explore the potential
causative exosomal factors, we again performed an IPA. The
analysis allowed further refinement of the underlying molecular
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FIGURE 4 | Melanoma exosomes promote tumor progression and metastasis formation in vivo. (A) Tumor coverage of lungs on day 15 in different animal groups. The
graph represents mean + SD (n = 3). (B) Number of distant metastases on day 25. One dot represents one animal in each group, red lines show the average number
of metastases per animal. (C) FISH analysis of a paraortic lymph node metastases, which showed the presence of exosome-exposed MSC. Y chromosome (red dot)
of the male mouse-derived MSC was detected in the metastases of a female mouse. (D) Heatmap and cluster analysis of gene expression pattern, which show
protooncogenic dominance in exosome or MSCPD-1+ groups. Robust hierarchical clustering based on fold changes in the gene expression data between selected
groups divide the treated groups into several upper classes. Groups treated by exosomes or MSCPD-1+ were compared to untreated controls. Exosomes MSCPD-1+
treatments were closely related. (E) QRT-PCR analysis of PD-1 in the lung samples using TaqMan probes (n = 3). (F) The Venn diagram shows possible relations
between a finite collections of different sets of genes measured during gene expression profiling (D).
processes and pathways involved in the summarized effect of
this gene expression profile. The previously described 40-gene
QRT-PCR panel was enriched in genes related to cellular
movement and migration, cell survival and connective tissue
development and function, involving tumor cells. Additional
processes included growth and proliferation of tumor cells as
well as the PD-1:PD-L1 interaction (and its consequences).
Focusing on PD-1 and mTOR pathway, a network was
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FIGURE 5 | Integrated associative network of the in vivo overexpressed genes supplemented with the interacting exosomal factors. The network of overexpressed
genes (red symbols) was conceived by us based on literature data. The relationships between molecules were supported also by the IPA knowledge base. Network
visualization was performed using the Path Explorer tool of the IPA Path Designer. The exosomal proteins and miRNAs (gray boxes) were connected to elements of
the network by the Grow tool of the IPA Path Designer based on experimental data of the IPA knowledge base. Activation of the established network by exosomal
components may support the survival, migration, growth, and metastasis of tumor cells.
built from the overexpressed genes, and their complexes
known to be related to tumor progression using the Path
Explorer tool in the IPA Path Designer. Then a list was
generated that contained the exosomal proteins detected
by MS and the exosomal miRNAs identified by SOLiD
sequencing. The Grow tool in the IPA Path Designer revealed
significant interactions between the exosome-induced expression
network and the molecular content of these vesicles. The
resulting interaction network shows both direct and indirect
interactions, but it contains only experimentally observed
relationships based on the Ingenuity Knowledge Base. This
network demonstrates that 61 exosomal molecules (Table 4)
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TABLE 4 | List of exosomal proteins and miRNAs connected to the integrated associative network by IPA Path Designer.
ID Symbol Entrez gene name Symbol Seed regio ID
Q640N1 AEBP1 AE binding protein 1 let-7a-3p UAUACAA mmu-let-7a-1-3p, mmu-let-7b-3p
P48036 ANXA5 Annexin A5 mmu-let-7c-2-3p, mmu-let-7f-1-3p
P08226 APOE Apolipoprotein E let-7a-5p GAGGUAG mmu-let-7a-5p, mmu-let-7b-5p
Q3TWT5 ASAH1 N-acylsphingosine amidohydrolase 1 mmu-let-7c-5p, mmu-let-7d-5p
Q3TXF9 ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 mmu-let-7e-5p, mmu-let-7f-5p
O55107 BSG Basigin (Ok blood group) mmu-let-7g-5p, mmu-mir-98-5p
Q9WVT6 CA14 Carbonic anhydrase 14 miR-100-5p ACCCGUA mmu-mir-99a-5p, mmu-mir-99b-5p
P41731 CD63 CD63 molecule miR-125b-5p CCCUGAG mmu-mir-125a-5p, mmu-mir-125b-5p
P35762 CD81 CD81 molecule mmu-mir-351-5p
P29812 DCT Dopachrome tautomerase miR-126a-5p AUUAUUA mmu-mir-126a-5p
Q3UAM9 ENG Endoglin miR-139-5p CUACAGU mmu-mir-139-5p
P17182 ENO1 Enolase 1 miR-16-5p AGCAGCA mmu-mir-15a-5p, mmu-mir-15b-5p
P19096 FASN Fatty acid synthase mmu-mir-16-5p, mmu-mir-195a-5p
P11276 FN1 Fibronectin 1 mmu-mir-322-5p, mmu-mir-497a-5p
P09528 FTH1 Ferritin heavy chain 1 miR-17-5p AAAGUGC mmu-mir-106b-5p, mmu-mir-17-5p
P16858 GAPDH glyceraldehyde-3-phosphate dehydrogenase mmu-mir-20a-5p, mmu-mir-93-5p
P08752 GNAI2 G protein subunit alpha i2 miR-181a-5p ACAUUCA mmu-mir-181a-5p, mmu-mir-181b-5p
Q3TAV1 GPNMB Glycoprotein nmb mmu-mir-181c-5p, mmu-mir-181d-5p
P19157 GSTP1 glutathione S-transferase pi 1 miR-18a-5p AAGGUGC mmu-mir-18a-5p
P11499 HSP90AB1 Heat shock protein 90 alpha family class B member 1 miR-193a-3p ACUGGCC mmu-mir-193a-3p
B1B0C7 HSPG2 Heparan sulfate proteoglycan 2 miR-199a-3p CAGUAGU mmu-mir-199a-3p, mmu-mir-199b-3p
P02468 LAMC1 Laminin subunit gamma 1 miR-199a-5p CCAGUGU mmu-mir-199a-5p, mmu-mir-199b-5p
Q3U2W5 LGALS8 Galectin 8 miR-19b-3p GUGCAAA mmu-mir-19a-3p,
P21956 MFGE8 Milk fat globule-EGF factor 8 protein mmu-mir-19b-3p
P62962 PFN1 Profilin 1 miR-21-5p AGCUUAU mmu-mir-21a-5p
P52480 PKM Pyruvate kinase, muscle miR-221-3p GCUACAU mmu-mir-222-3p
P17742 PPIA Peptidylprolyl isomerase A miR-223-3p GUCAGUU mmu-mir-223-3p
Q61171 PRDX2 Peroxiredoxin 2 miR-23a-3p UCACAUU mmu-mir-23a-3p
Q8CCG5 RALB RAS like proto-oncogene B mmu-mir-23b-3p
O08992 SDCBP Syndecan binding protein miR-30c-5p GUAAACA mmu-mir-30a-5p
Q0VGP2 SEMA3B Semaphorin 3B mmu-mir-30b-5p
P10852 SLC3A2 Solute carrier family 3 member 2 mmu-mir-30c-5p
Q3UQM7 SLC7A5 Solute carrier family 7 member 5 mmu-mir-30d-5p
O09044 SNAP23 Synaptosome associated protein 23 mmu-mir-30e-5p
Q64337 SQSTM1 Sequestosome 1 miR-330-5p CUCUGGG mmu-mir-326-3p
Q542D9 TFRC Transferrin receptor miR-34a-5p GGCAGUG mmu-mir-34a-5p
P39876 TIMP3 TIMP metallopeptidase inhibitor 3 mmu-mir-34b-5p
Q9R1Q6 TMEM176B Transmembrane protein 176B mmu-mir-34c-5p
Q3UCW0 TSG101 Tumor susceptibility 101 miR-7a-5p GGAAGAC mmu-mir-7a-5p
may affect tumor progression through pathways controlled by
key components including MET, Ras, RAF1, Mek, ERK1/2,
MITF, BCL2, PI3K, Akt, mTOR, PD-1, KIT, JAK STAT3,
or ETS1.
Taken together, these findings demonstrate that interaction
between exosomes and MSCs induces a tumor-like phenotype
with PD-1 overexpression of naïve MSC in vitro and a fast tumor
progression in vivo.
DISCUSSION
Considering the fact that metastatic complications are
responsible for almost 90% of cancer-driven mortality (48),
a deep understanding of tumor metastatic processes is one
of the most important challenges in both fundamental and
applied research directions in tumor biology. Whilst certain
organotropic aspects of tumor cells were addressed by Paget’s
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“seed-and-soil” hypothesis in the early nineteenth century (49),
the detailed description of the spatiotemporal characteristics
of the metastatic processes requires an extended model.
MSCs, as multipotent stromal cells, are important players in
dynamic tumor microenvironment (12). MSCs could stimulate
angiogenesis via paracrine signaling and participate in metastasis
formation to promote the epithelial-mesenchymal transition
(12). Consequently, in the last decade, numerous studies
suggested the importance of soluble and vesicle-like components
of the tumor microenvironment in epithelial-mesenchymal
transition as crucial factors in the metastatic establishment (50).
Among these, recent findings of intercellular communication
mechanisms unquestionably highlighted the crucial role of EVs
(e.g., exosomes) serving as “information packages” within the
coordinated cell-to-cell signaling (51).
In the current study, we demonstrate that MSCs, widely
abundant in solid tumors as well as in healthy tissues,
undergo a marked re-education process upon communication
with metastatic cancer cells via exosome-mediated information
transfer. This transformation process results in characteristic
response-patterns corresponding to a given cancerous cell
lines (12).
First, we intended to precisely define the EV population
which we later employed via in vitro and in vivo experimental
approaches. Besides applying the experimental requirements of
the International Society for Extracellular Vesicles (ISEV) (i.e.,
determination of shape, size distribution and protein markers)
(52), we thoroughly defined the miRNA and protein content of
melanoma exosomes. These systematic assays concluded that the
isolated vesicles contained factors, which may regulate signaling
pathways related to cell death and survival, cellular movement,
development and cell proliferation. Given the appropriate uptake
of these vesicles by the targeted, multipotent recipient cells, it is
highly probable that most signaling pathways mentioned above
were significantly affected. In accordance with previous results in
the literature, we showed successful internalization of exosomes
by recipient MSCs. As expected, following 72 h of exposure,
MSCs displayed accelerated proliferation presumably initiated
by the transforming exosome cargo. Moreover, melanoma
exosomes were able to hinder the induction of the cell death
response commonly triggered by TNFα. TNFα is a frequently
identified, soluble, tumor-suppressing factor in cancerous
microenvironments (53). This inhibition strongly suggested
that exosomes initialize and sustain malignant transformation
of MSCs.
Further, we described numerous, exosome-induced
phenotypic manifestation of the above malignant re-education
process in the recipient cells. Apart from identifying tumor
markers, the transformation of exposed cells is characterized
by markedly modified gene expression patterns. As discussed
previously, specific gene expression alterations are often
associated with specific steps of cancerous transformation.
Malignant cell lines possess altered expression of genes
responsible for apoptotic regulation (Bax, Bcl2, caspases),
regulating metastasis (integrins, ITGA2-6, ITGB1, KIT) or
various growth factors (ETS1, HGF, MET, etc.). Importantly,
we successfully identified two melanoma-specific markers,
i.e., MITF (Microphthalmia-associated transcription factor)
and MLANA (Melanoma antigen recognized by T-cells) in
the exosome-exposed MSCs. MLANA and its regulator MITF
play a fundamental role in melanocyte development, tumor
progression and are overexpressed in melanoma cells (54). The
presence of these markers in exosome-exposed MSCs shows
effective transfer of the encoded tumorigenic information, and
may have a pivotal role in disease progression. Besides, we also
identified a characteristic set of genes, belonging mostly to proto-
oncogenes, whose expression was significantly elevated upon
exosome treatment. Among these molecules, we emphasize the
increased expression of CD44 which was previously assigned as
cancer stem cell marker and of mTOR, a characteristic indicator
of the engagement of the PD-1:PD-L1 pathway (15). Indeed,
activation of mTOR signaling is particularly important. As it was
previously demonstrated by Kleffel et al., overexpression of PD-1
in exceptionally aggressive melanoma subpopulations facilitated
tumor progression by activating the mTOR signaling pathway
(actually, this response was highly unexpected compared to that
of the classic PD-1:PD-L1 dependent T-cell anergy, a crucial
aspect of immunotherapy in the clinics) (15). Quite strikingly,
in exosome treated MSCs, we detected a significant induction
of PD-1 and mTOR. These novel data strongly support that
these vesicles might trigger the formation of an aggressive,
melanoma-like subpopulation of re-educated recipient MSCs.
Our findings therefore propose that the re-educated
melanoma-like MSCPD-1+ subpopulation, originating from
multipotent tissue-derived MSCs, is an autonomous entity. It is
characterized by typical properties of cancerous transformation
such as hyperproliferation, resistance to apoptosis, expression
of melanoma markers, proto-oncogenic gene expression
patterns, and PD-1 over-expression. Indeed, those melanoma
exosomes that induced in vitro generation of the melanoma-like
MSCPD-1+ cells, also facilitated in vivo metastasis formation in
the lungs or other distant organs of treated animals. Actually,
our findings that melanoma exosomes or exosome re-educated
MSCPD-1+ promote tumor progression, are in good accordance
with previous finding of Kleffel et al. describing that shRNA
or antibody mediated inhibition of PD-1 signaling inhibits
metastasis formation and tumor progression in experimental
animals (15). Assessment of the expression patterns of genes
related to tumor progression in the exposed animal tissues
revealed numerous cases of exosome-induced overexpression;
this supports our hypothesis that melanoma exosomes should be
considered as oncosomes (6).
Our results also demonstrated that melanoma exosomes
also generated a characteristic signaling pattern in MSCPD-1+
recipient population. As it was shown in numerous studies
PI3K/Akt, Ras/MAPK, and STAT3 pathways are commonly
activated in tumor cells (47, 55). In this study, based on
our in vitro and in vivo results and literature data, we
introduce a novel, comprehensive network of common tumor-
related proteins, such as PD-1, MET, RAF1, STAT3, BCL2,
or mTOR. The network highlights not only the relationship
of these elements, but also contains upstream exosomal
regulating factors which may contribute to the activation
of tumorigenic signaling, and hence, fast tumor progression.
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According to our best knowledge, this associative network
between overexpressed genes and the potential exosomal
inducers, is the first tumor progression signaling pattern which
connected experimental response-patterns with experimentally
detected exosomal-molecular-patterns. Further, our data also
indicate that the above complexity of exosomal communication
requires system-level approaches.
Finally, it is important to note that our conclusions are
not based on in silico predictions exclusively, but rather on
carefully designed and systematically executed in vitro and
in vivo experiments, all suggesting that the specific, robust,
molecular content of the isolated exosomes can indeed generate
a unique intercellular niche responsible for the re-education
of neighboring cells via oncogenic transformation. These re-
educated melanoma-like MSCPD-1+ cells, in turn, facilitate
metastatic disease progression via ignition of a complex series of
subsequent events both locally and systematically. Thus, based
on our results and recently published, additional evidences about
exosomes, there is an urgent demand to supplement and extend
the outdated “seed-and-soil” hypothesis with the oncosome-
driven re-education process.
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The initiative of this study was the un-
expected complete tumor regression
in a patient with stage IV cutaneous
metastatic melanoma, who suffered
multifactorial sepsis syndrome during
BOLD (bleomycin, oncovin, lomustine,
and dacarbazine) chemotherapy (see
Supplementary Figure S1 online).
After targeted antibiotic treatment and
combined complication-free chemo-
therapy, the patient’s physical con-
dition improved, and the metastasesunexpectedly disappeared. The patient
has been asymptomatic and metastasis-
free since the end of BOLD therapy. A
significant decrease in the volume of
the previously palpable axillary and
abdominal metastases had already
been observed when BOLD therapy
was interrupted because of sepsis. A
timeline of events is given in Table 1.
Molecular genetics research in the
last decade assisted in the development
of BRAF inhibitors and immuno-
oncological agents, which resulted insignificant improvement in the life
expectancy of melanoma patients.
Dacarbazine-based chemotherapies,
once the gold standard (Hobohm,
2001; Wiemann and Starnes, 1994),
are still approved and widely applied in
melanoma therapy, but their efficacy is
relatively low (Garbe et al., 2011).
Therefore, the fact that clinical
improvement was observed quite early
during the chemotherapy suggested
other factors behind the outcome, and
the concurrent sepsis seemed to offer a
potential explanation.
It has long been recognized that
cancer patients might recover after
bacterial infections (Hobohm, 2001).
The hypothesis was that fever and tu-
mor necrosis factor-a induced by the
Table 1. Timeline of clinical case report
Day
e360 The patient herself detected a bleeding nevus-like lesion on the back and an enlarged
axillary lymph node. No steps were taken.
120 Hospital visit. X-ray, mammography, and abdominal Doppler seem to be negative. Axillary
lymph node biopsy was proposed. The patient was temporarily lost to follow-up.
0 Hospital visit for abdominal pain. Gastritis was diagnosed, and a gastric polyp was
removed. Tumor masses were discovered in the retroperitoneal lymph nodes (15e20 mm),
spleen (67 mm), and bladder (40  68 mm). Another tumor was detected in the brain by
computerized tomography (40 mm).
4 The intracranial tumor mass was removed surgically and diagnosed as amelanotic
melanoma metastasis.
24 Cranial radiotherapy was initiated.
30 Leukocytosis, fever. Amoxicillin þ clavulanic acid treatment.
32 Radiotherapy completed.
35 BOLD (bleomycin, oncovin, lomustine, and dacarbazine) chemotherapy initiated.
37 Chemotherapy was suspended on the third day because of vomiting and fever. Gastric
fluid contained Escherichia coli and Candida albicans. Clostridium difficile toxin also
was detected. Fluconazole and ceftriaxone (later metronidazole) treatment was initiated.
52 Central venous catheter was removed because of putative Pseudomonas aeruginosa
infection, which was later confirmed by blood test.
59 The primary tumor was excised and analyzed (melanoma malignum, Br 1.52 mm,
C1. III., pT2b).
77 BOLD, second treatment cycle. Decrease of axillary and abdominal metastases was
detected.
120 BOLD, third cycle. Further improvement of the axillary and intra-abdominal metastases
was recorded. No intra-abdominal lymphadenomegaly was seen, and a single liver
metastasis and shrinking splenic metastasis were detected.
162 BOLD, fourth cycle. Complete remission of the axillary and abdominal metastases was
observed.
210 BOLD, fifth cycle. Complete remission of the axillary and abdominal metastases was
observed.
255 BOLD, sixth cycle. The patient was asymptomatic, verified by positron emission
tomography/computerized tomography to be metastases-free.
>1,500 The patient is asymptomatic, verified by positron emission tomography/computerized
tomography to be metastases-free.
K Buzás et al.
C. Pneumoniae Increases Survival in Melanomainfectious agents caused tumor regres-
sion, but this could not be reproduced
by administration of tumor necrosis
factor-a or by hyperthermia (Nauts
et al., 1946; Tsung and Norton, 2006).
It has been observed that an attenuated
form of Listeria monocytogenes can
infect cancer cells but not normal cells,
and this phenomenon resulted in a
potentially effective experimental can-
cer therapy (Quispe-Tintaya et al.,
2013).
Vaccination with intracellular path-
ogens such as bacille Calmette-Guérin
or vaccinia virus significantly decreased
the incidence of melanoma (Krone
et al., 2005). However, a convincing
explanation is still missing.
Although it is generally accepted that
antitumor immune mechanisms overlap
with antibacterial immune responses
(Adams, 2009; Chen et al., 2007), the
exact mechanism induced by microbes
is not understood.Because immune responses also
appear to be decisive factors in the
outcome of melanoma (Ridnour et al.,
2013; Shimanovsky et al., 2013), we hy-
pothesized that sepsis, by triggering
polarized, “joint” antibacterial and anti-
tumor immune responses, could induce
tumor regression. This hypothesis was
tested in our experimental model.
To clarify the role of the adaptive im-
mune system in the antitumor immune
mechanisms inducedbyChlamydophila
pneumoniae (CP; successfully identified
in the primary melanoma after our
patient recovered from sepsis; see
Supplementary Figure S1f), lung
metastases (LMs) were induced in
immunocompetent C57BL/6 mice or
immunodeficient NSG mice. Animals
were then CP- or mock-treated (see
Supplementary Materials online). To
assess the effects of treatment, histolog-
ical, immunological, and molecular
analyses were performed.In immunocompetent, CP-treated
animals, the number of LMs signifi-
cantly decreased (P ¼ 0.003)
(Figure 1a) and survival (Figure 1t)
significantly increased (P ¼ 0.04)
compared to mock treatment. This was
not observed in immunodeficient mice,
and the treated animals did not develop
fever (33.2 C  1.0 C mock vs.
34.8 C  0.5 C CP) or high plasma
levels of tumor necrosis factor-a,
which is against the “fever hypothesis”
(Hobohm, 2001; Wiemann and
Starnes, 1994).
Histological analysis of slices from
the lungs of mock-treated melanoma-
bearing immunocompetent mice
showed a high number of LMs,
with frequent intratumor necrosis
(Figure 1e). In contrast, fewer and
smaller foci of regressive LMs were
observed in the CP-treated immuno-
competent animals (Figure 1f). More-
over, in this group, high numbers of
tumor-infiltrating mononuclear histio-
cytes and lymphoid cells were identi-
fied in the LMs. The LMs did not exhibit
significant intratumor immune re-
actions in the immunodeficient mice,
regardless of treatment type (Figure 1g
and h). Markedly increased immune
reaction in the lungs of the CP-treated
mice was also verified by immuno-
labeling of the cell surface activa-
tion markers CD11b and CD80
(Figure 1iel). Immune cell invasion was
not detected after mock treatment; the
immune cells were concentrated in the
marginal zones of the tumors (Figure 1i
and k). In contrast, after CP treatment,
marked infiltration by activated lym-
phocytes was seen in the internal tumor
stroma (Figure 1j and l), and the differ-
ences were significant (P ¼ 0.0001)
(Figure 1m and n).
To assess macrophage polarization,
M1 (antitumor) or M2 (protumor)
macrophage-specific cytokine and
chemokine transcriptome profiling was
performed (Mantovani et al., 2004).
Macrophage markers were detected
with quantitative PCR from pooled lung
samples 2, 4, and 12 hours after mock
or CP treatment. Four hours after CP
application, markedly increased levels
of M1-specific mRNA transcripts for
CCL2, CCL3, IL-6, CXCL10, CCL7,
CD80, CXCL11, CXCL9, IL-23, and tu-
mor necrosis factor-a were detected. In
line with this, mRNA expression ofwww.jidonline.org 863
Figure 1. Chlamydophila pneumoniae treatment results in melanoma metastasis regression and increases survival of animals as well as of CD11bD and
CD80D immune cell infiltration of tumor tissues. (a, c) Number of lung metastases, (b, d) melanoma antigen MART, and (t) survival rate of mock or
Chlamydophila pneumoniae (CP)-treated immunocompetent C57BL/6 and immunodeficient NSGmice. (eeh) Representative images and hematoxylin and eosin-
stained histological sections of dissected lungs of (e) mock and (f) CP-treated immunocompetent mice, as well as of (g) mock and (h) CP-treated immunodeficient
(NSG) animals. Note that subpleural metastasis formation is extensive in diameter but not in thickness in NSG mice (arrowheads). Bars ¼ 100 mm. (e) Trophical
necroses indicate high tumor burden. Inset: atypical tumor cells and regions of necrosis. (f) Circles and right inset: foci of regressive metastases. Left inset: areas of
residual pneumonitis after CP treatment. (g, h) In both mock and CP-treated NSG mice, miliary metastases were developed subpleurally (arrowheads) and
intraparenchymally (circles) without significant inflammatory reactions (insets: highermagnification of intraparenchymalmetastases). (iel) Immunohistochemistry
of (i, j) CD11b (diaminobenzidine, brown) and (k, l) CD80 (Fast red, red) on lungs of (i, k)mockor (j, l) CP-treated C57BL/6mice.Dashed lines indicate tumor border.
(ier) Arrows indicate infiltrating immune cells. Intratumoral number of (m) CD11bþ and (n) CD80þ cells determined as a ratio of 100 tumor cells in C57BL/6 mice.
(s) CD80þ cells in NSG lungs counted by square millimeter. Data are given as mean  standard deviation.
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864most M2-specific markers decreased.
Interestingly, the levels of some impor-
tant M2 markers (CXCL13, IL1Ra) were
actually increased (see Supplementary
Figure S2a and b online). Upon CP
administration, the quantity of M1-
specific cytokine and chemokine
mRNA was significantly increased (P ¼
0.014) after 4 hours in comparison to
M2 markers.
Alteration in the expression pattern of
cyclooxygenase (COX)-1 and COX-2 is
one of the key markers of macrophage
polarization (Mantovani et al., 2013;
Martinez et al., 2006). Western blotJournal of Investigative Dermatology (2016), Volumanalysis revealed that 12 hours after CP
treatment, protein expression of the
M2-specific COX-1 decreased by half,
whereas protein expression of the M1-
specific COX-2 increased more than
twofold (see Supplementary Figure S2c
and d).
Two hours after CP treatment but
not after mock treatment, CXCL1
melanoma growth factor immuno-
reactivity become undetectable (see
Supplementary Figure S3a and b on-
line). To assess whether this in vivo
phenomenon was due to a direct CP-
CXCL1 interaction, equal amounts ofe 136recombinant CXCL1 were incubated
in vitro (in the presence of protease
inhibitors) with increasing quantities of
CP. CXCL1 levels were determined by
western blotting. CP depleted CXCL1 in
a dose-dependent manner, suggesting
strong and direct binding by CP (see
Supplementary Figure S3c and d).
Our results seem to indicate that CP
treatment does indeed induce a com-
plex antitumor response. We showed
that CP treatment can suppress LM
formation in immunocompetent (but
not in immunodeficient) mice. M1-
type macrophage polarization was
SUPPLEMENTARY MATERIAL
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antitumor effects (Sica et al., 2008).
The antitumor immune polarization/
activation was further supported by the
profound enrichment of CD80- and
CD11b-expressing immune cells in the
lungs of CP-treated animals (Prebeck
et al., 2001). Of special importance,
the melanoma growth factor CXCL1
was completely depleted by CP, both
in vivo and in vitro.
Because (i) CXCL1-induced NF-kB
activity was shown to facilitate mela-
noma transformation by allowing
melanocytes to escape apoptosis and
(ii) IkB-a DN (super-repressor of
NF-rkB) reduced tumor growth and
metastatic potential of melanoma
cells (Dhawan et al., 2002), we
consider the possible scenario not only
that CP induced M1-type macrophage
polarization but that CXCL1-induced
depletion could significantly
contribute to tumor regression.
Evidently, results of the animal study
strongly support our assumption about
the role of sepsis in the observed
outcome; however, these data cannot
exclude the role of the BOLD therapy.
The conclusion that can be safely
drawn at this point is that sepsis, in the
context of BOLD therapy, resulted in
dramatic improvement, otherwise not
seen in uncomplicated therapy, which
suggests that the occurrence of sepsis
was an event of key importance.
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Lajos Kemény6,8
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